<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Medroxyprogesterone acetate</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Medroxyprogesterone_acetate">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/mediawiki.page.gallery.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/mediawiki.page.gallery.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Medroxyprogesterone acetate</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Medroxyprogesterone acetate</b> (<b>MPA</b>), also known as <b>depot medroxyprogesterone acetate</b> (<b>DMPA</b>) in injectable form and sold under the brand name <b>Depo-Provera</b> among others, is a hormonal medication of the progestin type.<span class="mw-ref" id="cite_ref-AHFS2016_9-0"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_3-3"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is used as a method of birth control and as a part of menopausal hormone therapy.<span class="mw-ref" id="cite_ref-AHFS2016_9-1"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_3-4"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is also used to treat endometriosis, abnormal uterine bleeding, abnormal sexuality in males, and certain types of cancer.<span class="mw-ref" id="cite_ref-AHFS2016_9-2"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> The medication is available both alone and in combination with an estrogen.<span class="mw-ref" id="cite_ref-Drugs.com_10-0"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-0"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> It is taken by mouth, used under the tongue, or by injection into a muscle or fat.<span class="mw-ref" id="cite_ref-AHFS2016_9-3"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>



<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Medroxyprogesterone acetate</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Medroxyprogesterone_acetate.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Medroxyprogesterone_acetate.svg.png" data-file-width="512" data-file-height="356" data-file-type="drawing" height="174" width="250"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Medroxyprogesterone_acetate_molecule_ball.png" tppabs="https://ptable.com/wiki/compounds/I/m/Medroxyprogesterone_acetate_molecule_ball.png" data-file-width="2560" data-file-height="2000" data-file-type="bitmap" height="184" width="235"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>m</span><span>ɛ</span><span>ˌ</span><span>d</span><span>r</span><span>ɒ</span><span>k</span><span>s</span><span>i</span><span>p</span><span>r</span><span>oʊ</span><span>ˈ</span><span>dʒ</span><span>ɛ</span><span>s</span><span>t</span><span>ər</span><span>oʊ</span><span>n</span></span><span class="wrap"> </span><span style="border-bottom:1px dotted"><span>ˈ</span><span>æ</span><span>s</span><span>ɪ</span><span>t</span><span>eɪ</span><span>t</span></span>/</span></span> <i title="English pronunciation respelling">me-<span style="font-size:90%">DROKS</span>-ee-proh-<span style="font-size:90%">JES</span>-tər-ohn <span style="font-size:90%">ASS</span>-i-tayt</i><span class="mw-ref" id="cite_ref-Drugs.com-2_1-0"><a href="#cite_note-Drugs.com-2-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Provera, Depo-Provera, Depo-SubQ Provera 104, Curretab, Cycrin, Farlutal, Gestapuran, Perlutex, Veramix, others<span class="mw-ref" id="cite_ref-IndexNominum2000_2-0"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>MPA; DMPA; Methylhydroxy<wbr>progesterone acetate; Methylacetoxy<wbr>progesterone; MAP; Methypregnone; Metipregnone; 6α-Methyl-17α-hydroxyprogesterone acetate; 6α-Methyl-17α-acetoxyprogesterone; 6α-Methyl-17α-hydroxypregn-4-ene-3,20-dione acetate; NSC-26386</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/medroxyprogesterone-acetate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/medroxyprogesterone-acetate.html'" tppabs="https://www.drugs.com/monograph/medroxyprogesterone-acetate.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a604039.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a604039.html'" tppabs="https://medlineplus.gov/druginfo/meds/a604039.html" class="external text external">a604039</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>X (Contraindicated)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth, sublingual, intramuscular injection, subcutaneous injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Progestogen; Progestin; Progestogen ester; Antigonadotropin; Steroidal antiandrogen</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>G03AC06<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=G03AC06  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=G03AC06'" tppabs="https://www.whocc.no/atc_ddd_index/?code=G03AC06" class="external text external">WHO</a></span>)<span> </span>G03DA02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=G03DA02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=G03DA02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=G03DA02" class="external text external">WHO</a></span>), L02AB02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L02AB02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L02AB02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L02AB02" class="external text external">WHO</a></span>)</li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>By mouth: ~100%<span class="mw-ref" id="cite_ref-pmid16112947_3-0"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid19434889_4-0"><a href="#cite_note-pmid19434889-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>88% (to <a href="Serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serum_albumin" title="Serum albumin">albumin</a>)<span class="mw-ref" id="cite_ref-pmid19434889_4-1"><a href="#cite_note-pmid19434889-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver (hydroxylation (CYP3A4), reduction, conjugation)<span class="mw-ref" id="cite_ref-ProveraLabel_5-0"><a href="#cite_note-ProveraLabel-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_3-1"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid26291834_6-0"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>By mouth: 12–33 hours<span class="mw-ref" id="cite_ref-ProveraLabel_5-1"><a href="#cite_note-ProveraLabel-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_3-2"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><br><abbr>IM</abbr> (<abbr>aq. susp.</abbr>): ~50 days<span class="mw-ref" id="cite_ref-DepoProveraLabel_7-0"><a href="#cite_note-DepoProveraLabel-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><br><abbr>SC</abbr> (<abbr>aq. susp.</abbr>): ~40 days<span class="mw-ref" id="cite_ref-DepoSubQProveraLabel_8-0"><a href="#cite_note-DepoSubQProveraLabel-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Urine (as conjugates)<span class="mw-ref" id="cite_ref-ProveraLabel_5-2"><a href="#cite_note-ProveraLabel-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">[(6<i>S</i>,8<i>R</i>,9<i>S</i>,10<i>R</i>,13<i>S</i>,14<i>S</i>,17<i>R</i>)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthren-17-yl] acetate</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=71-58-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=71-58-9'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=71-58-9" class="external text external">71-58-9</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/6279  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/6279'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/6279" class="external text external">6279</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2879  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2879'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2879" class="external text external">2879</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00603  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00603'" tppabs="https://www.drugbank.ca/drugs/DB00603" class="external text external">DB00603</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.6043.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.6043.html'" tppabs="http://www.chemspider.com/Chemical-Structure.6043.html" class="external text external">6043</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=C2QI4IOI2G  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=C2QI4IOI2G'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=C2QI4IOI2G" class="external text external">C2QI4IOI2G</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/C08150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/C08150'" tppabs="https://www.kegg.jp/entry/C08150" class="external text external">C08150</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6716  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6716'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6716" class="external text external">CHEBI:6716</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL717  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL717'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL717" class="external text external">ChEMBL717</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID0025527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID0025527'" tppabs="https://comptox.epa.gov/dashboard/DTXSID0025527" class="external text external">DTXSID0025527</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.000.689  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.000.689'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.000.689" class="external text external">100.000.689</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>24</sub><span>H</span><sub>34</sub><span>O</span><sub>4</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">386.532</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=C%5BC%40H%5D1C%5BC%40%40H%5D2%5BC%40H%5D%28CC%5BC%40%5D3%28%5BC%40H%5D2CC%5BC%40%40%5D3%28C%28%3DO%29C%29OC%28%3DO%29C%29C%29%5BC%40%40%5D4%28C1%3DCC%28%3DO%29CC4%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=C%5BC%40H%5D1C%5BC%40%40H%5D2%5BC%40H%5D%28CC%5BC%40%5D3%28%5BC%40H%5D2CC%5BC%40%40%5D3%28C%28%3DO%29C%29OC%28%3DO%29C%29C%29%5BC%40%40%5D4%28C1%3DCC%28%3DO%29CC4%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=C%5BC%40H%5D1C%5BC%40%40H%5D2%5BC%40H%5D%28CC%5BC%40%5D3%28%5BC%40H%5D2CC%5BC%40%40%5D3%28C%28%3DO%29C%29OC%28%3DO%29C%29C%29%5BC%40%40%5D4%28C1%3DCC%28%3DO%29CC4%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>207 to 209<span>&nbsp;</span>°C (405 to 408<span>&nbsp;</span>°F)</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1</div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:PSGAAPLEWMOORI-PEINSRQWSA-N</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=307255781&page2=Medroxyprogesterone+acetate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=307255781&page2=Medroxyprogesterone+acetate'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=307255781&page2=Medroxyprogesterone+acetate" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common side effects include menstrual disturbances such as absence of periods, abdominal pain, and headaches.<span class="mw-ref" id="cite_ref-AHFS2016_9-4"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> More serious side effects include bone loss, blood clots, allergic reactions, and liver problems.<span class="mw-ref" id="cite_ref-AHFS2016_9-5"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Use is not recommended during pregnancy as it may harm the baby.<span class="mw-ref" id="cite_ref-AHFS2016_9-6"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> MPA is an artificial progestogen, and as such activates the progesterone receptor, the biological target of <a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">progesterone</a>.<span class="mw-ref" id="cite_ref-pmid16112947_3-5"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It also has weak glucocorticoid activity and very weak androgenic activity but no other important hormonal activity.<span class="mw-ref" id="cite_ref-pmid16112947_3-6"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid10077001_12-0"><a href="#cite_note-pmid10077001-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Due to its progestogenic activity, MPA decreases the body's release of gonadotropins and can suppress sex hormone levels.<span class="mw-ref" id="cite_ref-Genazzani1993_13-0"><a href="#cite_note-Genazzani1993-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> It works as a form of birth control by preventing ovulation.<span class="mw-ref" id="cite_ref-AHFS2016_9-7"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


<p>MPA was discovered in 1956 and was introduced for medical use in the United States in 1959.<span class="mw-ref" id="cite_ref-Roberts2013_14-0"><a href="#cite_note-Roberts2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-Sneader2005_15-0"><a href="#cite_note-Sneader2005-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2016_9-8"><a href="#cite_note-AHFS2016-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.<span class="mw-ref" id="cite_ref-WHO21st_16-0"><a href="#cite_note-WHO21st-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> The wholesale cost in the developing world is about US$0.59–1.57 per vial.<span class="mw-ref" id="cite_ref-ERC2014_17-0"><a href="#cite_note-ERC2014-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> In the United Kingdom this dose costs the NHS about £6.01.<span class="mw-ref" id="cite_ref-BNF69_18-0"><a href="#cite_note-BNF69-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> In the United States it costs less than $25 a dose as of 2015.<span class="mw-ref" id="cite_ref-Ric2015_19-0"><a href="#cite_note-Ric2015-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> MPA is the most widely used progestin in menopausal hormone therapy and in progestogen-only birth control.<span class="mw-ref" id="cite_ref-Meikle1999_20-0"><a href="#cite_note-Meikle1999-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Organization)Organization2002_21-0"><a href="#cite_note-Organization)Organization2002-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> DMPA is approved for use as a form of long-acting birth control in more than 100<span>&nbsp;</span>countries.<span class="mw-ref" id="cite_ref-BagadePawar2014_22-0"><a href="#cite_note-BagadePawar2014-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-Gunasheela2011_23-0"><a href="#cite_note-Gunasheela2011-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> In 2017, it was the 222nd most commonly prescribed medication in the United States, with more than two million prescriptions.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>The most common use of MPA is in the form of DMPA as a long-acting progestogen-only injectable contraceptive to prevent pregnancy in women. It is an extremely effective contraceptive when used with relatively high doses to prevent ovulation. MPA is also used in combination with an estrogen in menopausal hormone therapy in postmenopausal women to treat and prevent menopausal symptoms such as hot flashes, vaginal atrophy, and osteoporosis.<span class="mw-ref" id="cite_ref-pmid16112947_3-7"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is used in menopausal hormone therapy specifically to prevent endometrial hyperplasia and cancer that would otherwise be induced by prolonged unopposed estrogen therapy in women with intact uteruses.<span class="mw-ref" id="cite_ref-pmid16112947_3-8"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid22895916_26-0"><a href="#cite_note-pmid22895916-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> In addition to contraception and menopausal hormone therapy, MPA is used in the treatment of gynecological and menstrual disorders such as dysmenorrhea, amenorrhea, and endometriosis.<span class="mw-ref" id="cite_ref-Medline_27-0"><a href="#cite_note-Medline-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Along with other progestins, MPA was developed to allow for oral progestogen therapy, as progesterone (the progestogen hormone made by the human body) could not be taken orally for many decades before the process of micronization was developed and became feasible in terms of pharmaceutical manufacturing.<span class="mw-ref" id="cite_ref-Panay2010_28-0"><a href="#cite_note-Panay2010-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>

<p>DMPA reduces sex drive in men and is used as a form of chemical castration to control inappropriate or unwanted sexual behavior in those with paraphilias or hypersexuality, including in convicted sex offenders.<span class="mw-ref" id="cite_ref-pmid16575429_29-0"><a href="#cite_note-pmid16575429-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-Salon2000_30-0"><a href="#cite_note-Salon2000-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> DMPA has also been used to treat benign prostatic hyperplasia, as a palliative appetite stimulant for cancer patients, and at high doses (800<span>&nbsp;</span>mg per day) to treat certain hormone-dependent cancers including endometrial cancer, renal cancer, and breast cancer.<span class="mw-ref" id="cite_ref-Drugs@FDA-Depo-Provera_31-0"><a href="#cite_note-Drugs@FDA-Depo-Provera-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-Meyler_32-0"><a href="#cite_note-Meyler-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-pmid390798_33-0"><a href="#cite_note-pmid390798-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-pmid2974757_34-0"><a href="#cite_note-pmid2974757-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span><span class="mw-ref" id="cite_ref-pmid1534051_35-0"><a href="#cite_note-pmid1534051-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span> MPA has also been prescribed in feminizing hormone therapy for transgender women due to its progestogenic and functional antiandrogenic effects.<span class="mw-ref" id="cite_ref-pmid16286768_36-0"><a href="#cite_note-pmid16286768-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> It has been used to delay puberty in children with precocious puberty but is not satisfactory for this purpose as it is not able to completely suppress puberty.<span class="mw-ref" id="cite_ref-SachdevaDutta2012_37-0"><a href="#cite_note-SachdevaDutta2012-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> DMPA at high doses has been reported to be definitively effective in the treatment of hirsutism as well.<span class="mw-ref" id="cite_ref-Hammerstein1990_38-0"><a href="#cite_note-Hammerstein1990-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<p>Though not used as a treatment for epilepsy, MPA has been found to reduce the frequency of seizures and does not interact with antiepileptic medications. MPA does not interfere with blood clotting and appears to improve blood parameters for women with sickle cell anemia. Similarly, MPA does not appear to affect liver metabolism, and may improve primary biliary cirrhosis and chronic active hepatitis. Women taking MPA may experience spotting shortly after starting the medication but is not usually serious enough to require medical intervention. With longer use amenorrhea (absence of menstruation) can occur as can irregular menstruation which is a major source of dissatisfaction, though both can result in improvements with iron deficiency and risk of pelvic inflammatory disease and often do not result in discontinuation of the medication.<span class="mw-ref" id="cite_ref-Meyler_32-1"><a href="#cite_note-Meyler-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Birth_control">Birth control</h3></summary>
    
<table class="infobox" style="width:22em"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color:lavender">Depot medroxyprogesterone acetate (DMPA)</th></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Prikpil.JPG" tppabs="https://ptable.com/wiki/compounds/I/m/Prikpil.JPG" data-file-width="2272" data-file-height="1704" data-file-type="bitmap" height="188" width="250"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background-color:lavender">Background</th></tr><tr><th scope="row">Type</th><td>Hormonal</td></tr><tr><th scope="row">First use</th><td>1969<span class="mw-ref" id="cite_ref-Nadakavukaren2011_39-0"><a href="#cite_note-Nadakavukaren2011-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></td></tr><tr><th scope="row">Trade names</th><td>Depo-Provera, Depo-SubQ Provera 104, others</td></tr><tr><th scope="row">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/depo-provera.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/depo-provera.html'" tppabs="https://www.drugs.com/depo-provera.html" class="external text external">depo-provera</a></span></td></tr><tr><th colspan="2" style="text-align:center;background-color:lavender">Failure rates (first year)</th></tr><tr><th scope="row">Perfect use</th><td>0.2%<span class="mw-ref" id="cite_ref-Trussell_2011_40-0"><a href="#cite_note-Trussell_2011-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></td></tr><tr><th scope="row">Typical use</th><td>6%<span class="mw-ref" id="cite_ref-Trussell_2011_40-1"><a href="#cite_note-Trussell_2011-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background-color:lavender">Usage</th></tr><tr><th scope="row">Duration effect</th><td>3 months<br>(12–14 weeks)</td></tr><tr><th scope="row">Reversibility</th><td>3–18 months</td></tr><tr><th scope="row">User reminders</th><td>Maximum interval is just under 3 months</td></tr><tr><th scope="row">Clinic review</th><td>12 weeks</td></tr><tr><th colspan="2" style="text-align:center;background-color:lavender">Advantages and disadvantages</th></tr><tr><th scope="row">STI protection</th><td>No</td></tr><tr><th scope="row">Period disadvantages</th><td>Especially in first injection may be frequent spotting</td></tr><tr><th scope="row">Period advantages</th><td>Usually no periods from 2nd injection</td></tr><tr><th scope="row">Benefits</th><td>Especially good if poor pill compliance.<br>Reduced endometrial cancer risk.</td></tr><tr><th scope="row">Risks</th><td>Reduced bone density, which may reverse after discontinuation</td></tr><tr><th colspan="2" style="text-align:center;background-color:lavender">Medical notes</th></tr><tr><td colspan="2" style="text-align:center;background-color: #eee; font-size:x-small">For those intending to start family, suggest switch 6 months prior to alternative method (e.g. POP) allowing more reliable return fertility.</td></tr></tbody></table>

<p>DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women.<span class="mw-ref" id="cite_ref-pmid18470526_41-0"><a href="#cite_note-pmid18470526-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-westhoff_42-0"><a href="#cite_note-westhoff-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> It is given by intramuscular or subcutaneous injection and forms a long-lasting depot, from which it is slowly released over a period of several months. It takes one week to take effect if given after the first five days of the period cycle, and is effective immediately if given during the first five days of the period cycle. Estimates of first-year failure rates are about 0.3%.<span class="mw-ref" id="cite_ref-trussell_2004a_43-0"><a href="#cite_note-trussell_2004a-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span> MPA is effective in preventing pregnancy, but offers no protection against sexually transmitted infections (STIs).</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Effectiveness">Effectiveness</h4></summary>
    
<p>Trussell's estimated <i>perfect use</i> first-year failure rate for DMPA as the average of failure rates in seven clinical trials at 0.3%.<span class="mw-ref" id="cite_ref-trussell_2004a_43-1"><a href="#cite_note-trussell_2004a-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-trussell_2004b_44-0"><a href="#cite_note-trussell_2004b-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> It was considered <i>perfect use</i> because the clinical trials measured efficacy during actual use of DMPA defined as being no longer than 14 or 15 weeks after an injection (i.e., no more than 1 or 2 weeks late for a next injection).</p>

<p>Prior to 2004, Trussell's <i>typical use</i> failure rate for DMPA was the same as his <i>perfect use</i> failure rate: 0.3%.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span></p>

<ul><li>DMPA estimated <i>typical use</i> first-year failure rate = 0.3% in:
<ul><li><i>Contraceptive Technology, 16th revised edition</i> (1994)<span class="mw-ref" id="cite_ref-trussell_1994_46-0"><a href="#cite_note-trussell_1994-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></li>
<li><i>Contraceptive Technology, 17th revised edition</i> (1998)<span class="mw-ref" id="cite_ref-trussell_1998_47-0"><a href="#cite_note-trussell_1998-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span>
<ul><li>Adopted in 1998 by the FDA for its current <i>Uniform Contraceptive Labeling</i> guidance<span class="mw-ref" id="cite_ref-fda_guidance_48-0"><a href="#cite_note-fda_guidance-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></li></ul></li></ul></li></ul>

<p>In 2004, using the 1995 NSFG failure rate, Trussell increased (by 10 times) his <i>typical use</i> failure rate for DMPA from 0.3% to 3%.<span class="mw-ref" id="cite_ref-trussell_2004a_43-2"><a href="#cite_note-trussell_2004a-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-trussell_2004b_44-1"><a href="#cite_note-trussell_2004b-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>

<ul><li>DMPA estimated <i>typical use</i> first-year failure rate = 3% in:
<ul><li><i>Contraceptive Technology, 18th revised edition</i> (2004)<span class="mw-ref" id="cite_ref-trussell_2004a_43-3"><a href="#cite_note-trussell_2004a-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></li>
<li><i>Contraceptive Technology, 19th revised edition</i> (2007)<span class="mw-ref" id="cite_ref-trussell_2007_49-0"><a href="#cite_note-trussell_2007-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span></li></ul></li></ul>

<p>Trussell did not use 1995 NSFG failure rates as <i>typical use</i> failure rates for the other two then newly available long-acting contraceptives, the Norplant implant (2.3%) and the ParaGard copper T 380A IUD (3.7%), which were (as with DMPA) an order of magnitude higher than in clinical trials. Since Norplant and ParaGard allow no scope for user error, their much higher 1995 NSFG failure rates were attributed by Trussell to contraceptive overreporting at the time of a conception leading to a live birth.<span class="mw-ref" id="cite_ref-trussell_2004a_43-4"><a href="#cite_note-trussell_2004a-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-trussell_1999_50-0"><a href="#cite_note-trussell_1999-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-trussell_2004b_44-2"><a href="#cite_note-trussell_2004b-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Advantages">Advantages</h4></summary>
    
<p>DMPA has a number of advantages and benefits:<span class="mw-ref" id="cite_ref-hatcher_51-0"><a href="#cite_note-hatcher-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-speroff_52-0"><a href="#cite_note-speroff-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-westhoff_42-1"><a href="#cite_note-westhoff-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span><span class="mw-ref" id="cite_ref-mishell_53-0"><a href="#cite_note-mishell-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span></p>

<ul><li>Highly effective at preventing pregnancy.</li>
<li>Injected every 12 weeks. The only continuing action is to book subsequent follow-up injections every twelve weeks, and to monitor side effects to ensure that they do not require medical attention.</li>
<li>No estrogen. No increased risk of deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction.</li>
<li>Minimal drug interactions (compared to other hormonal contraceptives).</li>
<li>Decreased risk of endometrial cancer. DMPA reduces the risk of endometrial cancer by 80%.<span class="mw-ref" id="cite_ref-Kaunitz_54-0"><a href="#cite_note-Kaunitz-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span><span class="mw-ref" id="cite_ref-BrJFP_Bigrigg1999_55-0"><a href="#cite_note-BrJFP_Bigrigg1999-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-WHO_DMPA_EC_56-0"><a href="#cite_note-WHO_DMPA_EC-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span> The reduced risk of endometrial cancer in DMPA users is thought to be due to both the direct anti-proliferative effect of progestogen on the endometrium and the indirect reduction of estrogen levels by suppression of ovarian follicular development.<span class="mw-ref" id="cite_ref-Santen_57-0"><a href="#cite_note-Santen-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span></li>
<li>Decreased risk of iron deficiency anemia, pelvic inflammatory disease (PID), ectopic pregnancy,<span class="mw-ref" id="cite_ref-Bartz_2011_58-0"><a href="#cite_note-Bartz_2011-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-59"><a href="#cite_note-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> and uterine fibroids.</li>
<li>Decreased symptoms of endometriosis.</li>
<li>Decreased incidence of primary dysmenorrhea, ovulation pain, and functional ovarian cysts.</li>
<li>Decreased incidence of seizures in women with epilepsy. Additionally, unlike most other hormonal contraceptives, DMPA's contraceptive effectiveness is not affected by enzyme-inducing antiepileptic drugs.<span class="mw-ref" id="cite_ref-obrien_60-0"><a href="#cite_note-obrien-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span></li>
<li>Decreased incidence and severity of sickle cell crises in women with sickle-cell disease.<span class="mw-ref" id="cite_ref-westhoff_42-2"><a href="#cite_note-westhoff-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></li></ul>

<p>The United Kingdom Department of Health has actively promoted Long Acting Reversible Contraceptive use since 2008, particularly for young people;<span class="mw-ref" id="cite_ref-61"><a href="#cite_note-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span> following on from the October 2005 National Institute for Health and Clinical Excellence guidelines.<span class="mw-ref" id="cite_ref-62"><a href="#cite_note-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span> Giving advice on these methods of contraception has been included in the 2009 Quality and Outcomes Framework "good practice" for primary care.<span class="mw-ref" id="cite_ref-63"><a href="#cite_note-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Comparison">Comparison</h3></summary>
    
<p>Proponents of bioidentical hormone therapy believe that progesterone offers fewer side effects and improved quality of life compared to MPA.<span class="mw-ref" id="cite_ref-Holtorf2009_64-0"><a href="#cite_note-Holtorf2009-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span> The evidence for this view has been questioned; MPA is better absorbed when taken by mouth, with a much longer elimination half-life leading to more stable blood levels<span class="mw-ref" id="cite_ref-Cirigliano_65-0"><a href="#cite_note-Cirigliano-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span> though it may lead to greater breast tenderness and more sporadic vaginal bleeding.<span class="mw-ref" id="cite_ref-Holtorf2009_64-1"><a href="#cite_note-Holtorf2009-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span> The two compounds do not differentiate in their ability to suppress endometrial hyperplasia,<span class="mw-ref" id="cite_ref-Holtorf2009_64-2"><a href="#cite_note-Holtorf2009-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span> nor does either increase the risk of pulmonary embolism.<span class="mw-ref" id="cite_ref-66"><a href="#cite_note-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span> The two medications have not been adequately compared in direct tests to clear conclusions about safety and superiority.<span class="mw-ref" id="cite_ref-Panay2010_28-1"><a href="#cite_note-Panay2010-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Available_forms">Available forms</h3></summary>
    


<p>MPA is available alone in the form of 2.5, 5, and 10<span>&nbsp;</span>mg oral tablets, as a 150<span>&nbsp;</span>mg/mL (1<span>&nbsp;</span>mL) or 400<span>&nbsp;</span>mg/mL (2.5<span>&nbsp;</span>mL) microcrystalline aqueous suspension for intramuscular injection, and as a 104<span>&nbsp;</span>mg (0.65<span>&nbsp;</span>mL of 160<span>&nbsp;</span>mg/mL) microcrystalline aqueous suspension for subcutaneous injection.<span class="mw-ref" id="cite_ref-Drugs@FDA_67-0"><a href="#cite_note-Drugs@FDA-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-HospitalEngorn2014_68-0"><a href="#cite_note-HospitalEngorn2014-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> It has also been marketed in the form of 100, 200, 250, 400, and 500<span>&nbsp;</span>mg oral tablets; 500 and 1,000<span>&nbsp;</span>mg oral suspensions; and as a 50<span>&nbsp;</span>mg/mL microcrystalline aqueous suspension for intramuscular injection.<span class="mw-ref" id="cite_ref-Tiziani2013_69-0"><a href="#cite_note-Tiziani2013-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span><span class="mw-ref" id="cite_ref-Leidenberger2013_70-0"><a href="#cite_note-Leidenberger2013-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span> A 100<span>&nbsp;</span>mg/mL microcrystalline aqueous suspension for intramuscular injection was previously available as well.<span class="mw-ref" id="cite_ref-Drugs@FDA_67-1"><a href="#cite_note-Drugs@FDA-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> In addition to single-drug formulations, MPA is available in the form of oral tablets in combination with conjugated estrogens (CEEs), estradiol, and estradiol valerate for use in menopausal hormone therapy, and is available in combination with estradiol cypionate in a microcrystalline aqueous suspension as a combined injectable contraceptive.<span class="mw-ref" id="cite_ref-Drugs.com_10-1"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-1"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-Drugs@FDA_67-2"><a href="#cite_note-Drugs@FDA-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-BagadePawar2014_22-1"><a href="#cite_note-BagadePawar2014-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>Depo-Provera is the brand name for a 150<span>&nbsp;</span>mg microcrystalline aqueous suspension of DMPA that is administered by intramuscular injection. The shot must be injected into thigh, buttock, or deltoid muscle four times a year (every 11 to 13<span>&nbsp;</span>weeks), and provides pregnancy protection instantaneously after the first injection.<span class="mw-ref" id="cite_ref-Depo_Provera:_The_Birth_Control_Shot_71-0"><a href="#cite_note-Depo_Provera:_The_Birth_Control_Shot-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span> Depo-subQ Provera 104 is a variation of the original intramuscular DMPA that is instead a 104<span>&nbsp;</span>mg microcrystalline dose in aqueous suspension administered by subcutaneous injection. It contains 69% of the MPA found in the original intramuscular DMPA formulation. It can be injected using a smaller injection needle inserting the medication just below the skin, instead of into the muscle, in either the abdomen or thigh. This subcutaneous injection claims to reduce the side effects of DMPA while still maintaining all the same benefits of the original intramuscular DMPA.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>MPA is not usually recommended because of unacceptable health risk or because it is not indicated in the following cases:<span class="mw-ref" id="cite_ref-who_mec_72-0"><a href="#cite_note-who_mec-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-ffprhc_mec_73-0"><a href="#cite_note-ffprhc_mec-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span></p>

<p>Conditions where the theoretical or proven risks usually outweigh the advantages of using DMPA:</p>

<ul><li>Multiple risk factors for arterial cardiovascular disease</li>
<li>Current deep vein thrombosis or pulmonary embolus</li>
<li>Migraine headache with aura while using DMPA</li>
<li>Before evaluation of unexplained vaginal bleeding suspected of being a serious condition</li>
<li>A history of breast cancer and no evidence of current disease for five years</li>
<li>Active liver disease: (acute viral hepatitis, severe decompensated cirrhosis, benign or malignant liver tumours)</li>
<li>Conditions of concern for estrogen deficiency and reduced HDL levels theoretically increasing cardiovascular risk:
<ul><li>Hypertension with vascular disease</li>
<li>Current and history of ischemic heart disease</li>
<li>History of stroke</li>
<li>Diabetes for over 20 years or with nephropathy/retinopathy/neuropathy or vascular disease</li></ul></li></ul>

<p>Conditions which represent an unacceptable health risk if DMPA is used:</p>

<ul><li>Current or recent breast cancer (a hormonally sensitive tumour)</li></ul>

<p>Conditions where use is not indicated and should not be initiated:</p>

<ul><li>Pregnancy</li></ul>

<p>MPA is not recommended for use prior to menarche or before or during recovery from surgery.<span class="mw-ref" id="cite_ref-Merck_74-0"><a href="#cite_note-Merck-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>In women, the most common adverse effects of MPA are acne, changes in menstrual flow, drowsiness, and can cause birth defects if taken by pregnant women. Other common side effects include breast tenderness, increased facial hair, decreased scalp hair, difficulty falling or remaining asleep, stomach pain, and weight loss or gain.<span class="mw-ref" id="cite_ref-Medline_27-1"><a href="#cite_note-Medline-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Lowered libido has been reported as a side effect of MPA in women.<span class="mw-ref" id="cite_ref-King2012_75-0"><a href="#cite_note-King2012-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span> DMPA can affect menstrual bleeding. After a year of use, 55% of women experience amenorrhea (missed periods); after 2 years, the rate rises to 68%. In the first months of use "irregular or unpredictable bleeding or spotting, or, rarely, heavy or continuous bleeding" was reported.<span class="mw-ref" id="cite_ref-depo_us_patient_info_76-0"><a href="#cite_note-depo_us_patient_info-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> MPA does not appear to be associated with vitamin B12 deficiency.<span class="mw-ref" id="cite_ref-pmid720068_77-0"><a href="#cite_note-pmid720068-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span> Data on weight gain with DMPA likewise are inconsistent.<span class="mw-ref" id="cite_ref-Nelson2014_78-0"><a href="#cite_note-Nelson2014-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2015_79-0"><a href="#cite_note-Aronson2015-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span></p>

<p>At high doses for the treatment of breast cancer, MPA can cause weight gain and can worsen diabetes mellitus and edema (particularly of the face). Adverse effects peak at five weeks, and are reduced with lower doses. Less frequent effects may include thrombosis (though it is not clear if this is truly a risk, it cannot be ruled out), painful urination, headache, nausea, and vomiting. When used as a form of androgen deprivation therapy in men, more frequent complaints include reduced libido, impotence, reduced ejaculate volume, and within three days, chemical castration. At extremely high doses (used to treat cancer, not for contraception) MPA may cause adrenal suppression and may interfere with carbohydrate metabolism, but does not cause diabetes.<span class="mw-ref" id="cite_ref-Meyler_32-2"><a href="#cite_note-Meyler-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>

<p>When used as a form of injected birth control, there is a delayed return of fertility. The average return to fertility is 9 to 10 months after the last injection, taking longer for overweight or obese women. By 18 months after the last injection, fertility is the same as that in former users of other contraceptive methods.<span class="mw-ref" id="cite_ref-hatcher_51-1"><a href="#cite_note-hatcher-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-speroff_52-1"><a href="#cite_note-speroff-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> Fetuses exposed to progestogens have demonstrated higher rates of genital abnormalities, low birth weight, and increased ectopic pregnancy particularly when MPA is used as an injected form of long-term birth control. A study of accidental pregnancies among poor women in Thailand found that infants who had been exposed to DMPA during pregnancy had a higher risk of low birth weight and an 80% greater-than-usual chance of dying in the first year of life.<span class="mw-ref" id="cite_ref-80"><a href="#cite_note-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mood_changes">Mood changes</h3></summary>
    
<p>There have been concerns about a possible risk of depression and mood changes with progestins like MPA, and this has led to reluctance of some clinicians and women to use them.<span class="mw-ref" id="cite_ref-Lobo2007_81-0"><a href="#cite_note-Lobo2007-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span><span class="mw-ref" id="cite_ref-pmid10338269_82-0"><a href="#cite_note-pmid10338269-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> However, contrary to widely-held beliefs, most research suggests that progestins do not cause adverse psychological effects such as depression or anxiety.<span class="mw-ref" id="cite_ref-Lobo2007_81-1"><a href="#cite_note-Lobo2007-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span> A 2018 systematic review of the relationship between progestin-based contraception and depression included three large studies of DMPA and reported no association between DMPA and depression.<span class="mw-ref" id="cite_ref-pmid29496297_83-0"><a href="#cite_note-pmid29496297-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> According to a 2003 review of DMPA, the majority of published clinical studies indicate that DMPA is not associated with depression, and the overall data support the notion that the medication does not significantly affect mood.<span class="mw-ref" id="cite_ref-pmid12954518_84-0"><a href="#cite_note-pmid12954518-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span></p>

<p>In the largest study to have assessed the relationship between MPA and depression to date, in which over 3,900<span>&nbsp;</span>women were treated with DMPA for up to 7<span>&nbsp;</span>years, the incidence of depression was infrequent at 1.5% and the discontinuation rate due to depression was 0.5%.<span class="mw-ref" id="cite_ref-pmid29496297_83-1"><a href="#cite_note-pmid29496297-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span><span class="mw-ref" id="cite_ref-pmid18470526_41-1"><a href="#cite_note-pmid18470526-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-pmid9649914_85-0"><a href="#cite_note-pmid9649914-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> This study did not include baseline data on depression,<span class="mw-ref" id="cite_ref-pmid9649914_85-1"><a href="#cite_note-pmid9649914-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> and due to the incidence of depression in the study, the FDA required package labeling for DMPA stating that women with depression should be observed carefully and that DMPA should be discontinued if depression recurs.<span class="mw-ref" id="cite_ref-pmid29496297_83-2"><a href="#cite_note-pmid29496297-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> A subsequent study of 495<span>&nbsp;</span>women treated with DMPA over the course of 1<span>&nbsp;</span>year found that the mean depression score slightly decreased in the whole group of continuing users from 7.4 to 6.7 (by 9.5%) and decreased in the quintile of that group with the highest depression scores at baseline from 15.4 to 9.5 (by 38%).<span class="mw-ref" id="cite_ref-pmid9649914_85-2"><a href="#cite_note-pmid9649914-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> Based on the results of this study and others, a consensus began emerging that DMPA does not in fact increase the risk of depression nor worsen the severity of pre-existing depression.<span class="mw-ref" id="cite_ref-Aronson2015_79-1"><a href="#cite_note-Aronson2015-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span><span class="mw-ref" id="cite_ref-pmid9649914_85-3"><a href="#cite_note-pmid9649914-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span><span class="mw-ref" id="cite_ref-pmid18470526_41-2"><a href="#cite_note-pmid18470526-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<p>Similarly to the case of DMPA for hormonal contraception, the Heart and Estrogen/Progestin Replacement Study (HERS), a study of 2,763 postmenopausal women treated with 0.625<span>&nbsp;</span>mg/day oral CEEs plus 2.5<span>&nbsp;</span>mg/day oral MPA or placebo for 36<span>&nbsp;</span>months as a method of menopausal hormone therapy, found no change in depressive symptoms.<span class="mw-ref" id="cite_ref-FinkPfaff2011_86-0"><a href="#cite_note-FinkPfaff2011-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span><span class="mw-ref" id="cite_ref-Ryden2009_87-0"><a href="#cite_note-Ryden2009-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-pmid11829697_88-0"><a href="#cite_note-pmid11829697-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> However, some small studies have reported that progestins like MPA might counteract beneficial effects of estrogens against depression.<span class="mw-ref" id="cite_ref-Lobo2007_81-2"><a href="#cite_note-Lobo2007-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_3-9"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid15358281_89-0"><a href="#cite_note-pmid15358281-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Long-term_effects">Long-term effects</h3></summary>
    
<p>The Women's Health Initiative investigated the use of a combination of oral CEEs and MPA compared to placebo. The study was prematurely terminated when previously unexpected risks were discovered, specifically the finding that though the all-cause mortality was not affected by the hormone therapy, the benefits of menopausal hormone therapy (reduced risk of hip fracture, colorectal and endometrial cancer and all other causes of death) were offset by increased risk of coronary heart disease, breast cancer, strokes and pulmonary embolism.<span class="mw-ref" id="cite_ref-90"><a href="#cite_note-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> However, the study focused on MPA only and extrapolated the benefits versus risks to all progestogens – a conclusion that has been challenged by several researchers as unjustified and leading to unnecessary avoidance of HRT for many women as progestogens are not alike.<span class="mw-ref" id="cite_ref-91"><a href="#cite_note-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span></p>

<p>When combined with CEEs, MPA has been associated with an increased risk of breast cancer, dementia, and thrombus in the eye. In combination with estrogens in general, MPA may increase the risk of cardiovascular disease, with a stronger association when used by postmenopausal women also taking CEEs. It was because of these unexpected interactions that the Women's Health Initiative study was ended early due the extra risks of menopausal hormone therapy,<span class="mw-ref" id="cite_ref-92"><a href="#cite_note-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span> resulting in a dramatic decrease in both new and renewal prescriptions for hormone therapy.<span class="mw-ref" id="cite_ref-93"><a href="#cite_note-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span></p>

<p>Long-term studies of users of DMPA have found slight or no increased overall risk of breast cancer. However, the study population did show a slightly increased risk of breast cancer in recent users (DMPA use in the last four years) under age 35, similar to that seen with the use of combined oral contraceptive pills.<span class="mw-ref" id="cite_ref-depo_us_patient_info_76-1"><a href="#cite_note-depo_us_patient_info-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span></p>

<span>
</span><table class="wikitable mw-collapsible mw-collapsed" style="font-size: small; margin-left: auto; margin-right: auto; border: none; text-align:center;">
<caption class="nowrap"> <span style="font-family:sans-serif;font-size:105%;color:black;background-color:transparent;;">Results of the Women's Health Initiative (WHI) menopausal hormone therapy randomized controlled trials</span></caption>
<tbody><tr><th rowspan="2">Clinical outcome</th>
<th rowspan="2">Hypothesized <br>effect on risk</th>
<th colspan="3">Estrogen and progestogen<br>(<abbr>CEs</abbr> 0.625<span>&nbsp;</span>mg/day p.o. + <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate"><abbr>MPA</abbr></a> 2.5<span>&nbsp;</span>mg/day p.o.)<br>(n = 16,608, with uterus, 5.2–5.6 years follow up)</th>
<th colspan="3">Estrogen alone<br>(<abbr>CEs</abbr> 0.625<span>&nbsp;</span>mg/day p.o.)<br>(n = 10,739, no uterus, 6.8–7.1 years follow up)</th></tr>
<tr>
<th width="100px"><abbr>HR</abbr></th>
<th width="100px">95% <abbr>CI</abbr></th>
<th width="100px"><abbr>AR</abbr></th>
<th width="100px"><abbr>HR</abbr></th>
<th width="100px">95% <abbr>CI</abbr></th>
<th width="100px "><abbr>AR</abbr></th></tr>
<tr>
<td style="text-align: left;">Coronary heart disease</td>
<td>Decreased</td>
<td style="background: #ffcccb;">1.24</td>
<td>1.00–1.54</td>
<td style="background: #ffcccb;">+6 / 10,000 PYs</td>
<td style="background: #cffbd4;">0.95</td>
<td>0.79–1.15</td>
<td style="background: #cffbd4;">−3 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Stroke</td>
<td>Decreased</td>
<td style="background: #ffcccb;">1.31</td>
<td>1.02–1.68</td>
<td style="background: #ffcccb;">+8 / 10,000 PYs</td>
<td style="background: #ffcccb;">1.37</td>
<td>1.09–1.73</td>
<td style="background: #ffcccb;">+12 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Pulmonary embolism</td>
<td>Increased</td>
<td style="background: #ffcccb;">2.13</td>
<td>1.45–3.11</td>
<td style="background: #ffcccb;">+10 / 10,000 PYs</td>
<td style="background: #ffcccb;">1.37</td>
<td>0.90–2.07</td>
<td style="background: #ffcccb;">+4 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Venous thromboembolism</td>
<td>Increased</td>
<td style="background: #ffcccb;">2.06</td>
<td>1.57–2.70</td>
<td style="background: #ffcccb;">+18 / 10,000 PYs</td>
<td style="background: #ffcccb;">1.32</td>
<td>0.99–1.75</td>
<td style="background: #ffcccb;">+8 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Breast cancer</td>
<td>Increased</td>
<td style="background: #ffcccb;">1.24</td>
<td>1.02–1.50</td>
<td style="background: #ffcccb;">+8 / 10,000 PYs</td>
<td style="background: #cffbd4;">0.80</td>
<td>0.62–1.04</td>
<td style="background: #cffbd4;">−6 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Colorectal cancer</td>
<td>Decreased</td>
<td style="background: #cffbd4;">0.56</td>
<td>0.38–0.81</td>
<td style="background: #cffbd4;">−7 / 10,000 PYs</td>
<td style="background: #ffcccb;">1.08</td>
<td>0.75–1.55</td>
<td style="background: #ffcccb;">+1 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Endometrial cancer</td>
<td>–</td>
<td style="background: #cffbd4;">0.81</td>
<td>0.48–1.36</td>
<td style="background: #cffbd4;">−1 / 10,000 PYs</td>
<td>–</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td style="text-align: left;">Hip fractures</td>
<td>Decreased</td>
<td style="background: #cffbd4;">0.67</td>
<td>0.47–0.96</td>
<td style="background: #cffbd4;">−5 / 10,000 PYs</td>
<td style="background: #cffbd4;">0.65</td>
<td>0.45–0.94</td>
<td style="background: #cffbd4;">−7 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Total fractures</td>
<td>Decreased</td>
<td style="background: #cffbd4;">0.76</td>
<td>0.69–0.83</td>
<td style="background: #cffbd4;">−47 / 10,000 PYs</td>
<td style="background: #cffbd4;">0.71</td>
<td>0.64–0.80</td>
<td style="background: #cffbd4;">−53 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Total mortality</td>
<td>Decreased</td>
<td style="background: #cffbd4;">0.98</td>
<td>0.82–1.18</td>
<td style="background: #cffbd4;">−1 / 10,000 PYs</td>
<td style="background: #ffcccb;">1.04</td>
<td>0.91–1.12</td>
<td style="background: #ffcccb;">+3 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Global index</td>
<td>–</td>
<td style="background: #ffcccb;">1.15</td>
<td>1.03–1.28</td>
<td style="background: #ffcccb;">+19 / 10,000 PYs</td>
<td style="background: #ffcccb;">1.01</td>
<td>1.09–1.12</td>
<td style="background: #ffcccb;">+2 / 10,000 PYs</td></tr>
<tr>
<td style="text-align: left;">Diabetes</td>
<td>–</td>
<td style="background: #cffbd4;">0.79</td>
<td>0.67–0.93</td>
<td></td>
<td style="background: #cffbd4;">0.88</td>
<td>0.77–1.01</td>
<td></td></tr>
<tr>
<td style="text-align: left;">Gallbladder disease</td>
<td>Increased</td>
<td style="background: #ffcccb;">1.59</td>
<td>1.28–1.97</td>
<td></td>
<td style="background: #ffcccb;">1.67</td>
<td>1.35–2.06</td>
<td></td></tr>
<tr>
<td style="text-align: left;">Stress incontinence</td>
<td>–</td>
<td style="background: #ffcccb;">1.87</td>
<td>1.61–2.18</td>
<td></td>
<td style="background: #ffcccb;">2.15</td>
<td>1.77–2.82</td>
<td></td></tr>
<tr>
<td style="text-align: left;">Urge incontinence</td>
<td>–</td>
<td style="background: #ffcccb;">1.15</td>
<td>0.99–1.34</td>
<td></td>
<td style="background: #ffcccb;">1.32</td>
<td>1.10–1.58</td>
<td></td></tr>
<tr>
<td style="text-align: left;">Peripheral artery disease</td>
<td>–</td>
<td style="background: #cffbd4;">0.89</td>
<td>0.63–1.25</td>
<td></td>
<td style="background: #ffcccb;">1.32</td>
<td>0.99–1.77</td>
<td></td></tr>
<tr>
<td style="text-align: left;">Probable dementia</td>
<td>Decreased</td>
<td style="background: #ffcccb;">2.05</td>
<td>1.21–3.48</td>
<td></td>
<td style="background: #ffcccb;">1.49</td>
<td>0.83–2.66</td>
<td></td></tr>
<tr>
<td colspan="8" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Abbreviations:</b> CEs = conjugated estrogens. MPA = <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a>. p.o. = per oral. HR = hazard ratio. AR = attributable risk. PYs = person–years. CI = confidence interval.  <b>Notes:</b> Sample sizes (n) include placebo recipients, which were about half of patients. "Global index" is defined for each woman as the time to earliest diagnosis for coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer (estrogen plus progestogen group only), hip fractures, and death from other causes. <b>Sources:</b> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Blood_clots">Blood clots</h4></summary>
    
<p>DMPA has been associated in multiple studies with a higher risk of venous thromboembolism (VTE) when used as a form of progestogen-only birth control in premenopausal women.<span class="mw-ref" id="cite_ref-pmid30008249_94-0"><a href="#cite_note-pmid30008249-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-pmid21559819_95-0"><a href="#cite_note-pmid21559819-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span><span class="mw-ref" id="cite_ref-ManthaKarp2012_96-0"><a href="#cite_note-ManthaKarp2012-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span><span class="mw-ref" id="cite_ref-pmid30741807_97-0"><a href="#cite_note-pmid30741807-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span> The increase in incidence of VTE ranges from 2.2-fold to 3.6-fold.<span class="mw-ref" id="cite_ref-pmid30008249_94-1"><a href="#cite_note-pmid30008249-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-pmid21559819_95-1"><a href="#cite_note-pmid21559819-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span><span class="mw-ref" id="cite_ref-ManthaKarp2012_96-1"><a href="#cite_note-ManthaKarp2012-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span><span class="mw-ref" id="cite_ref-pmid30741807_97-1"><a href="#cite_note-pmid30741807-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span> Elevated risk of VTE with DMPA is unexpected, as DMPA has little or no effect on coagulation and fibrinolytic factors,<span class="mw-ref" id="cite_ref-Van_Hylckama_VliegMiddeldorp2011_98-0"><a href="#cite_note-Van_Hylckama_VliegMiddeldorp2011-98" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span><span class="mw-ref" id="cite_ref-BenagianoPrimiero1983_99-0"><a href="#cite_note-BenagianoPrimiero1983-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span> and progestogens by themselves normally do not increase the risk of thrombosis.<span class="mw-ref" id="cite_ref-pmid21559819_95-2"><a href="#cite_note-pmid21559819-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span><span class="mw-ref" id="cite_ref-ManthaKarp2012_96-2"><a href="#cite_note-ManthaKarp2012-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span> It has been argued that the higher incidence with DMPA has reflected preferential prescription of DMPA to women considered to be at an increased risk of VTE.<span class="mw-ref" id="cite_ref-pmid21559819_95-3"><a href="#cite_note-pmid21559819-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span> Alternatively, it is possible that MPA may be an exception among progestins in terms of VTE risk.<span class="mw-ref" id="cite_ref-pmid30669160_100-0"><a href="#cite_note-pmid30669160-100" style="counter-reset: mw-Ref 100;"><span class="mw-reflink-text">[100]</span></a></span><span class="mw-ref" id="cite_ref-pmid29570359_101-0"><a href="#cite_note-pmid29570359-101" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span><span class="mw-ref" id="cite_ref-pmid21538049_102-0"><a href="#cite_note-pmid21538049-102" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span> A 2018 meta-analysis reported that MPA was associated with a 2.8-fold higher risk of VTE than other progestins.<span class="mw-ref" id="cite_ref-pmid29570359_101-1"><a href="#cite_note-pmid29570359-101" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span> It is possible that the glucocorticoid activity of MPA may increase the risk of VTE.<span class="mw-ref" id="cite_ref-pmid16112947_3-10"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Kuhl2011_103-0"><a href="#cite_note-Kuhl2011-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span><span class="mw-ref" id="cite_ref-pmid21538049_102-1"><a href="#cite_note-pmid21538049-102" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Bone_density">Bone density</h4></summary>
    
<p>DMPA may cause reduced bone density in premenopausal women and in men when used without an estrogen, particularly at high doses, though this appears to be reversible to a normal level even after years of use.</p>

<p>On November 17, 2004, the United States Food and Drug Administration put a black box warning on the label, indicating that there were potential adverse effects of loss of bone mineral density.<span class="mw-ref" id="cite_ref-104"><a href="#cite_note-104" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></span><span class="mw-ref" id="cite_ref-FDA2004-Warning_105-0"><a href="#cite_note-FDA2004-Warning-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span> While it causes temporary bone loss, most women fully regain their bone density after discontinuing use.<span class="mw-ref" id="cite_ref-Nelson2014_78-1"><a href="#cite_note-Nelson2014-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span> The World Health Organization (WHO) recommends that the use not be restricted.<span class="mw-ref" id="cite_ref-WHO2005_106-0"><a href="#cite_note-WHO2005-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span><span class="mw-ref" id="cite_ref-Contraception2006-Curtis_107-0"><a href="#cite_note-Contraception2006-Curtis-107" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></span> The American College of Obstetricians and Gynecologists notes that the potential adverse effects on BMD be balanced against the known negative effects of unintended pregnancy using other birth control methods or no method, particularly among adolescents.</p>

<p>Three studies have suggested that bone loss is reversible after the discontinuation of DMPA.<span class="mw-ref" id="cite_ref-108"><a href="#cite_note-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Scholes2002_109-0"><a href="#cite_note-Scholes2002-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span><span class="mw-ref" id="cite_ref-Scholes2005_110-0"><a href="#cite_note-Scholes2005-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span> Other studies have suggested that the effect of DMPA use on postmenopausal bone density is minimal,<span class="mw-ref" id="cite_ref-111"><a href="#cite_note-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> perhaps because DMPA users experience less bone loss at menopause.<span class="mw-ref" id="cite_ref-112"><a href="#cite_note-112" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span> Use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density.<span class="mw-ref" id="cite_ref-113"><a href="#cite_note-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span></p>

<p>The FDA recommends that DMPA not be used for longer than 2 years, unless there is no viable alternative method of contraception, due to concerns over bone loss.<span class="mw-ref" id="cite_ref-FDA2004-Warning_105-1"><a href="#cite_note-FDA2004-Warning-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span> However, a 2008 Committee Opinion from the American Congress of Obstetricians and Gynecologists (ACOG) advises healthcare providers that concerns about bone mineral density loss should neither prevent the prescription of or continuation of DMPA beyond 2 years of use.<span class="mw-ref" id="cite_ref-pmid18757687_114-0"><a href="#cite_note-pmid18757687-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="HIV_risk">HIV risk</h3></summary>
    
<p>There is uncertainty regarding the risk of HIV acquisition among DMPA users; some observational studies suggest an increased risk of HIV acquisition among women using DMPA, while others do not.<span class="mw-ref" id="cite_ref-115"><a href="#cite_note-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> The World Health Organization issued statements in February 2012 and July 2014 saying the data did not warrant changing their recommendation of no restriction – Medical Eligibility for Contraception (MEC) category 1 – on the use of DMPA in women at high risk for HIV.<span class="mw-ref" id="cite_ref-116"><a href="#cite_note-116" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></span><span class="mw-ref" id="cite_ref-117"><a href="#cite_note-117" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></span> Two meta-analyses of observational studies in sub-Saharan Africa were published in January 2015.<span class="mw-ref" id="cite_ref-118"><a href="#cite_note-118" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span> They found a 1.4- to 1.5-fold increase risk of HIV acquisition for DMPA users relative to no hormonal contraceptive use.<span class="mw-ref" id="cite_ref-119"><a href="#cite_note-119" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></span><span class="mw-ref" id="cite_ref-120"><a href="#cite_note-120" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span> In January 2015, the Faculty of Sexual &amp; Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists issued a statement reaffirming that there is no reason to advise against use of DMPA in the United Kingdom even for women at 'high risk' of HIV infection.<span class="mw-ref" id="cite_ref-121"><a href="#cite_note-121" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span> A systematic review and meta-analysis of risk of HIV infection in DMPA users published in fall of 2015 stated that "the epidemiological and biological evidence now make a compelling case that DMPA adds significantly to the risk of male-to-female HIV transmission."<span class="mw-ref" id="cite_ref-pmid26710371_122-0"><a href="#cite_note-pmid26710371-122" style="counter-reset: mw-Ref 122;"><span class="mw-reflink-text">[122]</span></a></span> In 2019, a randomized controlled trial found no significant association between DMPA use and HIV.<span class="mw-ref" id="cite_ref-ECHO2019_123-0"><a href="#cite_note-ECHO2019-123" style="counter-reset: mw-Ref 123;"><span class="mw-reflink-text">[123]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Breastfeeding">Breastfeeding</h2></summary>
    
<p>MPA may be used by breastfeeding mothers. Heavy bleeding is possible if given in the immediate postpartum time and is best delayed until six weeks after birth. It may be used within five days if not breast feeding. While a study showed "no significant difference in birth weights or incidence of birth defects" and "no significant alternation of immunity to infectious disease caused by breast milk containing DMPA", a subgroup of babies whose mothers started DMPA at 2 days postpartum had a 75% higher incidence of doctor visits for infectious diseases during their first year of life.<span class="mw-ref" id="cite_ref-124"><a href="#cite_note-124" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></span></p>

<p>A larger study with longer follow-up concluded that "use of DMPA during pregnancy or breastfeeding does not adversely affect the long-term growth and development of children". This study also noted that "children with DMPA exposure during pregnancy and lactation had an increased risk of suboptimal growth in height," but that "after adjustment for socioeconomic factors by multiple logistic regression, there was no increased risk of impaired growth among the DMPA-exposed children." The study also noted that effects of DMPA exposure on puberty require further study, as so few children over the age of 10 were observed.<span class="mw-ref" id="cite_ref-125"><a href="#cite_note-125" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    
<p>MPA has been studied at "massive" dosages of up to 5,000<span>&nbsp;</span>mg per day orally and 2,000<span>&nbsp;</span>mg per day via intramuscular injection, without major tolerability or safety issues described.<span class="mw-ref" id="cite_ref-pmid1390312_126-0"><a href="#cite_note-pmid1390312-126" style="counter-reset: mw-Ref 126;"><span class="mw-reflink-text">[126]</span></a></span><span class="mw-ref" id="cite_ref-pmid350387_127-0"><a href="#cite_note-pmid350387-127" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></span><span class="mw-ref" id="cite_ref-pmid9452274_128-0"><a href="#cite_note-pmid9452274-128" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> Overdose is not described in the Food and Drug Administration (FDA) product labels for injected MPA (Depo-Provera or Depo-SubQ Provera 104).<span class="mw-ref" id="cite_ref-DepoProveraLabel_7-1"><a href="#cite_note-DepoProveraLabel-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-DepoSubQProveraLabel_8-1"><a href="#cite_note-DepoSubQProveraLabel-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> In the FDA product label for oral MPA (Provera), it is stated that overdose of an estrogen and progestin may cause nausea and vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and withdrawal bleeding.<span class="mw-ref" id="cite_ref-ProveraLabel_5-3"><a href="#cite_note-ProveraLabel-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> According to the label, treatment of overdose should consist of discontinuation of MPA therapy and symptomatic care.<span class="mw-ref" id="cite_ref-ProveraLabel_5-4"><a href="#cite_note-ProveraLabel-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>MPA increases the risk of breast cancer, dementia, and thrombus when used in combination with CEEs to treat menopausal symptoms.<span class="mw-ref" id="cite_ref-Merck_74-1"><a href="#cite_note-Merck-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> When used as a contraceptive, MPA does not generally interact with other medications. The combination of MPA with <a href="Aminoglutethimide.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoglutethimide" title="Aminoglutethimide">aminoglutethimide</a> to treat metastases from breast cancer has been associated with an increase in depression.<span class="mw-ref" id="cite_ref-Meyler_32-3"><a href="#cite_note-Meyler-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> St John's wort may decrease the effectiveness of MPA as a contraceptive due to acceleration of its metabolism.<span class="mw-ref" id="cite_ref-Merck_74-2"><a href="#cite_note-Merck-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    
<p>MPA acts as an agonist of the progesterone, androgen, and glucocorticoid receptors (PR, AR, and GR, respectively),<span class="mw-ref" id="cite_ref-pmid19434889_4-2"><a href="#cite_note-pmid19434889-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> activating these receptors with EC<sub>50</sub> values of approximately 0.01 nM, 1 nM, and 10 nM, respectively.<span class="mw-ref" id="cite_ref-Organization2004_129-0"><a href="#cite_note-Organization2004-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span> It has negligible affinity for the estrogen receptor.<span class="mw-ref" id="cite_ref-pmid19434889_4-3"><a href="#cite_note-pmid19434889-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> The medication has relatively high affinity for the mineralocorticoid receptor, but in spite of this, it has no mineralocorticoid or antimineralocorticoid activity.<span class="mw-ref" id="cite_ref-pmid16112947_3-11"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> The intrinsic activities of MPA in activating the PR and the AR have been reported to be at least equivalent to those of progesterone and <a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT), respectively, indicating that it is a full agonist of these receptors.<span class="mw-ref" id="cite_ref-pmid10077001_12-1"><a href="#cite_note-pmid10077001-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-pmid10509795_130-0"><a href="#cite_note-pmid10509795-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span></p>

<table class="wikitable center sortable mw-collapsible mw-collapsed" style="width:475px; text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap">Relative affinities (%) of MPA and related steroids</caption>
<tbody><tr>
<th><center><b>Progestogen</b></center></th><th><b><abbr>PR</abbr></b></th><th><b><abbr>AR</abbr></b></th><th><b><abbr>ER</abbr></b></th><th><b><abbr>GR</abbr></b></th><th><b><abbr>MR</abbr></b></th></tr>
<tr>
<td>Progesterone</td><td>50</td><td>0</td><td>0</td><td>10</td><td>100</td></tr>
<tr>
<td>Chlormadinone acetate</td><td>67</td><td>5</td><td>0</td><td>8</td><td>0</td></tr>
<tr>
<td>Cyproterone acetate</td><td>90</td><td>6</td><td>0</td><td>6</td><td>8</td></tr>
<tr>
<td>Medroxyprogesterone acetate</td><td>115</td><td>5</td><td>0</td><td>29</td><td>160</td></tr>
<tr>
<td>Megestrol acetate</td><td>65</td><td>5</td><td>0</td><td>30</td><td>0</td></tr>
<tr class="sortbottom">
<td colspan="6" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Notes:</b> Values are percentages (%). Reference ligands (100%) were <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">promegestone</a> for the <abbr>PR</abbr>, <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">metribolone</a> for the <abbr>AR</abbr>, estradiol for the <abbr>ER</abbr>, <a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">dexamethasone</a> for the <abbr>GR</abbr>, and <a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">aldosterone</a> for the <abbr>MR</abbr>. <b>Sources:</b> <span class="mw-ref" id="cite_ref-pmid16112947_3-12"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Progestogenic_activity">Progestogenic activity</h4></summary>
    
<p>MPA is a potent agonist of the progesterone receptor with similar affinity and efficacy relative to progesterone.<span class="mw-ref" id="cite_ref-pmid16784762_131-0"><a href="#cite_note-pmid16784762-131" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span> While both MPA and its deacetylated analogue <a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">medroxyprogesterone</a> bind to and agonize the PR, MPA has approximately 100-fold higher binding affinity and transactivation potency in comparison.<span class="mw-ref" id="cite_ref-pmid16784762_131-1"><a href="#cite_note-pmid16784762-131" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span> As such, unlike MPA, medroxyprogesterone is not used clinically, though it has seen some use in veterinary medicine.<span class="mw-ref" id="cite_ref-IndexNominum2000_2-1"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> The oral dosage of MPA required to inhibit ovulation (i.e., the effective contraceptive dosage) is 10<span>&nbsp;</span>mg/day, whereas 5<span>&nbsp;</span>mg/day was not sufficient to inhibit ovulation in all women.<span class="mw-ref" id="cite_ref-pmid6233840_132-0"><a href="#cite_note-pmid6233840-132" style="counter-reset: mw-Ref 132;"><span class="mw-reflink-text">[132]</span></a></span> In accordance, the dosage of MPA used in oral contraceptives in the past was 10<span>&nbsp;</span>mg per tablet.<span class="mw-ref" id="cite_ref-Blum2013_133-0"><a href="#cite_note-Blum2013-133" style="counter-reset: mw-Ref 133;"><span class="mw-reflink-text">[133]</span></a></span> For comparison to MPA, the dosage of progesterone required to inhibit ovulation is 300<span>&nbsp;</span>mg/day, whereas that of the <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/19-nortestosterone" title="19-nortestosterone" class="mw-redirect">19-nortestosterone</a> derivatives <a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">norethisterone</a> and norethisterone acetate is only 0.4 to 0.5<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-SchindlerCampagnoli2003_134-0"><a href="#cite_note-SchindlerCampagnoli2003-134" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></span></p>

<p>The mechanism of action of progestogen-only contraceptives like DMPA depends on the progestogen activity and dose. High-dose progestogen-only contraceptives, such as DMPA, inhibit follicular development and prevent ovulation as their primary mechanism of action.<span class="mw-ref" id="cite_ref-glasier_135-0"><a href="#cite_note-glasier-135" style="counter-reset: mw-Ref 135;"><span class="mw-reflink-text">[135]</span></a></span><span class="mw-ref" id="cite_ref-loose_136-0"><a href="#cite_note-loose-136" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span> The progestogen decreases the pulse frequency of <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">gonadotropin-releasing hormone</a> (GnRH) release by the hypothalamus, which decreases the release of follicle-stimulating hormone (FSH) and <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> (LH) by the anterior pituitary. Decreased levels of FSH inhibit follicular development, preventing an increase in <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a> levels. Progestogen negative feedback and the lack of <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogen</a> positive feedback on LH release prevent a LH surge. Inhibition of follicular development and the absence of a LH surge prevent ovulation.<span class="mw-ref" id="cite_ref-hatcher_51-2"><a href="#cite_note-hatcher-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-speroff_52-2"><a href="#cite_note-speroff-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> A secondary mechanism of action of all progestogen-containing contraceptives is inhibition of sperm penetration by changes in the cervical mucus.<span class="mw-ref" id="cite_ref-rivera_137-0"><a href="#cite_note-rivera-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span> Inhibition of ovarian function during DMPA use causes the endometrium to become thin and atrophic. These changes in the endometrium could, theoretically, prevent implantation. However, because DMPA is highly effective in inhibiting ovulation and sperm penetration, the possibility of fertilization is negligible. No available data support prevention of implantation as a mechanism of action of DMPA.<span class="mw-ref" id="cite_ref-rivera_137-1"><a href="#cite_note-rivera-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span></p>

<table class="wikitable sortable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap">MPA and related steroids at the progesterone receptor</caption>
<tbody><tr>
<th>Compound</th><th><abbr>K<sub>i</sub></abbr> (nM)</th><th><abbr>EC<sub>50</sub></abbr> (nM)<sup>a</sup></th><th><abbr>EC<sub>50</sub></abbr> (nM)<sup>b</sup></th></tr>
<tr>
<td>Progesterone</td><td>4.3</td><td>0.9</td><td>25</td></tr>
<tr>
<td><a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">Medroxyprogesterone</a></td><td>241</td><td>47</td><td>32</td></tr>
<tr>
<td>Medroxyprogesterone acetate</td><td>1.2</td><td>0.6</td><td>0.15</td></tr>
<tr class="sortbottom">
<td colspan="4" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Coactivator recruitment. <sup>b</sup> = Reporter cell line. <b>Sources:</b> <span class="mw-ref" id="cite_ref-pmid16784762_131-2"><a href="#cite_note-pmid16784762-131" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span></td></tr>
</tbody></table>

<table class="wikitable center sortable mw-collapsible mw-collapsed" style="width:650px; text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap">Oral potencies of MPA and related steroids</caption>
<tbody><tr>
<th>Progestogen</th><th><abbr>OID</abbr><br><small>(mg/day)</small></th><th><abbr>TFD</abbr><br><small>(mg/cycle)</small></th><th><abbr>TFD</abbr><br><small>(mg/day)</small></th><th><abbr>ODP</abbr><br><small>(mg/day)</small></th><th><abbr>ECD</abbr><br><small>(mg/day)</small></th></tr>
<tr>
<td>Progesterone</td><td>300</td><td>4200</td><td>200–300</td><td>–</td><td>200</td></tr>
<tr>
<td>Chlormadinone acetate</td><td>1.7</td><td>20–30</td><td>10</td><td>2.0</td><td>5–10</td></tr>
<tr>
<td>Cyproterone acetate</td><td>1.0</td><td>20</td><td>1.0</td><td>2.0</td><td>1.0</td></tr>
<tr>
<td>Medroxyprogesterone acetate</td><td>10</td><td>50</td><td>5–10</td><td>?</td><td>5.0</td></tr>
<tr>
<td>Megestrol acetate</td><td>?</td><td>50</td><td>?</td><td>?</td><td>5.0</td></tr>
<tr class="sortbottom">
<td colspan="6" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Abbreviations:</b> OID = ovulation-inhibiting dosage (without additional estrogen). TFD = endometrial transformation dosage. ODP = oral dosage in commercial contraceptive preparations. ECD = estimated comparable dosage. <b>Sources:</b> <span class="mw-ref" id="cite_ref-SchindlerCampagnoli2003_134-1"><a href="#cite_note-SchindlerCampagnoli2003-134" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></span><span class="mw-ref" id="cite_ref-Kuhl2011_103-1"><a href="#cite_note-Kuhl2011-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span><span class="mw-ref" id="cite_ref-FritzSperoff2012_138-0"><a href="#cite_note-FritzSperoff2012-138" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span></td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="font-size:small; margin: 1em auto;">
<caption class="nowrap"> <span style="font-family:sans-serif;font-size:105%;color:black;background-color:transparent;;">Parenteral potencies and durations of progestogens</span></caption>
<tbody><tr>
<th>Progestogen</th><th>Form</th><th>Major brand names</th><th>Class</th><th data-sort-type="number"><abbr>TFD</abbr><br><small>(14 days)</small></th><th style="white-space: nowrap;" data-sort-type="number"><abbr>POIC-D</abbr><br><small>(2–3 months)</small></th><th data-sort-type="number"><abbr>CIC-D</abbr><br><small>(month)</small></th><th data-sort-type="number">Duration</th></tr>
<tr>
<td>Algestone acetophenide</td><td>Oil solution</td><td>Perlutal, Topasel, Yectames</td><td>Pregnane</td><td>?</td><td>–</td><td>75–150 mg</td><td>100 mg ≈ 14–32 days</td></tr>
<tr>
<td>Cyproterone acetate</td><td>Oil solution</td><td>Androcur Depot</td><td>Pregnane</td><td>?</td><td>–</td><td>–</td><td>300 mg ≈ 20 days</td></tr>
<tr>
<td><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a><sup>a</sup></td><td>Aqueous suspension</td><td>–</td><td>Retropregnane</td><td>?</td><td>–</td><td>–</td><td>100 mg ≈ 16–38 days</td></tr>
<tr>
<td>Gestonorone caproate</td><td>Oil solution</td><td>Depostat, Primostat</td><td>Norpregnane</td><td>25–50 mg</td><td>–</td><td>–</td><td>25–50 mg ≈ 8–13 days</td></tr>
<tr>
<td>Hydroxyprogesterone acetate<sup>a</sup></td><td>Aqueous suspension</td><td>–</td><td>Pregnane</td><td>350 mg</td><td>–</td><td>–</td><td>150–350 mg ≈ 9–16 days</td></tr>
<tr>
<td>Hydroxyprogesterone caproate</td><td>Oil solution</td><td>Delalutin, Proluton, Makena</td><td>Pregnane</td><td style="white-space: nowrap;">250–500 mg<sup>b</sup></td><td>–</td><td style="white-space: nowrap;">250–500 mg</td><td>65–500 mg ≈ 5–21 days</td></tr>
<tr>
<td>Levonorgestrel butanoate<sup>a</sup></td><td>Aqueous suspension</td><td>–</td><td>Gonane</td><td>?</td><td>–</td><td>–</td><td>5–50 mg ≈ 3–6 months</td></tr>
<tr>
<td>Lynestrenol phenylpropionate<sup>a</sup></td><td>Oil solution</td><td>–</td><td>Estrane</td><td>?</td><td>–</td><td>–</td><td>50–100 mg ≈ 14–30 days</td></tr>
<tr>
<td>Medroxyprogesterone acetate</td><td>Aqueous suspension</td><td>Depo-Provera</td><td>Pregnane</td><td>50–100 mg</td><td>150 mg</td><td>25 mg</td><td style="white-space: nowrap;">50–150 mg ≈ 14–50+ days</td></tr>
<tr>
<td>Megestrol acetate</td><td>Aqueous suspension</td><td>Mego-E</td><td>Pregnane</td><td>?</td><td>–</td><td>25 mg</td><td>25 mg ≈ &gt;14 days<sup>c</sup></td></tr>
<tr>
<td>Norethisterone enanthate</td><td>Oil solution</td><td>Noristerat, Mesigyna</td><td>Estrane</td><td>100–200 mg</td><td>200 mg</td><td>50 mg</td><td>50–200 mg ≈ 11–52 days</td></tr>
<tr>
<td>Oxogestone phenylpropionate<sup>a</sup></td><td>Oil solution</td><td>–</td><td>Norpregnane</td><td>?</td><td>–</td><td>–</td><td>100 mg ≈ 19–20 days</td></tr>
<tr>
<td rowspan="2">Progesterone</td><td>Oil solution</td><td>Progestaject, Gestone, Strone</td><td>Pregnane</td><td>200 mg<sup>b</sup></td><td>–</td><td>–</td><td>25–350 mg ≈ 2–6 days</td></tr>
<tr>
<td>Aqueous suspension</td><td>Agolutin Depot</td><td>Pregnane</td><td>50–200 mg</td><td>–</td><td>–</td><td>50–300 mg ≈ 7–14 days</td></tr>
<tr class="sortbottom">
<td colspan="9" style="width: 1px; background-color:#eaecf0; background-color:#eaecf0; text-align: center;"><b>Note:</b> All by intramuscular or subcutaneous injection. All are synthetic except for <a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone"><abbr>P4</abbr></a>, which is bioidentical. <abbr>P4</abbr> production during the luteal phase is ~25<span>&nbsp;</span>(15–50)<span>&nbsp;</span>mg/day. The <abbr>OID</abbr> of OHPC is 250 to 500<span>&nbsp;</span>mg/month. <b>Footnotes:</b> <sup>a</sup> = Never marketed by this route. <sup>b</sup> = In divided doses (2 × 125 or 250<span>&nbsp;</span>mg for <abbr>OHPC</abbr>, 10 × 20<span>&nbsp;</span>mg for <abbr>P4</abbr>). <sup>c</sup> = Half-life is ~14 days. <b>Sources:</b> <i>Main:</i> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Antigonadotropic_and_anticorticotropic_effects">Antigonadotropic and anticorticotropic effects</h4></summary>
    
<p>MPA suppresses the hypothalamic–pituitary–adrenal (HPA) and hypothalamic–pituitary–gonadal (HPG) axes at sufficient dosages, resulting decreased levels of gonadotropins, androgens, <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogens</a>, <a href="Adrenocorticotropic_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenocorticotropic_hormone" title="Adrenocorticotropic hormone">adrenocorticotropic hormone</a> (ACTH), and <a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">cortisol</a>, as well as levels of sex hormone-binding globulin (SHBG).<span class="mw-ref" id="cite_ref-Genazzani1993_13-1"><a href="#cite_note-Genazzani1993-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> There is evidence that the suppressive effects of MPA on the HPG axis are mediated by activation of both the PR and the AR in the pituitary gland.<span class="mw-ref" id="cite_ref-pmid2525057_139-0"><a href="#cite_note-pmid2525057-139" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span><span class="mw-ref" id="cite_ref-pmid12641635_140-0"><a href="#cite_note-pmid12641635-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span> Due to its effects on androgen levels, MPA can produce strong functional antiandrogenic effects, and is used in the treatment of androgen-dependent conditions such as precocious puberty in boys and hypersexuality in men.<span class="mw-ref" id="cite_ref-SalehGrudzinskas2009_141-0"><a href="#cite_note-SalehGrudzinskas2009-141" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span> In addition, since the medication suppresses estrogen levels as well, MPA can produce strong functional antiestrogenic effects similarly, and has been used to treat estrogen-dependent conditions such as precocious puberty in girls and endometriosis in women. Due to low estrogen levels, the use of MPA without an estrogen poses a risk of decreased bone mineral density and other symptoms of estrogen deficiency.<span class="mw-ref" id="cite_ref-WHO2008_142-0"><a href="#cite_note-WHO2008-142" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span></p>

<p>Oral MPA has been found to suppress testosterone levels in men by about 30% (from 831<span>&nbsp;</span>ng/dL to 585<span>&nbsp;</span>ng/dL) at a dosage of 20<span>&nbsp;</span>mg/day, by about 45 to 75% (average 60%; to 150–400<span>&nbsp;</span>ng/dL) at a dosage of 60<span>&nbsp;</span>mg/day,<span class="mw-ref" id="cite_ref-Lothstein1996_143-0"><a href="#cite_note-Lothstein1996-143" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span><span class="mw-ref" id="cite_ref-APA1999_144-0"><a href="#cite_note-APA1999-144" style="counter-reset: mw-Ref 144;"><span class="mw-reflink-text">[144]</span></a></span><span class="mw-ref" id="cite_ref-pmid8891323_145-0"><a href="#cite_note-pmid8891323-145" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span> and by about 70 to 75% (from 832–862<span>&nbsp;</span>ng/dL to 214–251<span>&nbsp;</span>ng/dL) at a dosage of 100<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-pmid6449127_146-0"><a href="#cite_note-pmid6449127-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span><span class="mw-ref" id="cite_ref-pmid5066846_147-0"><a href="#cite_note-pmid5066846-147" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span> Dosages of oral MPA of 2.5 to 30<span>&nbsp;</span>mg/day in combination with estrogens have been used to help suppress testosterone levels in transgender women.<span class="mw-ref" id="cite_ref-AsschemanGooren1993_148-0"><a href="#cite_note-AsschemanGooren1993-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span><span class="mw-ref" id="cite_ref-pmid25692882_149-0"><a href="#cite_note-pmid25692882-149" style="counter-reset: mw-Ref 149;"><span class="mw-reflink-text">[149]</span></a></span><span class="mw-ref" id="cite_ref-pmid17986639_150-0"><a href="#cite_note-pmid17986639-150" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span><span class="mw-ref" id="cite_ref-Deutsch2016_151-0"><a href="#cite_note-Deutsch2016-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-DahlFeldman2015_152-0"><a href="#cite_note-DahlFeldman2015-152" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span><span class="mw-ref" id="cite_ref-pmid29756046_153-0"><a href="#cite_note-pmid29756046-153" style="counter-reset: mw-Ref 153;"><span class="mw-reflink-text">[153]</span></a></span> Very high dosages of intramuscular MPA of 150 to 500<span>&nbsp;</span>mg per week (but up to 900<span>&nbsp;</span>mg per week) can suppress testosterone levels to less than 100<span>&nbsp;</span>ng/dL.<span class="mw-ref" id="cite_ref-Lothstein1996_143-1"><a href="#cite_note-Lothstein1996-143" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span><span class="mw-ref" id="cite_ref-MeyerWalker1985_154-0"><a href="#cite_note-MeyerWalker1985-154" style="counter-reset: mw-Ref 154;"><span class="mw-reflink-text">[154]</span></a></span> The typical initial dose of intramuscular MPA for testosterone suppression in men with paraphilias is 400 or 500<span>&nbsp;</span>mg per week.<span class="mw-ref" id="cite_ref-Lothstein1996_143-2"><a href="#cite_note-Lothstein1996-143" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Androgenic_activity">Androgenic activity</h4></summary>
    
<p>MPA is a potent full agonist of the AR. Its activation of the AR may play an important and major role in its antigonadotropic effects and in its beneficial effects against breast cancer.<span class="mw-ref" id="cite_ref-pmid2525057_139-1"><a href="#cite_note-pmid2525057-139" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span><span class="mw-ref" id="cite_ref-pmid10819508_155-0"><a href="#cite_note-pmid10819508-155" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span><span class="mw-ref" id="cite_ref-pmid16166329_156-0"><a href="#cite_note-pmid16166329-156" style="counter-reset: mw-Ref 156;"><span class="mw-reflink-text">[156]</span></a></span> However, although MPA may produce androgenic side effects such as acne and hirsutism in some women,<span class="mw-ref" id="cite_ref-ReesHope2005_157-0"><a href="#cite_note-ReesHope2005-157" style="counter-reset: mw-Ref 157;"><span class="mw-reflink-text">[157]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_158-0"><a href="#cite_note-Aronson2009-158" style="counter-reset: mw-Ref 158;"><span class="mw-reflink-text">[158]</span></a></span> it rarely does so, and when such symptoms occur, they tend to be mild, regardless of the dosage used.<span class="mw-ref" id="cite_ref-pmid2525057_139-2"><a href="#cite_note-pmid2525057-139" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> In fact, likely due to its suppressive actions on androgen levels, it has been reported that MPA is generally highly effective in improving pre-existing symptoms of hirsutism in women with the condition.<span class="mw-ref" id="cite_ref-pmid590535_159-0"><a href="#cite_note-pmid590535-159" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span><span class="mw-ref" id="cite_ref-pmid1200527_160-0"><a href="#cite_note-pmid1200527-160" style="counter-reset: mw-Ref 160;"><span class="mw-reflink-text">[160]</span></a></span> Moreover, MPA rarely causes any androgenic effects in children with precocious puberty, even at very high doses.<span class="mw-ref" id="cite_ref-pmid4332067_161-0"><a href="#cite_note-pmid4332067-161" style="counter-reset: mw-Ref 161;"><span class="mw-reflink-text">[161]</span></a></span> The reason for the general lack of virilizing effects with MPA, despite it binding to and activating the AR with high affinity and this action potentially playing an important role in many of its physiological and therapeutic effects, is not entirely clear. However, MPA has been found to interact with the AR differently compared to other agonists of the receptor such as <a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT).<span class="mw-ref" id="cite_ref-pmid10077001_12-2"><a href="#cite_note-pmid10077001-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> The result of this difference appears to be that MPA binds to the AR with a similar affinity and intrinsic activity to that of DHT, but requires about 100-fold higher concentrations for a comparable induction of gene transcription, while at the same time not antagonizing the transcriptional activity of normal androgens like DHT at any concentration.<span class="mw-ref" id="cite_ref-pmid10077001_12-3"><a href="#cite_note-pmid10077001-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Thus, this may explain the low propensity of MPA for producing androgenic side effects.<span class="mw-ref" id="cite_ref-pmid10077001_12-4"><a href="#cite_note-pmid10077001-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>MPA shows weak androgenic effects on liver protein synthesis, similarly to other weakly androgenic progestins like megestrol acetate and <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/19-nortestosterone" title="19-nortestosterone" class="mw-redirect">19-nortestosterone</a> derivatives.<span class="mw-ref" id="cite_ref-pmid16112947_3-13"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid26291834_6-1"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> While it does not antagonize estrogen-induced increases in levels of triglycerides and HDL cholesterol, DMPA every other week may decrease levels of HDL cholesterol.<span class="mw-ref" id="cite_ref-pmid16112947_3-14"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> In addition, MPA has been found to suppress sex hormone-binding globulin (SHBG) production by the liver.<span class="mw-ref" id="cite_ref-pmid26291834_6-2"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Luciano1992_162-0"><a href="#cite_note-Luciano1992-162" style="counter-reset: mw-Ref 162;"><span class="mw-reflink-text">[162]</span></a></span><span class="mw-ref" id="cite_ref-pmid10914617_163-0"><a href="#cite_note-pmid10914617-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span> At a dosage of 10<span>&nbsp;</span>mg/day oral MPA, it has been found to decrease circulating SHBG levels by 14 to 18% in women taking 4<span>&nbsp;</span>mg/day oral estradiol valerate.<span class="mw-ref" id="cite_ref-pmid26291834_6-3"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Conversely, in a study that combined 2.5<span>&nbsp;</span>mg/day oral MPA with various oral estrogens, no influence of MPA on estrogen-induced increases in SHBG levels was discerned.<span class="mw-ref" id="cite_ref-pmid10914617_163-1"><a href="#cite_note-pmid10914617-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span> In another, higher-dose study, SHBG levels were lower by 59% in a group of women treated with 50<span>&nbsp;</span>mg/day oral MPA alone relative to an untreated control group of women.<span class="mw-ref" id="cite_ref-Luciano1992_162-1"><a href="#cite_note-Luciano1992-162" style="counter-reset: mw-Ref 162;"><span class="mw-reflink-text">[162]</span></a></span></p>

<p>Unlike the related steroids megestrol acetate and cyproterone acetate, MPA is not an antagonist of the AR and does not have direct antiandrogenic activity.<span class="mw-ref" id="cite_ref-pmid16112947_3-15"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> As such, although MPA is sometimes described as an antiandrogen, it is not a "true" antiandrogen (i.e., AR antagonist).<span class="mw-ref" id="cite_ref-APA1999_144-1"><a href="#cite_note-APA1999-144" style="counter-reset: mw-Ref 144;"><span class="mw-reflink-text">[144]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Glucocorticoid_activity">Glucocorticoid activity</h4></summary>
    
<p>As an agonist of the GR, MPA has glucocorticoid activity, and as a result can cause symptoms of Cushing's syndrome,<span class="mw-ref" id="cite_ref-164"><a href="#cite_note-164" style="counter-reset: mw-Ref 164;"><span class="mw-reflink-text">[164]</span></a></span> steroid diabetes, and adrenal insufficiency at sufficiently high doses.<span class="mw-ref" id="cite_ref-165"><a href="#cite_note-165" style="counter-reset: mw-Ref 165;"><span class="mw-reflink-text">[165]</span></a></span> It has been suggested that the glucocorticoid activity of MPA may contribute to bone loss.<span class="mw-ref" id="cite_ref-pmid12181616_166-0"><a href="#cite_note-pmid12181616-166" style="counter-reset: mw-Ref 166;"><span class="mw-reflink-text">[166]</span></a></span> The glucocorticoid activity of MPA may also result in an upregulation of the thrombin receptor in blood vessel walls, which may contribute to procoagulant effects of MPA and risk of venous thromboembolism and atherosclerosis.<span class="mw-ref" id="cite_ref-pmid16112947_3-16"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> The relative glucocorticoid activity of MPA is among the highest of the clinically used progestins.<span class="mw-ref" id="cite_ref-pmid16112947_3-17"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="width:475px; text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> Glucocorticoid activity of selected steroids <i>in vitro</i></caption>
<tbody><tr>
<th>Steroid</th><th>Class</th><th><abbr>TR</abbr> (<abbr>↑</abbr>)<sup>a</sup></th><th><abbr>GR</abbr> (%)<sup>b</sup></th></tr>
<tr>
<td><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></td><td>Corticosteroid</td><td>++</td><td>100</td></tr>
<tr>
<td>Ethinylestradiol</td><td>Estrogen</td><td>–</td><td>0</td></tr>
<tr>
<td><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></td><td>Progestin</td><td>+</td><td>14</td></tr>
<tr>
<td><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></td><td>Progestin</td><td>+</td><td>27</td></tr>
<tr>
<td><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></td><td>Progestin</td><td>–</td><td>1</td></tr>
<tr>
<td>Medroxyprogesterone acetate</td><td>Progestin</td><td>+</td><td>29</td></tr>
<tr>
<td><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone</a></td><td>Progestin</td><td>–</td><td>0</td></tr>
<tr>
<td><a href="Norgestimate.htm" tppabs="https://ptable.com/wiki/compounds/A/Norgestimate" title="Norgestimate">Norgestimate</a></td><td>Progestin</td><td>–</td><td>1</td></tr>
<tr>
<td>Progesterone</td><td>Progestogen</td><td>+</td><td>10</td></tr>
<tr class="sortbottom">
<td colspan="4" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Thrombin receptor (TR) upregulation (↑) in vascular smooth muscle cells (VSMCs). <sup>b</sup> = <abbr>RBA</abbr> (%) for the glucocorticoid receptor (GR). <b>Strength:</b> – = No effect. + = Pronounced effect. ++ = Strong effect. <b>Sources:</b> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Steroidogenesis_inhibition">Steroidogenesis inhibition</h4></summary>
    


<p>MPA has been found to act as a competitive inhibitor of rat 3α-hydroxysteroid dehydrogenase (3α-HSD).<span class="mw-ref" id="cite_ref-pmid6213817_167-0"><a href="#cite_note-pmid6213817-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-pmid2933398_168-0"><a href="#cite_note-pmid2933398-168" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span><span class="mw-ref" id="cite_ref-pmid15181090_169-0"><a href="#cite_note-pmid15181090-169" style="counter-reset: mw-Ref 169;"><span class="mw-reflink-text">[169]</span></a></span><span class="mw-ref" id="cite_ref-pmid18291663_170-0"><a href="#cite_note-pmid18291663-170" style="counter-reset: mw-Ref 170;"><span class="mw-reflink-text">[170]</span></a></span> This enzyme is essential for the transformation of <a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">progesterone</a>, deoxycorticosterone, and DHT into inhibitory neurosteroids such as <a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">allopregnanolone</a>, <abbr>THDOC</abbr>, and 3α-androstanediol, respectively.<span class="mw-ref" id="cite_ref-pmid11750861_171-0"><a href="#cite_note-pmid11750861-171" style="counter-reset: mw-Ref 171;"><span class="mw-reflink-text">[171]</span></a></span> MPA has been described as very potent in its inhibition of rat 3α-HSD, with an IC<sub>50</sub> of 0.2<span>&nbsp;</span>μM and a K<sub>i</sub> (in rat testicular homogenates) of 0.42<span>&nbsp;</span>μM.<span class="mw-ref" id="cite_ref-pmid6213817_167-1"><a href="#cite_note-pmid6213817-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-pmid2933398_168-1"><a href="#cite_note-pmid2933398-168" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span> However, inhibition of 3α-HSD by MPA does not appear to have been confirmed using human proteins yet, and the concentrations required with rat proteins are far above typical human therapeutic concentrations.<span class="mw-ref" id="cite_ref-pmid6213817_167-2"><a href="#cite_note-pmid6213817-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-pmid2933398_168-2"><a href="#cite_note-pmid2933398-168" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span></p>

<p>MPA has been identified as a competitive inhibitor of human 3β-hydroxysteroid dehydrogenase/Δ<sup>5-4</sup> isomerase II (3β-HSD II).<span class="mw-ref" id="cite_ref-pmid10372718_172-0"><a href="#cite_note-pmid10372718-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span> This enzyme is essential for the biosynthesis of sex steroids and corticosteroids.<span class="mw-ref" id="cite_ref-pmid10372718_172-1"><a href="#cite_note-pmid10372718-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span> The K<sub>i</sub> of MPA for inhibition of 3β-HSD II is 3.0<span>&nbsp;</span>μM, and this concentration is reportedly near the circulating levels of the medication that are achieved by very high therapeutic dosages of MPA of 5 to 20<span>&nbsp;</span>mg/kg/day (dosages of 300 to 1,200<span>&nbsp;</span>mg/day for a 60<span>&nbsp;</span>kg (132<span>&nbsp;</span>lb) person).<span class="mw-ref" id="cite_ref-pmid10372718_172-2"><a href="#cite_note-pmid10372718-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span> Aside from 3β-HSD II, other human steroidogenic enzymes, including cholesterol side-chain cleavage enzyme (P450scc/CYP11A1) and 17α-hydroxylase/17,20-lyase (CYP17A1), were not found to be inhibited by MPA.<span class="mw-ref" id="cite_ref-pmid10372718_172-3"><a href="#cite_note-pmid10372718-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span> MPA has been found to be effective in the treatment of gonadotropin-independent precocious puberty and in breast cancer in postmenopausal women at high dosages, and inhibition of 3β-HSD II could be responsible for its effectiveness in these conditions.<span class="mw-ref" id="cite_ref-pmid10372718_172-4"><a href="#cite_note-pmid10372718-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="GABAA_receptor_allosteric_modulation">GABA<sub>A</sub> receptor allosteric modulation</h4></summary>
    
<p>Progesterone, via transformation into neurosteroids such as <a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-dihydroprogesterone" title="5α-dihydroprogesterone" class="mw-redirect">5α-dihydroprogesterone</a>, 5β-dihydroprogesterone, <a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">allopregnanolone</a>, and pregnanolone (catalyzed by the enzymes 5α- and 5β-reductase and 3α- and 3β-HSD), is a positive allosteric modulator of the GABA<sub>A</sub> receptor, and is associated with a variety of effects mediated by this property including dizziness, sedation, hypnotic states, mood changes, anxiolysis, and cognitive/memory impairment, as well as effectiveness as an anticonvulsant in the treatment of catamenial epilepsy.<span class="mw-ref" id="cite_ref-pmid11750861_171-1"><a href="#cite_note-pmid11750861-171" style="counter-reset: mw-Ref 171;"><span class="mw-reflink-text">[171]</span></a></span><span class="mw-ref" id="cite_ref-pmid14644065_173-0"><a href="#cite_note-pmid14644065-173" style="counter-reset: mw-Ref 173;"><span class="mw-reflink-text">[173]</span></a></span> It has also been found to produce anesthesia via this action in animals when administered at sufficiently high dosages.<span class="mw-ref" id="cite_ref-pmid14644065_173-1"><a href="#cite_note-pmid14644065-173" style="counter-reset: mw-Ref 173;"><span class="mw-reflink-text">[173]</span></a></span> MPA was found to significantly reduce seizure incidence when added to existing anticonvulsant regimens in 11 of 14 women with uncontrolled epilepsy, and has also been reported to induce anesthesia in animals, raising the possibility that it might modulate the GABA<sub>A</sub> receptor similarly to progesterone.<span class="mw-ref" id="cite_ref-pmid8516376_174-0"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span><span class="mw-ref" id="cite_ref-Weizman2008_175-0"><a href="#cite_note-Weizman2008-175" style="counter-reset: mw-Ref 175;"><span class="mw-reflink-text">[175]</span></a></span></p>

<p>MPA shares some of the same metabolic routes of progesterone and, analogously, can be transformed into metabolites such as 5α-dihydro-MPA (DHMPA) and 3α,5α-tetrahydro-MPA (THMPA).<span class="mw-ref" id="cite_ref-pmid8516376_174-1"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> However, unlike the reduced metabolites of progesterone, DHMPA and THMPA have been found not to modulate the GABA<sub>A</sub> receptor.<span class="mw-ref" id="cite_ref-pmid8516376_174-2"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> Conversely, unlike progesterone, MPA itself actually modulates the GABA<sub>A</sub> receptor, although notably not at the neurosteroid binding site.<span class="mw-ref" id="cite_ref-pmid8516376_174-3"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> However, rather than act as a potentiator of the receptor, MPA appears to act as a negative allosteric modulator.<span class="mw-ref" id="cite_ref-pmid8516376_174-4"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> Whereas the reduced metabolites of progesterone enhance binding of the benzodiazepine <a href="Flunitrazepam.htm" tppabs="https://ptable.com/wiki/compounds/A/Flunitrazepam" title="Flunitrazepam">flunitrazepam</a> to the GABA<sub>A</sub> receptor <i>in vitro</i>, MPA can partially inhibit the binding of flunitrazepam by up to 40% with half-maximal inhibition at 1<span>&nbsp;</span>μM.<span class="mw-ref" id="cite_ref-pmid8516376_174-5"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> However, the concentrations of MPA required for inhibition are high relative to therapeutic concentrations, and hence, this action is probably of little or no clinical relevance.<span class="mw-ref" id="cite_ref-pmid8516376_174-6"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> The lack of potentiation of the GABA<sub>A</sub> receptor by MPA or its metabolites is surprising in consideration of the apparent anticonvulsant and anesthetic effects of MPA described above, and they remain unexplained.<span class="mw-ref" id="cite_ref-pmid8516376_174-7"><a href="#cite_note-pmid8516376-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span></p>

<p>Clinical studies using massive dosages of up to 5,000<span>&nbsp;</span>mg/day oral MPA and 2,000<span>&nbsp;</span>mg/day intramuscular MPA for 30 days in women with advanced breast cancer have reported "no relevant side effects", which suggests that MPA has no meaningful direct action on the GABA<sub>A</sub> receptor in humans even at extremely high dosages.<span class="mw-ref" id="cite_ref-pmid1390312_126-1"><a href="#cite_note-pmid1390312-126" style="counter-reset: mw-Ref 126;"><span class="mw-reflink-text">[126]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Appetite_stimulation">Appetite stimulation</h4></summary>
    
<p>Although MPA and the closely related medication megestrol acetate are effective appetite stimulants at very high dosages,<span class="mw-ref" id="cite_ref-HofbauerAnker2005_176-0"><a href="#cite_note-HofbauerAnker2005-176" style="counter-reset: mw-Ref 176;"><span class="mw-reflink-text">[176]</span></a></span> the mechanism of action of their beneficial effects on appetite is not entirely clear. However, glucocorticoid, cytokine, and possibly anabolic-related mechanisms are all thought to possibly be involved, and a number of downstream changes have been implicated, including stimulation of the release of neuropeptide Y in the hypothalamus, modulation of calcium channels in the ventromedial hypothalamus, and inhibition of the secretion of proinflammatory cytokines including IL-1α, IL-1β, IL-6, and TNF-α, actions that have all been linked to an increase in appetite.<span class="mw-ref" id="cite_ref-DoyleHanks2005_177-0"><a href="#cite_note-DoyleHanks2005-177" style="counter-reset: mw-Ref 177;"><span class="mw-reflink-text">[177]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Other_activity">Other activity</h4></summary>
    
<p>MPA weakly stimulates the proliferation of MCF-7 breast cancer cells <i>in vitro</i>, an action that is independent of the classical PRs and is instead mediated via the progesterone receptor membrane component-1 (PGRMC1).<span class="mw-ref" id="cite_ref-pmid23758160_178-0"><a href="#cite_note-pmid23758160-178" style="counter-reset: mw-Ref 178;"><span class="mw-reflink-text">[178]</span></a></span> Certain other progestins are also active in this assay, whereas progesterone acts neutrally.<span class="mw-ref" id="cite_ref-pmid23758160_178-1"><a href="#cite_note-pmid23758160-178" style="counter-reset: mw-Ref 178;"><span class="mw-reflink-text">[178]</span></a></span> It is unclear if these findings may explain the different risks of breast cancer observed with progesterone, <a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">dydrogesterone</a>, and other progestins such as medroxyprogesterone acetate and <a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">norethisterone</a> in clinical studies.<span class="mw-ref" id="cite_ref-pmid31512725_179-0"><a href="#cite_note-pmid31512725-179" style="counter-reset: mw-Ref 179;"><span class="mw-reflink-text">[179]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Absorption">Absorption</h4></summary>
    
<p>Surprisingly few studies have been conducted on the pharmacokinetics of MPA at postmenopausal replacement dosages.<span class="mw-ref" id="cite_ref-pmid24291402_180-0"><a href="#cite_note-pmid24291402-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_3-18"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> The bioavailability of MPA with oral administration is approximately 100%.<span class="mw-ref" id="cite_ref-pmid16112947_3-19"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> A single oral dose of 10<span>&nbsp;</span>mg MPA has been found to result in peak MPA levels of 1.2 to 5.2<span>&nbsp;</span>ng/mL within 2<span>&nbsp;</span>hours of administration using radioimmunoassay.<span class="mw-ref" id="cite_ref-pmid24291402_180-1"><a href="#cite_note-pmid24291402-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span><span class="mw-ref" id="cite_ref-VictorJohansson1976_181-0"><a href="#cite_note-VictorJohansson1976-181" style="counter-reset: mw-Ref 181;"><span class="mw-reflink-text">[181]</span></a></span> Following this, levels of MPA decreased to 0.09 to 0.35<span>&nbsp;</span>ng/mL 12<span>&nbsp;</span>hours post-administration.<span class="mw-ref" id="cite_ref-pmid24291402_180-2"><a href="#cite_note-pmid24291402-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span><span class="mw-ref" id="cite_ref-VictorJohansson1976_181-1"><a href="#cite_note-VictorJohansson1976-181" style="counter-reset: mw-Ref 181;"><span class="mw-reflink-text">[181]</span></a></span> In another study, peak levels of MPA were 3.4 to 4.4<span>&nbsp;</span>ng/mL within 1 to 4<span>&nbsp;</span>hours of administration of 10<span>&nbsp;</span>mg oral MPA using radioimmunoassay.<span class="mw-ref" id="cite_ref-pmid24291402_180-3"><a href="#cite_note-pmid24291402-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span><span class="mw-ref" id="cite_ref-HiroiStanczyk1975_182-0"><a href="#cite_note-HiroiStanczyk1975-182" style="counter-reset: mw-Ref 182;"><span class="mw-reflink-text">[182]</span></a></span> Subsequently, MPA levels fell to 0.3 to 0.6<span>&nbsp;</span>ng/mL 24<span>&nbsp;</span>hours after administration.<span class="mw-ref" id="cite_ref-pmid24291402_180-4"><a href="#cite_note-pmid24291402-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span><span class="mw-ref" id="cite_ref-HiroiStanczyk1975_182-1"><a href="#cite_note-HiroiStanczyk1975-182" style="counter-reset: mw-Ref 182;"><span class="mw-reflink-text">[182]</span></a></span> In a third study, MPA levels were 4.2 to 4.4<span>&nbsp;</span>ng/mL after an oral dose of 5<span>&nbsp;</span>mg MPA and 6.0<span>&nbsp;</span>ng/mL after an oral dose of 10<span>&nbsp;</span>mg MPA, both using radioimmunoassay as well.<span class="mw-ref" id="cite_ref-pmid24291402_180-5"><a href="#cite_note-pmid24291402-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span><span class="mw-ref" id="cite_ref-SvenssonJohnson1994_183-0"><a href="#cite_note-SvenssonJohnson1994-183" style="counter-reset: mw-Ref 183;"><span class="mw-reflink-text">[183]</span></a></span></p>

<p>Treatment of postmenopausal women with 2.5 or 5<span>&nbsp;</span>mg/day MPA in combination with estradiol valerate for two weeks has been found to rapidly increase circulating MPA levels, with steady-state concentrations achieved after 3<span>&nbsp;</span>days and peak concentrations occurring 1.5 to 2<span>&nbsp;</span>hours after ingestion.<span class="mw-ref" id="cite_ref-pmid16112947_3-20"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-JärvinenKainulainen2004_184-0"><a href="#cite_note-JärvinenKainulainen2004-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span> With 2.5<span>&nbsp;</span>mg/day MPA, levels of the medication were 0.3<span>&nbsp;</span>ng/mL (0.8<span>&nbsp;</span>nmol/L) in women under 60 years of age and 0.45<span>&nbsp;</span>ng/mL (1.2<span>&nbsp;</span>nmol/L) in women 65 years of age or over, and with 5<span>&nbsp;</span>mg/day MPA, levels were 0.6<span>&nbsp;</span>ng/mL (1.6<span>&nbsp;</span>nmol/L) in women under 60 years of age and in women 65 years of age or over.<span class="mw-ref" id="cite_ref-pmid16112947_3-21"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-JärvinenKainulainen2004_184-1"><a href="#cite_note-JärvinenKainulainen2004-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span> Hence, area-under-curve levels of the medication were 1.6 to 1.8<span>&nbsp;</span>times higher in those who were 65<span>&nbsp;</span>years of age or older relative to those who were 60<span>&nbsp;</span>years of age or younger.<span class="mw-ref" id="cite_ref-pmid26291834_6-4"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-JärvinenKainulainen2004_184-2"><a href="#cite_note-JärvinenKainulainen2004-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span> As such, levels of MPA have been found to vary with age, and MPA may have an increased risk of side effects in elderly postmenopausal women.<span class="mw-ref" id="cite_ref-pmid26291834_6-5"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_3-22"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-JärvinenKainulainen2004_184-3"><a href="#cite_note-JärvinenKainulainen2004-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span> This study assessed MPA levels using liquid-chromatography–tandem mass spectrometry (LC–MS/MS), a more accurate method of blood determinations.<span class="mw-ref" id="cite_ref-JärvinenKainulainen2004_184-4"><a href="#cite_note-JärvinenKainulainen2004-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span></p>

<p>Oral MPA tablets can be administered sublingually instead of orally.<span class="mw-ref" id="cite_ref-PDR-MPA_185-0"><a href="#cite_note-PDR-MPA-185" style="counter-reset: mw-Ref 185;"><span class="mw-reflink-text">[185]</span></a></span><span class="mw-ref" id="cite_ref-pmid1101759_186-0"><a href="#cite_note-pmid1101759-186" style="counter-reset: mw-Ref 186;"><span class="mw-reflink-text">[186]</span></a></span><span class="mw-ref" id="cite_ref-pmid31127826_187-0"><a href="#cite_note-pmid31127826-187" style="counter-reset: mw-Ref 187;"><span class="mw-reflink-text">[187]</span></a></span> Rectal administration of MPA has also been studied.<span class="mw-ref" id="cite_ref-pmid1884566_188-0"><a href="#cite_note-pmid1884566-188" style="counter-reset: mw-Ref 188;"><span class="mw-reflink-text">[188]</span></a></span></p>

<p>With intramuscular administration of 150<span>&nbsp;</span>mg microcrystalline MPA in aqueous suspension, the medication is detectable in the circulation within 30<span>&nbsp;</span>minutes, serum concentrations vary but generally plateau at 1.0<span>&nbsp;</span>ng/mL (2.6<span>&nbsp;</span>nmol/L) for 3<span>&nbsp;</span>months.<span class="mw-ref" id="cite_ref-Mishell_189-0"><a href="#cite_note-Mishell-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span> Following this, there is a gradual decline in MPA levels, and the medication can be detected in the circulation for as long as 6 to 9<span>&nbsp;</span>months post-injection.<span class="mw-ref" id="cite_ref-Mishell_189-1"><a href="#cite_note-Mishell-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span> The particle size of MPA crystals significantly influences its rate of absorption into the body from the local tissue depot when used as a microcrystalline aqueous suspension via intramuscular injection.<span class="mw-ref" id="cite_ref-pmid8013220_190-0"><a href="#cite_note-pmid8013220-190" style="counter-reset: mw-Ref 190;"><span class="mw-reflink-text">[190]</span></a></span><span class="mw-ref" id="cite_ref-pmid1958567_191-0"><a href="#cite_note-pmid1958567-191" style="counter-reset: mw-Ref 191;"><span class="mw-reflink-text">[191]</span></a></span><span class="mw-ref" id="cite_ref-GabelnickHall1987_192-0"><a href="#cite_note-GabelnickHall1987-192" style="counter-reset: mw-Ref 192;"><span class="mw-reflink-text">[192]</span></a></span> Smaller crystals dissolve faster and are absorbed more rapidly, resulting in a shorter duration of action.<span class="mw-ref" id="cite_ref-pmid8013220_190-1"><a href="#cite_note-pmid8013220-190" style="counter-reset: mw-Ref 190;"><span class="mw-reflink-text">[190]</span></a></span><span class="mw-ref" id="cite_ref-pmid1958567_191-1"><a href="#cite_note-pmid1958567-191" style="counter-reset: mw-Ref 191;"><span class="mw-reflink-text">[191]</span></a></span><span class="mw-ref" id="cite_ref-GabelnickHall1987_192-1"><a href="#cite_note-GabelnickHall1987-192" style="counter-reset: mw-Ref 192;"><span class="mw-reflink-text">[192]</span></a></span> Particle sizes can differ between different formulations of MPA, potentially influencing clinical efficacy and tolerability.<span class="mw-ref" id="cite_ref-pmid8013220_190-2"><a href="#cite_note-pmid8013220-190" style="counter-reset: mw-Ref 190;"><span class="mw-reflink-text">[190]</span></a></span><span class="mw-ref" id="cite_ref-pmid1958567_191-2"><a href="#cite_note-pmid1958567-191" style="counter-reset: mw-Ref 191;"><span class="mw-reflink-text">[191]</span></a></span><span class="mw-ref" id="cite_ref-GabelnickHall1987_192-2"><a href="#cite_note-GabelnickHall1987-192" style="counter-reset: mw-Ref 192;"><span class="mw-reflink-text">[192]</span></a></span><span class="mw-ref" id="cite_ref-AntalDick1989_193-0"><a href="#cite_note-AntalDick1989-193" style="counter-reset: mw-Ref 193;"><span class="mw-reflink-text">[193]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Distribution">Distribution</h4></summary>
    
<p>The plasma protein binding of MPA is 88%.<span class="mw-ref" id="cite_ref-pmid16112947_3-23"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid26291834_6-6"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It is weakly bound to <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a> and is not bound to sex hormone-binding globulin or corticosteroid-binding globulin.<span class="mw-ref" id="cite_ref-pmid16112947_3-24"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid26291834_6-7"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Metabolism">Metabolism</h4></summary>
    
<p>The elimination half-life of MPA via oral administration has been reported as both 11.6 to 16.6<span>&nbsp;</span>hours<span class="mw-ref" id="cite_ref-ProveraLabel_5-5"><a href="#cite_note-ProveraLabel-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> and 33<span>&nbsp;</span>hours,<span class="mw-ref" id="cite_ref-pmid16112947_3-25"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> whereas the elimination half-lives with intramuscular and subcutaneous injection of microcrystalline MPA in aqueous suspension are 50 and 40<span>&nbsp;</span>days, respectively.<span class="mw-ref" id="cite_ref-DepoProveraLabel_7-2"><a href="#cite_note-DepoProveraLabel-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-DepoSubQProveraLabel_8-2"><a href="#cite_note-DepoSubQProveraLabel-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> The metabolism of MPA is mainly via hydroxylation, including at positions C6β, C21, C2β, and C1β, mediated primarily via CYP3A4, but 3- and 5-dihydro and 3,5-tetrahydro metabolites of MPA are also formed.<span class="mw-ref" id="cite_ref-pmid16112947_3-26"><a href="#cite_note-pmid16112947-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid26291834_6-8"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Deacetylation of MPA and its metabolites (into, e.g., <a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">medroxyprogesterone</a>) has been observed to occur in non-human primate research to a substantial extent as well (30 to 70%).<span class="mw-ref" id="cite_ref-pmid1271819_194-0"><a href="#cite_note-pmid1271819-194" style="counter-reset: mw-Ref 194;"><span class="mw-reflink-text">[194]</span></a></span> MPA and/or its metabolites are also metabolized via conjugation.<span class="mw-ref" id="cite_ref-Merck_74-3"><a href="#cite_note-Merck-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> The C6α <a href="Methyl_group.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyl_group" title="Methyl group">methyl</a> and C17α acetoxy groups of MPA make it more resistant to metabolism and allow for greater bioavailability than oral progesterone.<span class="mw-ref" id="cite_ref-pmid26291834_6-9"><a href="#cite_note-pmid26291834-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Elimination">Elimination</h4></summary>
    
<p>MPA is eliminated 20 to 50% in urine and 5 to 10% in feces following intravenous administration.<span class="mw-ref" id="cite_ref-Jr.Lawrence2015_195-0"><a href="#cite_note-Jr.Lawrence2015-195" style="counter-reset: mw-Ref 195;"><span class="mw-reflink-text">[195]</span></a></span> Less than 3% of a dose is excreted in unconjugated form.<span class="mw-ref" id="cite_ref-Jr.Lawrence2015_195-1"><a href="#cite_note-Jr.Lawrence2015-195" style="counter-reset: mw-Ref 195;"><span class="mw-reflink-text">[195]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Level–effect_relationships">Level–effect relationships</h4></summary>
    
<p>With intramuscular administration, the high levels of MPA in the blood inhibit <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> and ovulation for several months, with an accompanying decrease in serum progesterone to below 0.4<span>&nbsp;</span>ng/mL.<span class="mw-ref" id="cite_ref-Mishell_189-2"><a href="#cite_note-Mishell-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span> Ovulation resumes when once blood levels of MPA fall below 0.1<span>&nbsp;</span>ng/mL.<span class="mw-ref" id="cite_ref-Mishell_189-3"><a href="#cite_note-Mishell-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span> Serum estradiol remains at approximately 50<span>&nbsp;</span>pg/mL for approximately four months post-injection (with a range of 10–92<span>&nbsp;</span>pg/mL after several years of use), rising once MPA levels fall below 0.5<span>&nbsp;</span>ng/mL.<span class="mw-ref" id="cite_ref-Mishell_189-4"><a href="#cite_note-Mishell-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span></p>

<p>Hot flashes are rare while MPA is found at significant blood levels in the body, and the vaginal lining remains moist and creased. The endometrium undergoes atrophy, with small, straight glands and a stroma that is decidualized. Cervical mucus remains viscous. Because of its steady blood levels over the long term and multiple effects that prevent fertilization, MPA is a very effective means of birth control.<span class="mw-ref" id="cite_ref-Mishell_189-5"><a href="#cite_note-Mishell-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Time–concentration_curves">Time–concentration curves</h4></summary>
    
<div class="center" style="width:auto; margin-left:auto; margin-right:auto;"><style data-mw-deduplicate="TemplateStyles:r959344415">@media all and (max-width:720px){.mw-parser-output .mod-gallery{width:100%!important}}.mw-parser-output .mod-gallery{display:table}.mw-parser-output .mod-gallery-default{background:transparent;margin-top:4px}.mw-parser-output .mod-gallery-center{margin-left:auto;margin-right:auto}.mw-parser-output .mod-gallery-left{float:left}.mw-parser-output .mod-gallery-right{float:right}.mw-parser-output .mod-gallery-none{float:none}.mw-parser-output .mod-gallery-collapsible{width:100%}.mw-parser-output .mod-gallery .title,.mw-parser-output .mod-gallery .main,.mw-parser-output .mod-gallery .footer{display:table-row}.mw-parser-output .mod-gallery .title>div{display:table-cell;text-align:center;font-weight:bold}.mw-parser-output .mod-gallery .main>div{display:table-cell}.mw-parser-output .mod-gallery .caption{display:table-row;vertical-align:top}.mw-parser-output .mod-gallery .caption>div{display:table-cell;display:block;font-size:94%;padding:0}.mw-parser-output .mod-gallery .footer>div{display:table-cell;text-align:right;font-size:80%;line-height:1em}.mw-parser-output .mod-gallery .gallerybox img{background:none!important}.mw-parser-output .mod-gallery .bordered-images .thumb img{border:solid #eee 1px}.mw-parser-output .mod-gallery .whitebg .gallerybox,.mw-parser-output .mod-gallery .whitebg .thumb{background:#fff!important}.mw-parser-output .mod-gallery .whitebg .thumb{margin-top:1px}</style><div class="mod-gallery mod-gallery-center" style="&quot;font-size:small;&quot;"><div class="title"><div> Hormone levels with medroxyprogesterone acetate</div></div><div class="main"><div><ul class="gallery mw-gallery-traditional nochecker bordered-images whitebg" style="line-height:130%;">
<li class="gallerybox" style="width: 435px;"><div class="thumb" style="width: 430px; height: 330px;"><figure-inline><img src="../I/m/Levels_of_medroxyprogesterone_acetate_with_2.5_or_5_mg_per_day_oral_medroxyprogesterone_acetate_in_postmenopausal_women.png" tppabs="https://ptable.com/wiki/compounds/I/m/Levels_of_medroxyprogesterone_acetate_with_2.5_or_5_mg_per_day_oral_medroxyprogesterone_acetate_in_postmenopausal_women.png" data-file-width="2200" data-file-height="1087" data-file-type="bitmap" height="198" width="400"></figure-inline></div><div class="gallerytext">MPA levels with 2.5 or 5 mg/day oral MPA in combination with 1 or 2<span>&nbsp;</span>mg/day estradiol valerate (Indivina) in postmenopausal women.<span class="mw-ref" id="cite_ref-196"><a href="#cite_note-196" style="counter-reset: mw-Ref 196;"><span class="mw-reflink-text">[196]</span></a></span></div></li>
<li class="gallerybox" style="width: 435px;"><div class="thumb" style="width: 430px; height: 330px;"><figure-inline><img src="../I/m/Medroxyprogesterone_acetate_levels_after_a_single_150_mg_intramuscular_injection_of_medroxyprogesterone_acetate_in_women.png" tppabs="https://ptable.com/wiki/compounds/I/m/Medroxyprogesterone_acetate_levels_after_a_single_150_mg_intramuscular_injection_of_medroxyprogesterone_acetate_in_women.png" data-file-width="1679" data-file-height="1098" data-file-type="bitmap" height="262" width="400"></figure-inline></div><div class="gallerytext">MPA levels after a single 150<span>&nbsp;</span>mg intramuscular injection of MPA (Depo-Provera) in aqueous suspension in women.<span class="mw-ref" id="cite_ref-Goebelsmann1986_197-0"><a href="#cite_note-Goebelsmann1986-197" style="counter-reset: mw-Ref 197;"><span class="mw-reflink-text">[197]</span></a></span><span class="mw-ref" id="cite_ref-pmid833262_198-0"><a href="#cite_note-pmid833262-198" style="counter-reset: mw-Ref 198;"><span class="mw-reflink-text">[198]</span></a></span></div></li>
<li class="gallerybox" style="width: 435px;"><div class="thumb" style="width: 430px; height: 330px;"><figure-inline><img src="../I/m/Medroxyprogesterone_acetate_levels_after_a_single_intramuscular_injection_of_different_doses_of_medroxyprogesterone_acetate_in_women.png" tppabs="https://ptable.com/wiki/compounds/I/m/Medroxyprogesterone_acetate_levels_after_a_single_intramuscular_injection_of_different_doses_of_medroxyprogesterone_acetate_in_women.png" data-file-width="1674" data-file-height="1094" data-file-type="bitmap" height="261" width="400"></figure-inline></div><div class="gallerytext">MPA levels after a single 25 to 150<span>&nbsp;</span>mg intramuscular injection of MPA (Depo-Provera) in aqueous suspension in women.<span class="mw-ref" id="cite_ref-Goebelsmann1986_197-1"><a href="#cite_note-Goebelsmann1986-197" style="counter-reset: mw-Ref 197;"><span class="mw-reflink-text">[197]</span></a></span><span class="mw-ref" id="cite_ref-pmid6451351_199-0"><a href="#cite_note-pmid6451351-199" style="counter-reset: mw-Ref 199;"><span class="mw-reflink-text">[199]</span></a></span></div></li>
<li class="gallerybox" style="width: 435px;"><div class="thumb" style="width: 430px; height: 330px;"><figure-inline><img src="../I/m/Medroxyprogesterone_acetate_levels_with_a_subcutaneous_injection_of_104_mg_medroxyprogesterone_acetate_in_women.png" tppabs="https://ptable.com/wiki/compounds/I/m/Medroxyprogesterone_acetate_levels_with_a_subcutaneous_injection_of_104_mg_medroxyprogesterone_acetate_in_women.png" data-file-width="1685" data-file-height="1097" data-file-type="bitmap" height="260" width="400"></figure-inline></div><div class="gallerytext">MPA levels after a single 104<span>&nbsp;</span>mg subcutaneous injection of MPA (Depo-SubQ Provera) in aqueous suspension in women.<span class="mw-ref" id="cite_ref-DepoSubQProveraLabel_8-3"><a href="#cite_note-DepoSubQProveraLabel-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></div></li>
</ul></div></div></div></div>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    


<p>MPA is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone.<span class="mw-ref" id="cite_ref-Elks2014_200-0"><a href="#cite_note-Elks2014-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-2"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Specifically, it is the 17α-acetate ester of <a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">medroxyprogesterone</a> or the 6α-methylated analogue of hydroxyprogesterone acetate.<span class="mw-ref" id="cite_ref-Elks2014_200-1"><a href="#cite_note-Elks2014-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-3"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> MPA is known chemically as 6α-methyl-17α-acetoxyprogesterone or as 6α-methyl-17α-acetoxypregn-4-ene-3,20-dione, and its generic name is a contraction of 6α-methyl-17α-hydroxyprogesterone acetate.<span class="mw-ref" id="cite_ref-Elks2014_200-2"><a href="#cite_note-Elks2014-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-4"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> MPA is closely related to other 17α-hydroxyprogesterone derivatives such as chlormadinone acetate, cyproterone acetate, and megestrol acetate, as well as to medrogestone and nomegestrol acetate.<span class="mw-ref" id="cite_ref-Elks2014_200-3"><a href="#cite_note-Elks2014-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-5"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> 9α-Fluoromedroxyprogesterone acetate (FMPA), the C9α <a href="Fluorine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoro" title="Fluoro" class="mw-redirect">fluoro</a> analogue of MPA and an angiogenesis inhibitor with two orders of magnitude greater potency in comparison to MPA, was investigated for the potential treatment of cancers but was never marketed.<span class="mw-ref" id="cite_ref-pmid19158035_201-0"><a href="#cite_note-pmid19158035-201" style="counter-reset: mw-Ref 201;"><span class="mw-reflink-text">[201]</span></a></span><span class="mw-ref" id="cite_ref-AdisInsight-FMPA_202-0"><a href="#cite_note-AdisInsight-FMPA-202" style="counter-reset: mw-Ref 202;"><span class="mw-reflink-text">[202]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>MPA was independently discovered in 1956 by Syntex and the Upjohn Company.<span class="mw-ref" id="cite_ref-Roberts2013_14-1"><a href="#cite_note-Roberts2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-Sneader2005_15-1"><a href="#cite_note-Sneader2005-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-FR1295307_203-0"><a href="#cite_note-FR1295307-203" style="counter-reset: mw-Ref 203;"><span class="mw-reflink-text">[203]</span></a></span><span class="mw-ref" id="cite_ref-US3377364_204-0"><a href="#cite_note-US3377364-204" style="counter-reset: mw-Ref 204;"><span class="mw-reflink-text">[204]</span></a></span> It was first introduced on 18 June 1959 by Upjohn in the United States under the brand name Provera (2.5, 5, and 10<span>&nbsp;</span>mg tablets) for the treatment of amenorrhea, metrorrhagia, and recurrent miscarriage.<span class="mw-ref" id="cite_ref-Green1987_205-0"><a href="#cite_note-Green1987-205" style="counter-reset: mw-Ref 205;"><span class="mw-reflink-text">[205]</span></a></span><span class="mw-ref" id="cite_ref-pmid23617013_206-0"><a href="#cite_note-pmid23617013-206" style="counter-reset: mw-Ref 206;"><span class="mw-reflink-text">[206]</span></a></span> An intramuscular formulation of MPA, now known as DMPA (400<span>&nbsp;</span>mg/mL MPA), was also introduced, under the brand name brand name Depo-Provera, in 1960 in the U.S. for the treatment of endometrial and renal cancer.<span class="mw-ref" id="cite_ref-Drugs@FDA-Depo-Provera_31-1"><a href="#cite_note-Drugs@FDA-Depo-Provera-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> MPA in combination with ethinylestradiol was introduced in 1964 by Upjohn in the U.S. under the brand name Provest (10<span>&nbsp;</span>mg MPA and 50<span>&nbsp;</span>μg ethinylestradiol tablets) as an oral contraceptive, but this formulation was discontinued in 1970.<span class="mw-ref" id="cite_ref-Gelijns1991_207-0"><a href="#cite_note-Gelijns1991-207" style="counter-reset: mw-Ref 207;"><span class="mw-reflink-text">[207]</span></a></span><span class="mw-ref" id="cite_ref-Publishing2013_208-0"><a href="#cite_note-Publishing2013-208" style="counter-reset: mw-Ref 208;"><span class="mw-reflink-text">[208]</span></a></span><span class="mw-ref" id="cite_ref-Blum2013_133-1"><a href="#cite_note-Blum2013-133" style="counter-reset: mw-Ref 133;"><span class="mw-reflink-text">[133]</span></a></span> This formulation was marketed by Upjohn outside of the U.S. under the brand names Provestral and Provestrol, while Cyclo-Farlutal (or Ciclofarlutal) and Nogest-S<span class="mw-ref" id="cite_ref-209"><a href="#cite_note-209" style="counter-reset: mw-Ref 209;"><span class="mw-reflink-text">[209]</span></a></span> were formulations available outside of the U.S. with a different dosage (5<span>&nbsp;</span>mg MPA and 50 or 75<span>&nbsp;</span>μg ethinylestradiol tablets).<span class="mw-ref" id="cite_ref-Lee1966_210-0"><a href="#cite_note-Lee1966-210" style="counter-reset: mw-Ref 210;"><span class="mw-reflink-text">[210]</span></a></span><span class="mw-ref" id="cite_ref-211"><a href="#cite_note-211" style="counter-reset: mw-Ref 211;"><span class="mw-reflink-text">[211]</span></a></span></p>

<p>Following its development in the late 1950s, DMPA was first assessed in clinical trials for use as an injectable contraceptive in 1963.<span class="mw-ref" id="cite_ref-Li2009_212-0"><a href="#cite_note-Li2009-212" style="counter-reset: mw-Ref 212;"><span class="mw-reflink-text">[212]</span></a></span> Upjohn sought <abbr>FDA</abbr> approval of intramuscular DMPA as a long-acting contraceptive under the brand name Depo-Provera (150<span>&nbsp;</span>mg/mL MPA) in 1967, but the application was rejected.<span class="mw-ref" id="cite_ref-Levitt2015_213-0"><a href="#cite_note-Levitt2015-213" style="counter-reset: mw-Ref 213;"><span class="mw-reflink-text">[213]</span></a></span><span class="mw-ref" id="cite_ref-Women1998_214-0"><a href="#cite_note-Women1998-214" style="counter-reset: mw-Ref 214;"><span class="mw-reflink-text">[214]</span></a></span> However, this formulation was successfully introduced in countries outside of the United States for the first time in 1969, and was available in over 90<span>&nbsp;</span>countries worldwide by 1992.<span class="mw-ref" id="cite_ref-Nadakavukaren2011_39-1"><a href="#cite_note-Nadakavukaren2011-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Upjohn attempted to gain FDA approval of DMPA as a contraceptive again in 1978, and yet again in 1983, but both applications failed similarly to the 1967 application.<span class="mw-ref" id="cite_ref-Levitt2015_213-1"><a href="#cite_note-Levitt2015-213" style="counter-reset: mw-Ref 213;"><span class="mw-reflink-text">[213]</span></a></span><span class="mw-ref" id="cite_ref-Women1998_214-1"><a href="#cite_note-Women1998-214" style="counter-reset: mw-Ref 214;"><span class="mw-reflink-text">[214]</span></a></span> However, in 1992, the medication was finally approved by the FDA, under the brand name Depo-Provera, for use in contraception.<span class="mw-ref" id="cite_ref-Levitt2015_213-2"><a href="#cite_note-Levitt2015-213" style="counter-reset: mw-Ref 213;"><span class="mw-reflink-text">[213]</span></a></span> A subcutaneous formulation of DMPA was introduced in the United States as a contraceptive under the brand name Depo-SubQ Provera 104 (104<span>&nbsp;</span>mg/0.65<span>&nbsp;</span>mL MPA) in December 2004, and subsequently was also approved for the treatment of endometriosis-related pelvic pain.<span class="mw-ref" id="cite_ref-ShoupeJr.2015_215-0"><a href="#cite_note-ShoupeJr.2015-215" style="counter-reset: mw-Ref 215;"><span class="mw-reflink-text">[215]</span></a></span></p>

<p>MPA has also been marketed widely throughout the world under numerous other brand names such as Farlutal, Perlutex, and Gestapuran, among others.<span class="mw-ref" id="cite_ref-IndexNominum2000_2-6"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_10-2"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Generic_names">Generic names</h3></summary>
    
<p><i>Medroxyprogesterone acetate</i> is the generic name of the drug and its <abbr>INN</abbr>, <abbr>USAN</abbr>, <abbr>BAN</abbr>, and <abbr>JAN</abbr>, while <i>medrossiprogesterone</i> is the <abbr>DCIT</abbr> and <i>médroxyprogestérone</i> the <abbr>DCF</abbr> of its free alcohol form.<span class="mw-ref" id="cite_ref-Elks2014_200-4"><a href="#cite_note-Elks2014-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-2"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-7"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-MortonHall1999_216-0"><a href="#cite_note-MortonHall1999-216" style="counter-reset: mw-Ref 216;"><span class="mw-reflink-text">[216]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_10-3"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> It is also known as <i>6α-methyl-17α-acetoxyprogesterone</i> (<i>MAP</i>) or <i>6α-methyl-17α-hydroxyprogesterone acetate</i>.<span class="mw-ref" id="cite_ref-Elks2014_200-5"><a href="#cite_note-Elks2014-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-3"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-8"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_10-4"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>MPA is marketed under a large number of brand names throughout the world.<span class="mw-ref" id="cite_ref-Drugs.com_10-5"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-4"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-9"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Its most major brand names are Provera as oral tablets and Depo-Provera as an aqueous suspension for intramuscular injection.<span class="mw-ref" id="cite_ref-Drugs.com_10-6"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-5"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-10"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> A formulation of MPA as an aqueous suspension for subcutaneous injection is also available in the United States under the brand name Depo-SubQ Provera 104.<span class="mw-ref" id="cite_ref-Drugs.com_10-7"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-6"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Other brand names of MPA formulated alone include Farlutal and Sayana for clinical use and Depo-Promone, Perlutex, Promone-E, and Veramix for veterinary use.<span class="mw-ref" id="cite_ref-Drugs.com_10-8"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-7"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-11"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> In addition to single-drug formulations, MPA is marketed in combination with the estrogens CEEs, estradiol, and estradiol valerate.<span class="mw-ref" id="cite_ref-Drugs.com_10-9"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-8"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-12"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Brand names of MPA in combination with CEEs as oral tablets in different countries include Prempro, Premphase, Premique, Premia, and Premelle.<span class="mw-ref" id="cite_ref-Drugs.com_10-10"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-9"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-13"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Brand names of MPA in combination with estradiol as oral tablets include Indivina and Tridestra.<span class="mw-ref" id="cite_ref-Drugs.com_10-11"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Martindale_11-10"><a href="#cite_note-Martindale-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-14"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Availability">Availability</h3></summary>
    
<p>Oral MPA and DMPA are widely available throughout the world.<span class="mw-ref" id="cite_ref-Drugs.com_10-12"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> Oral MPA is available both alone and in combination with the estrogens CEEs, estradiol, and estradiol valerate.<span class="mw-ref" id="cite_ref-Drugs.com_10-13"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> DMPA is registered for use as a form of birth control in more than 100<span>&nbsp;</span>countries worldwide.<span class="mw-ref" id="cite_ref-BagadePawar2014_22-2"><a href="#cite_note-BagadePawar2014-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-Gunasheela2011_23-1"><a href="#cite_note-Gunasheela2011-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_10-14"><a href="#cite_note-Drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> The combination of injected MPA and estradiol cypionate is approved for use as a form of birth control in 18<span>&nbsp;</span>countries.<span class="mw-ref" id="cite_ref-BagadePawar2014_22-3"><a href="#cite_note-BagadePawar2014-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="United_States">United States</h4></summary>
    


<p><span>As of November</span><span>&nbsp;</span><span>2016</span>, MPA is available in the United States in the following formulations:<span class="mw-ref" id="cite_ref-Drugs@FDA_67-3"><a href="#cite_note-Drugs@FDA-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span></p>

<ul><li>Oral pills: Amen, Curretab, Cycrin, Provera – 2.5<span>&nbsp;</span>mg, 5<span>&nbsp;</span>mg, 10<span>&nbsp;</span>mg</li>
<li>Aqueous suspension for intramuscular injection: Depo-Provera – 150<span>&nbsp;</span>mg/mL (for contraception), 400<span>&nbsp;</span>mg/mL (for cancer)</li>
<li>Aqueous suspension for subcutaneous injection: Depo-SubQ Provera 104 – 104<span>&nbsp;</span>mg/0.65<span>&nbsp;</span>mL (for contraception)</li></ul>

<p>It is also available in combination with an estrogen in the following formulations:</p>

<ul><li>Oral pills: CEEs and MPA (Prempro, Prempro (Premarin, Cycrin), Premphase (Premarin, Cycrin 14/14), Premphase 14/14, Prempro/Premphase) – 0.3<span>&nbsp;</span>mg / 1.5<span>&nbsp;</span>mg; 0.45<span>&nbsp;</span>mg / 1.5<span>&nbsp;</span>mg; 0.625<span>&nbsp;</span>mg / 2.5<span>&nbsp;</span>mg; 0.625<span>&nbsp;</span>mg / 5<span>&nbsp;</span>mg</li></ul>

<p>While the following formulations have been discontinued:</p>

<ul><li>Oral pills: ethinylestradiol and MPA (Provest) – 50<span>&nbsp;</span>μg / 10<span>&nbsp;</span>mg</li>
<li>Aqueous suspension for intramuscular injection: estradiol cypionate and MPA (Lunelle) – 5<span>&nbsp;</span>mg / 25<span>&nbsp;</span>mg (for contraception)</li></ul>

<p>The state of Louisiana permits sex offenders to be given MPA.<span class="mw-ref" id="cite_ref-217"><a href="#cite_note-217" style="counter-reset: mw-Ref 217;"><span class="mw-reflink-text">[217]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Generation">Generation</h3></summary>
    
<p>Progestins in birth control pills are sometimes grouped by generation.<span class="mw-ref" id="cite_ref-UnzeitigLunsen2000_218-0"><a href="#cite_note-UnzeitigLunsen2000-218" style="counter-reset: mw-Ref 218;"><span class="mw-reflink-text">[218]</span></a></span><span class="mw-ref" id="cite_ref-HumansOrganization2007_219-0"><a href="#cite_note-HumansOrganization2007-219" style="counter-reset: mw-Ref 219;"><span class="mw-reflink-text">[219]</span></a></span> While the <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/19-nortestosterone" title="19-nortestosterone" class="mw-redirect">19-nortestosterone</a> progestins are consistently grouped into generations, the pregnane progestins that are or have been used in birth control pills are typically omitted from such classifications or are grouped simply as "miscellaneous" or "pregnanes".<span class="mw-ref" id="cite_ref-UnzeitigLunsen2000_218-1"><a href="#cite_note-UnzeitigLunsen2000-218" style="counter-reset: mw-Ref 218;"><span class="mw-reflink-text">[218]</span></a></span><span class="mw-ref" id="cite_ref-HumansOrganization2007_219-1"><a href="#cite_note-HumansOrganization2007-219" style="counter-reset: mw-Ref 219;"><span class="mw-reflink-text">[219]</span></a></span> In any case, based on its date of introduction in such formulations of 1964, MPA could be considered a "first-generation" progestin.<span class="mw-ref" id="cite_ref-Gordon2007_220-0"><a href="#cite_note-Gordon2007-220" style="counter-reset: mw-Ref 220;"><span class="mw-reflink-text">[220]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Controversy">Controversy</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Outside_the_United_States">Outside the United States</h4></summary>
    
<ul><li>In 1994, when DMPA was approved in India, India's <i>Economic and Political Weekly</i> reported that "The FDA finally licensed the drug in 1990 in response to concerns about the population explosion in the third world and the reluctance of third world governments to license a drug not licensed in its originating country." <span class="mw-ref" id="cite_ref-221"><a href="#cite_note-221" style="counter-reset: mw-Ref 221;"><span class="mw-reflink-text">[221]</span></a></span> Some scientists and women's groups in India continue to oppose DMPA.<span class="mw-ref" id="cite_ref-222"><a href="#cite_note-222" style="counter-reset: mw-Ref 222;"><span class="mw-reflink-text">[222]</span></a></span> In 2016, India introduced DMPA depo-medroxyprogesterone IM preparation in the public health system.<span class="mw-ref" id="cite_ref-223"><a href="#cite_note-223" style="counter-reset: mw-Ref 223;"><span class="mw-reflink-text">[223]</span></a></span></li>
<li>The Canadian Coalition on Depo-Provera, a coalition of women's health professional and advocacy groups, opposed the approval of DMPA in Canada.<span class="mw-ref" id="cite_ref-224"><a href="#cite_note-224" style="counter-reset: mw-Ref 224;"><span class="mw-reflink-text">[224]</span></a></span> Since the approval of DMPA in Canada in 1997, a $700 million class-action lawsuit has been filed against Pfizer by users of DMPA who developed osteoporosis. In response, Pfizer argued that it had met its obligation to disclose and discuss the risks of DMPA with the Canadian medical community.<span class="mw-ref" id="cite_ref-225"><a href="#cite_note-225" style="counter-reset: mw-Ref 225;"><span class="mw-reflink-text">[225]</span></a></span></li>
<li>Clinical trials for this medication regarding women in Zimbabwe were controversial with regard to human rights abuses and Medical Experimentation in Africa.</li>
<li>A controversy erupted in Israel when the government was accused of giving DMPA to Ethiopian immigrants without their consent. Some women claimed they were told it was a vaccination. The Israeli government denied the accusations but instructed the four health maintenance organizations to stop administering DMPA injections to women "if there is the slightest doubt that they have not understood the implications of the treatment".<span class="mw-ref" id="cite_ref-226"><a href="#cite_note-226" style="counter-reset: mw-Ref 226;"><span class="mw-reflink-text">[226]</span></a></span></li></ul>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="United_States_2">United States</h4></summary>
    
<p>There was a long, controversial history regarding the approval of DMPA by the U.S. Food and Drug Administration. The original manufacturer, Upjohn, applied repeatedly for approval. FDA advisory committees unanimously recommended approval in 1973, 1975 and 1992, as did the FDA's professional medical staff, but the FDA repeatedly denied approval. Ultimately, on October 29, 1992, the FDA approved DMPA for birth control, which had by then been used by over 30 million women since 1969 and was approved and being used by nearly 9<span>&nbsp;</span>million women in more than 90<span>&nbsp;</span>countries, including the United Kingdom, France, Germany, Sweden, Thailand, New Zealand and Indonesia.<span class="mw-ref" id="cite_ref-Leary1992_227-0"><a href="#cite_note-Leary1992-227" style="counter-reset: mw-Ref 227;"><span class="mw-reflink-text">[227]</span></a></span> Points in the controversy included:</p>
<ul><li>Animal testing for carcinogenicity – DMPA caused breast cancer tumors in dogs. Critics of the study claimed that dogs are more sensitive to artificial progesterone, and that the doses were too high to extrapolate to humans. The FDA pointed out that all substances carcinogenic to humans are carcinogenic to animals as well, and that if a substance is not carcinogenic it does not register as a carcinogen at high doses. Levels of DMPA which caused malignant mammary tumors in dogs were equivalent to 25 times the amount of the normal luteal phase progesterone level for dogs. This is lower than the pregnancy level of progesterone for dogs, and is species-specific.<span class="mw-ref" id="cite_ref-228"><a href="#cite_note-228" style="counter-reset: mw-Ref 228;"><span class="mw-reflink-text">[228]</span></a></span><br>DMPA caused endometrial cancer in monkeys – 2 of 12 monkeys tested, the first ever recorded cases of endometrial cancer in rhesus monkeys.<span class="mw-ref" id="cite_ref-MM_Goodman1985_229-0"><a href="#cite_note-MM_Goodman1985-229" style="counter-reset: mw-Ref 229;"><span class="mw-reflink-text">[229]</span></a></span> However, subsequent studies have shown that in humans, DMPA <i>reduces</i> the risk of endometrial cancer by approximately 80%.<span class="mw-ref" id="cite_ref-Kaunitz_54-1"><a href="#cite_note-Kaunitz-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span><span class="mw-ref" id="cite_ref-BrJFP_Bigrigg1999_55-1"><a href="#cite_note-BrJFP_Bigrigg1999-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-WHO_DMPA_EC_56-1"><a href="#cite_note-WHO_DMPA_EC-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span><br>Speaking in comparative terms regarding animal studies of carcinogenicity for medications, a member of the FDA's Bureau of Drugs testified at an agency DMPA hearing, "...Animal data for this drug is more worrisome than any other drug we know of that is to be given to well people."</li>
<li>Cervical cancer in Upjohn/NCI studies. Cervical cancer was found to be increased as high as 9-fold in the first human studies recorded by the manufacturer and the National Cancer Institute.<span class="mw-ref" id="cite_ref-230"><a href="#cite_note-230" style="counter-reset: mw-Ref 230;"><span class="mw-reflink-text">[230]</span></a></span> However, numerous larger subsequent studies have shown that DMPA use does not increase the risk of cervical cancer.<span class="mw-ref" id="cite_ref-231"><a href="#cite_note-231" style="counter-reset: mw-Ref 231;"><span class="mw-reflink-text">[231]</span></a></span><span class="mw-ref" id="cite_ref-232"><a href="#cite_note-232" style="counter-reset: mw-Ref 232;"><span class="mw-reflink-text">[232]</span></a></span><span class="mw-ref" id="cite_ref-233"><a href="#cite_note-233" style="counter-reset: mw-Ref 233;"><span class="mw-reflink-text">[233]</span></a></span><span class="mw-ref" id="cite_ref-234"><a href="#cite_note-234" style="counter-reset: mw-Ref 234;"><span class="mw-reflink-text">[234]</span></a></span><span class="mw-ref" id="cite_ref-235"><a href="#cite_note-235" style="counter-reset: mw-Ref 235;"><span class="mw-reflink-text">[235]</span></a></span></li>
<li>Coercion and lack of informed consent. Testing or use of DMPA was focused almost exclusively on women in developing countries and poor women in the United States,<span class="mw-ref" id="cite_ref-albion_236-0"><a href="#cite_note-albion-236" style="counter-reset: mw-Ref 236;"><span class="mw-reflink-text">[236]</span></a></span> raising serious questions about coercion and lack of informed consent, particularly for the illiterate<span class="mw-ref" id="cite_ref-237"><a href="#cite_note-237" style="counter-reset: mw-Ref 237;"><span class="mw-reflink-text">[237]</span></a></span> and for the mentally challenged, who in some reported cases were given DMPA long-term for reasons of "menstrual hygiene", although they were not sexually active.<span class="mw-ref" id="cite_ref-238"><a href="#cite_note-238" style="counter-reset: mw-Ref 238;"><span class="mw-reflink-text">[238]</span></a></span></li>
<li>Atlanta/Grady Study – Upjohn studied the effect of DMPA for 11 years in Atlanta, mostly on black women who were receiving public assistance, but did not file any of the required follow-up reports with the FDA. Investigators who eventually visited noted that the studies were disorganized. "They found that data collection was questionable, consent forms and protocol were absent; that those women whose consent had been obtained at all were not told of possible side effects. Women whose known medical conditions indicated that use of DMPA would endanger their health were given the shot. Several of the women in the study died; some of cancer, but some for other reasons, such as suicide due to depression. Over half the 13,000 women in the study were lost to followup due to sloppy record keeping." Consequently, no data from this study was usable.<span class="mw-ref" id="cite_ref-albion_236-1"><a href="#cite_note-albion-236" style="counter-reset: mw-Ref 236;"><span class="mw-reflink-text">[236]</span></a></span></li>
<li>WHO Review – In 1992, the WHO presented a review of DMPA in four developing countries to the FDA. The National Women's Health Network and other women's organizations testified at the hearing that the WHO was not objective, as the WHO had already distributed DMPA in developing countries. DMPA was approved for use in United States on the basis of the WHO review of previously submitted evidence from countries such as Thailand, evidence which the FDA had deemed insufficient and too poorly designed for assessment of cancer risk at a prior hearing.</li>
<li>The Alan Guttmacher Institute has speculated that United States approval of DMPA may increase its availability and acceptability in developing countries.<span class="mw-ref" id="cite_ref-albion_236-2"><a href="#cite_note-albion-236" style="counter-reset: mw-Ref 236;"><span class="mw-reflink-text">[236]</span></a></span><span class="mw-ref" id="cite_ref-239"><a href="#cite_note-239" style="counter-reset: mw-Ref 239;"><span class="mw-reflink-text">[239]</span></a></span></li>
<li>In 1995, several women's health groups asked the FDA to put a moratorium on DMPA, and to institute standardized informed consent forms.<span class="mw-ref" id="cite_ref-240"><a href="#cite_note-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span></li></ul>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>DMPA was studied by Upjohn for use as a progestogen-only injectable contraceptive in women at a dose of 50<span>&nbsp;</span>mg once a month but produced poor cycle control and was not marketed for this use at this dosage.<span class="mw-ref" id="cite_ref-pmid865726_241-0"><a href="#cite_note-pmid865726-241" style="counter-reset: mw-Ref 241;"><span class="mw-reflink-text">[241]</span></a></span> A combination of DMPA and polyestradiol phosphate, an estrogen and long-lasting prodrug of estradiol, was studied in women as a combined injectable contraceptive for use by intramuscular injection once every three months.<span class="mw-ref" id="cite_ref-GoldzieherFotherby1994_242-0"><a href="#cite_note-GoldzieherFotherby1994-242" style="counter-reset: mw-Ref 242;"><span class="mw-reflink-text">[242]</span></a></span><span class="mw-ref" id="cite_ref-pmid5925038_243-0"><a href="#cite_note-pmid5925038-243" style="counter-reset: mw-Ref 243;"><span class="mw-reflink-text">[243]</span></a></span><span class="mw-ref" id="cite_ref-Beckman1967_244-0"><a href="#cite_note-Beckman1967-244" style="counter-reset: mw-Ref 244;"><span class="mw-reflink-text">[244]</span></a></span></p>

<p>High-dose oral and intramuscular MPA monotherapy has been studied in the treatment of prostate cancer but was found to be inferior to monotherapy with cyproterone acetate or <a href="Diethylstilbestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylstilbestrol" title="Diethylstilbestrol">diethylstilbestrol</a>.<span class="mw-ref" id="cite_ref-PiotrowskiGreenberg2016_245-0"><a href="#cite_note-PiotrowskiGreenberg2016-245" style="counter-reset: mw-Ref 245;"><span class="mw-reflink-text">[245]</span></a></span><span class="mw-ref" id="cite_ref-pmid11842755_246-0"><a href="#cite_note-pmid11842755-246" style="counter-reset: mw-Ref 246;"><span class="mw-reflink-text">[246]</span></a></span><span class="mw-ref" id="cite_ref-pmid9088277_247-0"><a href="#cite_note-pmid9088277-247" style="counter-reset: mw-Ref 247;"><span class="mw-reflink-text">[247]</span></a></span> High-dose oral MPA has been studied in combination with diethylstilbestrol and CEEs as an addition to high-dose estrogen therapy for the treatment of prostate cancer in men, but was not found to provide better effectiveness than diethylstilbestrol alone.<span class="mw-ref" id="cite_ref-DenisGriffiths1999_248-0"><a href="#cite_note-DenisGriffiths1999-248" style="counter-reset: mw-Ref 248;"><span class="mw-reflink-text">[248]</span></a></span></p>

<p>DMPA has been studied for use as a potential male hormonal contraceptive in combination with the androgens/anabolic steroids testosterone and <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">nandrolone</a> (19-nortestosterone) in men.<span class="mw-ref" id="cite_ref-pmid20933120_249-0"><a href="#cite_note-pmid20933120-249" style="counter-reset: mw-Ref 249;"><span class="mw-reflink-text">[249]</span></a></span> However, it was never approved for this indication.<span class="mw-ref" id="cite_ref-pmid20933120_249-1"><a href="#cite_note-pmid20933120-249" style="counter-reset: mw-Ref 249;"><span class="mw-reflink-text">[249]</span></a></span></p>

<p>MPA was investigated by InKine Pharmaceutical, Salix Pharmaceuticals, and the University of Pennsylvania as a potential anti-inflammatory medication for the treatment of autoimmune hemolytic anemia, Crohn's disease, idiopathic thrombocytopenic purpura, and ulcerative colitis, but did not complete clinical development and was never approved for these indications.<span class="mw-ref" id="cite_ref-AdisInsight-MPA-AI_250-0"><a href="#cite_note-AdisInsight-MPA-AI-250" style="counter-reset: mw-Ref 250;"><span class="mw-reflink-text">[250]</span></a></span><span class="mw-ref" id="cite_ref-pmid15102587_251-0"><a href="#cite_note-pmid15102587-251" style="counter-reset: mw-Ref 251;"><span class="mw-reflink-text">[251]</span></a></span> It was formulated as an oral medication at very high dosages, and was thought to inhibit the signaling of proinflammatory cytokines such as interleukin 6 and tumor necrosis factor alpha, with a mechanism of action that was said to be similar to that of corticosteroids.<span class="mw-ref" id="cite_ref-AdisInsight-MPA-AI_250-1"><a href="#cite_note-AdisInsight-MPA-AI-250" style="counter-reset: mw-Ref 250;"><span class="mw-reflink-text">[250]</span></a></span><span class="mw-ref" id="cite_ref-pmid15102587_251-1"><a href="#cite_note-pmid15102587-251" style="counter-reset: mw-Ref 251;"><span class="mw-reflink-text">[251]</span></a></span> The formulation of MPA had the tentative brand names Colirest and Hematrol for these indications.<span class="mw-ref" id="cite_ref-AdisInsight-MPA-AI_250-2"><a href="#cite_note-AdisInsight-MPA-AI-250" style="counter-reset: mw-Ref 250;"><span class="mw-reflink-text">[250]</span></a></span></p>

<p>MPA has been found to be effective in the treatment of manic symptoms in women with bipolar disorder.<span class="mw-ref" id="cite_ref-SaxenaScaini2017_252-0"><a href="#cite_note-SaxenaScaini2017-252" style="counter-reset: mw-Ref 252;"><span class="mw-reflink-text">[252]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Veterinary_use">Veterinary use</h2></summary>
    
<p>MPA has been used to reduce aggression and spraying in male cats.<span class="mw-ref" id="cite_ref-pmid12701517_253-0"><a href="#cite_note-pmid12701517-253" style="counter-reset: mw-Ref 253;"><span class="mw-reflink-text">[253]</span></a></span> It may be particularly useful for controlling such behaviors in neutered male cats.<span class="mw-ref" id="cite_ref-pmid12701517_253-1"><a href="#cite_note-pmid12701517-253" style="counter-reset: mw-Ref 253;"><span class="mw-reflink-text">[253]</span></a></span> The medication can be administered in cats as an injection once per month.<span class="mw-ref" id="cite_ref-pmid12701517_253-2"><a href="#cite_note-pmid12701517-253" style="counter-reset: mw-Ref 253;"><span class="mw-reflink-text">[253]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Conjugated estrogens/medroxyprogesterone acetate</li>
<li>Estradiol/medroxyprogesterone acetate</li>
<li>Estradiol cypionate/medroxyprogesterone acetate</li>
<li>Polyestradiol phosphate/medroxyprogesterone acetate</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Notes">Notes</h2></summary>
    
<div class="reflist " style=" list-style-type: lower-alpha;">
<div class="mw-references-wrap"><ol class="mw-references references" data-mw-group="lower-alpha"></ol></div></div>
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap"><ol class="mw-references references" data-mw-group="note"></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com-2-1"> <span id="mw-reference-text-cite_note-Drugs.com-2-1" class="mw-reference-text"><a href="javascript:if(confirm('https://www.drugs.com/medroxyprogesterone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/medroxyprogesterone.html'" tppabs="https://www.drugs.com/medroxyprogesterone.html" class="external free external">https://www.drugs.com/medroxyprogesterone.html</a></span></li><li id="cite_note-IndexNominum2000-2"> <span id="mw-reference-text-cite_note-IndexNominum2000-2" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638'" tppabs="https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638" class="external text external"><i>Index Nominum 2000: International Drug Directory</i></a>. Taylor &amp; Francis. January 2000. pp.<span>&nbsp;</span>638–. ISBN<span>&nbsp;</span><bdi>978-3-88763-075-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20130619010022/http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130619010022/http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638'" tppabs="https://web.archive.org/web/20130619010022/http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA638" class="external text external">Archived</a> from the original on 2013-06-19.</cite></span></li><li id="cite_note-pmid16112947-3"> <span id="mw-reference-text-cite_note-pmid16112947-3" class="mw-reference-text"><cite id="CITEREFKuhl2005" class="citation journal cs1">Kuhl H (2005). <a href="javascript:if(confirm('http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf'" tppabs="http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf" class="external text external">"Pharmacology of estrogens and progestogens: influence of different routes of administration"</a> <span class="cs1-format">(PDF)</span>. <i>Climacteric</i>. 8 Suppl 1: 3–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F13697130500148875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F13697130500148875'" tppabs="https://doi.org/10.1080%2F13697130500148875" class="external text external">10.1080/13697130500148875</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16112947  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16112947'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16112947" class="external text external">16112947</a>.</cite></span></li><li id="cite_note-pmid19434889-4"> <span id="mw-reference-text-cite_note-pmid19434889-4" class="mw-reference-text"><cite id="CITEREFSchindlerCampagnoliDruckmannHuber2008" class="citation journal cs1">Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2008). "Classification and pharmacology of progestins". <i>Maturitas</i>. <b>61</b> (1–2): 171–80. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2008.11.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2008.11.013'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2008.11.013" class="external text external">10.1016/j.maturitas.2008.11.013</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19434889  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19434889'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19434889" class="external text external">19434889</a>.</cite></span></li><li id="cite_note-ProveraLabel-5"> <span id="mw-reference-text-cite_note-ProveraLabel-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20170211092207/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170211092207/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf'" tppabs="https://web.archive.org/web/20170211092207/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf" class="external text external">"Provera"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>. 2015. Archived from <a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 11 February 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">31 March</span> 2018</span>.</cite></span></li><li id="cite_note-pmid26291834-6"> <span id="mw-reference-text-cite_note-pmid26291834-6" class="mw-reference-text"><cite id="CITEREFStanczykBhavnani2015" class="citation journal cs1">Stanczyk FZ, Bhavnani BR (September 2015). "Reprint of "Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?<span class="cs1-kern-right">"</span>". <i>J. Steroid Biochem. Mol. Biol</i>. <b>153</b>: 151–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jsbmb.2015.08.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jsbmb.2015.08.013'" tppabs="https://doi.org/10.1016%2Fj.jsbmb.2015.08.013" class="external text external">10.1016/j.jsbmb.2015.08.013</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26291834  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26291834'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26291834" class="external text external">26291834</a>.</cite></span></li><li id="cite_note-DepoProveraLabel-7"> <span id="mw-reference-text-cite_note-DepoProveraLabel-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020246s058lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020246s058lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020246s058lbl.pdf" class="external text external">"Depo_Provera"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>. 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">31 March</span> 2018</span>.</cite></span></li><li id="cite_note-DepoSubQProveraLabel-8"> <span id="mw-reference-text-cite_note-DepoSubQProveraLabel-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021583s023lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021583s023lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021583s023lbl.pdf" class="external text external">"depo-subQ Provera"</a> <span class="cs1-format">(PDF)</span>. <i>FDA</i>. 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">31 March</span> 2018</span>.</cite></span></li><li id="cite_note-AHFS2016-9"> <span id="mw-reference-text-cite_note-AHFS2016-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/medroxyprogesterone-acetate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/medroxyprogesterone-acetate.html'" tppabs="https://www.drugs.com/monograph/medroxyprogesterone-acetate.html" class="external text external">"Medroxyprogesterone Acetate"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20161224100359/https://www.drugs.com/monograph/medroxyprogesterone-acetate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161224100359/https://www.drugs.com/monograph/medroxyprogesterone-acetate.html'" tppabs="https://web.archive.org/web/20161224100359/https://www.drugs.com/monograph/medroxyprogesterone-acetate.html" class="external text external">Archived</a> from the original on 24 December 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2016</span>.</cite></span></li><li id="cite_note-Drugs.com-10"> <span id="mw-reference-text-cite_note-Drugs.com-10" class="mw-reference-text"><a href="javascript:if(confirm('https://www.drugs.com/international/medroxyprogesterone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/medroxyprogesterone.html'" tppabs="https://www.drugs.com/international/medroxyprogesterone.html" class="external free external">https://www.drugs.com/international/medroxyprogesterone.html</a></span></li><li id="cite_note-Martindale-11"> <span id="mw-reference-text-cite_note-Martindale-11" class="mw-reference-text"><cite id="CITEREFSweetman,_Sean_C.2009" class="citation book cs1">Sweetman, Sean C., ed. (2009). <a href="javascript:if(confirm('https://www.medicinescomplete.com/mc/martindale/2009/9062-p.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicinescomplete.com/mc/martindale/2009/9062-p.htm'" tppabs="https://www.medicinescomplete.com/mc/martindale/2009/9062-p.htm" class="external text external">"Sex hormones and their modulators"</a>. <i>Martindale: The Complete Drug Reference</i> (36th ed.). London: Pharmaceutical Press. pp.<span>&nbsp;</span>2113–2114. ISBN<span>&nbsp;</span><bdi>978-0-85369-840-1</bdi>.</cite></span></li><li id="cite_note-pmid10077001-12"> <span id="mw-reference-text-cite_note-pmid10077001-12" class="mw-reference-text"><cite id="CITEREFKemppainenLangleyWongBobseine1999" class="citation journal cs1">Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM (March 1999). <a href="javascript:if(confirm('http://mend.endojournals.org/cgi/pmidlookup?view=long&pmid=10077001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://mend.endojournals.org/cgi/pmidlookup?view=long&pmid=10077001'" tppabs="http://mend.endojournals.org/cgi/pmidlookup?view=long&pmid=10077001" class="external text external">"Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone"</a>. <i>Molecular Endocrinology</i>. <b>13</b> (3): 440–54. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fmend.13.3.0255  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fmend.13.3.0255'" tppabs="https://doi.org/10.1210%2Fmend.13.3.0255" class="external text external">10.1210/mend.13.3.0255</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10077001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10077001'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10077001" class="external text external">10077001</a>.</cite></span></li><li id="cite_note-Genazzani1993-13"> <span id="mw-reference-text-cite_note-Genazzani1993-13" class="mw-reference-text"><cite id="CITEREFGenazzani1993" class="citation book cs1">Genazzani AR (15 January 1993). <a href="javascript:if(confirm('https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320'" tppabs="https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320" class="external text external"><i>Frontiers in Gynecologic and Obstetric Investigation</i></a>. Taylor &amp; Francis. p.<span>&nbsp;</span>320. ISBN<span>&nbsp;</span><bdi>978-1-85070-486-7</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160520164420/https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160520164420/https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320'" tppabs="https://web.archive.org/web/20160520164420/https://books.google.com/books?id=vNZ8Xb8lDF4C&pg=PA320" class="external text external">Archived</a> from the original on 20 May 2016.</cite></span></li><li id="cite_note-Roberts2013-14"> <span id="mw-reference-text-cite_note-Roberts2013-14" class="mw-reference-text"><cite id="CITEREFStanley_M._Roberts2013" class="citation book cs1">Stanley M. Roberts (7 May 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=GR11DAAAQBAJ&pg=PP9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=GR11DAAAQBAJ&pg=PP9'" tppabs="https://books.google.com/books?id=GR11DAAAQBAJ&pg=PP9" class="external text external"><i>Introduction to Biological and Small Molecule Drug Research and Development: Chapter 12. Hormone replacement therapy</i></a>. Elsevier Science. pp.<span>&nbsp;</span>9–. ISBN<span>&nbsp;</span><bdi>978-0-12-806202-9</bdi>. <q>[...] medroxyprogesterone acetate, also known as Provera<sup>®</sup> (discovered simultaneously by Searle and Upjohn in 1956) [..]</q></cite></span></li><li id="cite_note-Sneader2005-15"> <span id="mw-reference-text-cite_note-Sneader2005-15" class="mw-reference-text"><cite id="CITEREFSneader2005" class="citation book cs1">Sneader W (2005). "Chapter 18: Hormone analogs". <i>Drug discovery: a history</i>. New York: Wiley. p.<span>&nbsp;</span>204. ISBN<span>&nbsp;</span><bdi>0-471-89980-1</bdi>.</cite></span></li><li id="cite_note-WHO21st-16"> <span id="mw-reference-text-cite_note-WHO21st-16" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-ERC2014-17"> <span id="mw-reference-text-cite_note-ERC2014-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://mshpriceguide.org/en/single-drug-information/?DMFId=497&searchYear=2014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://mshpriceguide.org/en/single-drug-information/?DMFId=497&searchYear=2014'" tppabs="http://mshpriceguide.org/en/single-drug-information/?DMFId=497&searchYear=2014" class="external text external">"Medroxyprogesterone Acetate"</a>. <i>International Drug Price Indicator Guide</i><span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2016</span>.</cite></span></li><li id="cite_note-BNF69-18"> <span id="mw-reference-text-cite_note-BNF69-18" class="mw-reference-text"><cite class="citation book cs1"><i>British National Formulary<span>&nbsp;</span>: BNF 69</i> (69th ed.). British Medical Association. 2015. p.<span>&nbsp;</span>555. ISBN<span>&nbsp;</span><bdi>978-0-85711-156-2</bdi>.</cite></span></li><li id="cite_note-Ric2015-19"> <span id="mw-reference-text-cite_note-Ric2015-19" class="mw-reference-text"><cite id="CITEREFHamilton2015" class="citation book cs1">Hamilton R (2015). <i>Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition</i>. Jones &amp; Bartlett Learning. p.<span>&nbsp;</span>363. ISBN<span>&nbsp;</span><bdi>9781284057560</bdi>.</cite></span></li><li id="cite_note-Meikle1999-20"> <span id="mw-reference-text-cite_note-Meikle1999-20" class="mw-reference-text"><cite id="CITEREFA._Wayne_Meikle1999" class="citation book cs1">A. Wayne Meikle (1 June 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=ja2nBgAAQBAJ&pg=PA383  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=ja2nBgAAQBAJ&pg=PA383'" tppabs="https://books.google.com/books?id=ja2nBgAAQBAJ&pg=PA383" class="external text external"><i>Hormone Replacement Therapy</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>383–. ISBN<span>&nbsp;</span><bdi>978-1-59259-700-0</bdi>.</cite></span></li><li id="cite_note-Organization)Organization2002-21"> <span id="mw-reference-text-cite_note-Organization)Organization2002-21" class="mw-reference-text"><cite id="CITEREFSpecial_Programme_of_Research,_Development,_and_Research_Training_in_Human_Reproduction_(World_Health_Organization)World_Health_Organization2002" class="citation book cs1">Special Programme of Research, Development, and Research Training in Human Reproduction (World Health Organization); World Health Organization (2002). <a href="javascript:if(confirm('https://books.google.com/books?id=cvKaqyMOGjUC&pg=PP17  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=cvKaqyMOGjUC&pg=PP17'" tppabs="https://books.google.com/books?id=cvKaqyMOGjUC&pg=PP17" class="external text external"><i>Research on Reproductive Health at WHO: Biennial Report 2000-2001</i></a>. World Health Organization. pp.<span>&nbsp;</span>17–. ISBN<span>&nbsp;</span><bdi>978-92-4-156208-9</bdi>.</cite><span class="cs1-maint citation-comment">CS1 maint: multiple names: authors list (link)</span></span></li><li id="cite_note-BagadePawar2014-22"> <span id="mw-reference-text-cite_note-BagadePawar2014-22" class="mw-reference-text"><cite id="CITEREFBagadePawarPatelPatel2014" class="citation journal cs1">Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). <a href="javascript:if(confirm('https://web.archive.org/web/20170810000242/http://www.wjpps.com/download/article/1412071798.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170810000242/http://www.wjpps.com/download/article/1412071798.pdf'" tppabs="https://web.archive.org/web/20170810000242/http://www.wjpps.com/download/article/1412071798.pdf" class="external text external">"Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control"</a> <span class="cs1-format">(PDF)</span>. <i>World J Pharm Pharm Sci</i>. <b>3</b> (10): 364–392. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2278-4357  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2278-4357'" tppabs="https://www.worldcat.org/issn/2278-4357" class="external text external">2278-4357</a>. Archived from <a href="javascript:if(confirm('http://www.wjpps.com/download/article/1412071798.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wjpps.com/download/article/1412071798.pdf'" tppabs="http://www.wjpps.com/download/article/1412071798.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2017-08-10<span class="reference-accessdate">. Retrieved <span class="nowrap">2018-08-02</span></span>.</cite></span></li><li id="cite_note-Gunasheela2011-23"> <span id="mw-reference-text-cite_note-Gunasheela2011-23" class="mw-reference-text"><cite id="CITEREFSulochana_Gunasheela2011" class="citation book cs1">Sulochana Gunasheela (14 March 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=gZB-h_gqgS8C&pg=PA39  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=gZB-h_gqgS8C&pg=PA39'" tppabs="https://books.google.com/books?id=gZB-h_gqgS8C&pg=PA39" class="external text external"><i>Practical Management of Gynecological Problems</i></a>. JP Medical Ltd. pp.<span>&nbsp;</span>39–. ISBN<span>&nbsp;</span><bdi>978-93-5025-240-6</bdi>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/MedroxyprogesteroneAcetate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/MedroxyprogesteroneAcetate'" tppabs="https://clincalc.com/DrugStats/Drugs/MedroxyprogesteroneAcetate" class="external text external">"Medroxyprogesterone Acetate - Drug Usage Statistics"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-pmid22895916-26"> <span id="mw-reference-text-cite_note-pmid22895916-26" class="mw-reference-text"><cite id="CITEREFFurnessRobertsMarjoribanksLethaby2012" class="citation journal cs1">Furness S, Roberts H, Marjoribanks J, Lethaby A (August 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039145  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039145'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039145" class="external text external">"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia"</a>. <i>The Cochrane Database of Systematic Reviews</i> (8): CD000402. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD000402.pub4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD000402.pub4'" tppabs="https://doi.org/10.1002%2F14651858.CD000402.pub4" class="external text external">10.1002/14651858.CD000402.pub4</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039145  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039145'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039145" class="external text external">7039145</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22895916  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22895916'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22895916" class="external text external">22895916</a>.</cite></span></li><li id="cite_note-Medline-27"> <span id="mw-reference-text-cite_note-Medline-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682470.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682470.html'" tppabs="https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682470.html" class="external text external">"Medroxyprogesterone"</a>. <i>MedlinePlus</i>. 2008-01-09. <a href="javascript:if(confirm('https://web.archive.org/web/20100712043213/http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682470.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100712043213/http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682470.html'" tppabs="https://web.archive.org/web/20100712043213/http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682470.html" class="external text external">Archived</a> from the original on 2010-07-12<span class="reference-accessdate">. Retrieved <span class="nowrap">2010-07-02</span></span>.</cite></span></li><li id="cite_note-Panay2010-28"> <span id="mw-reference-text-cite_note-Panay2010-28" class="mw-reference-text"><cite id="CITEREFPanayFenton2010" class="citation journal cs1">Panay N, Fenton A (February 2010). "Bioidentical hormones: what is all the hype about?". <i>Climacteric</i>. <b>13</b> (1): 1–3. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F13697130903550250  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F13697130903550250'" tppabs="https://doi.org/10.3109%2F13697130903550250" class="external text external">10.3109/13697130903550250</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20067429  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20067429'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20067429" class="external text external">20067429</a>.</cite></span></li><li id="cite_note-pmid16575429-29"> <span id="mw-reference-text-cite_note-pmid16575429-29" class="mw-reference-text"><cite id="CITEREFLightHolroyd2006" class="citation journal cs1">Light SA, Holroyd S (March 2006). <a href="javascript:if(confirm('http://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-31/issue-2/pdf/pg132.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-31/issue-2/pdf/pg132.pdf'" tppabs="http://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-31/issue-2/pdf/pg132.pdf" class="external text external">"The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia"</a> <span class="cs1-format">(PDF)</span>. <i>Journal of Psychiatry &amp; Neuroscience</i>. <b>31</b> (2): 132–4. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413960  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413960'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413960" class="external text external">1413960</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16575429  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16575429'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16575429" class="external text external">16575429</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160307005616/https://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-31/issue-2/pdf/pg132.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160307005616/https://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-31/issue-2/pdf/pg132.pdf'" tppabs="https://web.archive.org/web/20160307005616/https://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-31/issue-2/pdf/pg132.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 2016-03-07.</cite></span></li><li id="cite_note-Salon2000-30"> <span id="mw-reference-text-cite_note-Salon2000-30" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090107134347/http://archive.salon.com/health/feature/2000/03/01/castration/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090107134347/http://archive.salon.com/health/feature/2000/03/01/castration/'" tppabs="https://web.archive.org/web/20090107134347/http://archive.salon.com/health/feature/2000/03/01/castration/" class="external text external">"The chemical knife"</a>. Archived from <a href="javascript:if(confirm('http://archive.salon.com/health/feature/2000/03/01/castration/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://archive.salon.com/health/feature/2000/03/01/castration/'" tppabs="http://archive.salon.com/health/feature/2000/03/01/castration/" class="external text external">the original</a> on 2009-01-07<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-01-22</span></span>.</cite></span></li><li id="cite_note-Drugs@FDA-Depo-Provera-31"> <span id="mw-reference-text-cite_note-Drugs@FDA-Depo-Provera-31" class="mw-reference-text"><cite class="citation cs2"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012541  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012541'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012541" class="external text external"><i>Depo-Provera (medroxyprogesterone acetate) (NDA # 012541) - Drugs@FDA: FDA Approved Drug Products</i></a><span class="reference-accessdate">, retrieved <span class="nowrap">2 April</span> 2018</span>, <q>Original Approvals or Tentative Approvals: 09/23/1960.</q></cite></span></li><li id="cite_note-Meyler-32"> <span id="mw-reference-text-cite_note-Meyler-32" class="mw-reference-text"><cite id="CITEREFMeyler2009" class="citation book cs1">Meyler L (2009). <a href="javascript:if(confirm('https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA281  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA281#v=onepage&q&f=false'" tppabs="https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA281#v=onepage&q&f=false" class="external text external"><i>Meyler's side effects of endocrine and metabolic drugs</i></a>. Amsterdam: Elsevier Science. pp.<span>&nbsp;</span>281–284]. ISBN<span>&nbsp;</span><bdi>978-0-444-53271-8</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20141023181123/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA281  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141023181123/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA281#v=onepage&q&f=false'" tppabs="https://web.archive.org/web/20141023181123/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA281#v=onepage&q&f=false" class="external text external">Archived</a> from the original on 2014-10-23.</cite></span></li><li id="cite_note-pmid390798-33"> <span id="mw-reference-text-cite_note-pmid390798-33" class="mw-reference-text"><cite id="CITEREFGanzina1979" class="citation journal cs1">Ganzina F (October 1979). "High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review". <i>Tumori</i>. <b>65</b> (5): 563–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F030089167906500507  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F030089167906500507'" tppabs="https://doi.org/10.1177%2F030089167906500507" class="external text external">10.1177/030089167906500507</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/390798  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/390798'" tppabs="https://pubmed.ncbi.nlm.nih.gov/390798" class="external text external">390798</a>.</cite></span></li><li id="cite_note-pmid2974757-34"> <span id="mw-reference-text-cite_note-pmid2974757-34" class="mw-reference-text"><cite id="CITEREFKjaer1988" class="citation journal cs1">Kjaer M (September 1988). "The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma". <i>Cancer Treat. Rev</i>. <b>15</b> (3): 195–209. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0305-7372%2888%2990003-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0305-7372%2888%2990003-5'" tppabs="https://doi.org/10.1016%2F0305-7372%2888%2990003-5" class="external text external">10.1016/0305-7372(88)90003-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2974757  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2974757'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2974757" class="external text external">2974757</a>.</cite></span></li><li id="cite_note-pmid1534051-35"> <span id="mw-reference-text-cite_note-pmid1534051-35" class="mw-reference-text"><cite id="CITEREFVanderstappenBonte1992" class="citation journal cs1">Vanderstappen D, Bonte J (1992). "New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies". <i>Eur. J. Gynaecol. Oncol</i>. <b>13</b> (2): 113–23. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1534051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1534051'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1534051" class="external text external">1534051</a>.</cite></span></li><li id="cite_note-pmid16286768-36"> <span id="mw-reference-text-cite_note-pmid16286768-36" class="mw-reference-text"><cite id="CITEREFGooren2005" class="citation journal cs1">Gooren L (2005). "Hormone treatment of the adult transsexual patient". <i>Horm. Res</i>. 64 Suppl 2 (2): 31–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000087751  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000087751'" tppabs="https://doi.org/10.1159%2F000087751" class="external text external">10.1159/000087751</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16286768  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16286768'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16286768" class="external text external">16286768</a>.</cite></span></li><li id="cite_note-SachdevaDutta2012-37"> <span id="mw-reference-text-cite_note-SachdevaDutta2012-37" class="mw-reference-text"><cite id="CITEREFAnupam_SachdevaAK_Dutta2012" class="citation book cs1">Anupam Sachdeva; AK Dutta (31 August 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=I2FHFyCaDeIC&pg=PA1202  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=I2FHFyCaDeIC&pg=PA1202'" tppabs="https://books.google.com/books?id=I2FHFyCaDeIC&pg=PA1202" class="external text external"><i>Advances in Pediatrics</i></a>. JP Medical Ltd. pp.<span>&nbsp;</span>1202–. ISBN<span>&nbsp;</span><bdi>978-93-5025-777-7</bdi>.</cite></span></li><li id="cite_note-Hammerstein1990-38"> <span id="mw-reference-text-cite_note-Hammerstein1990-38" class="mw-reference-text"><cite id="CITEREFHammerstein1990" class="citation book cs1">Hammerstein, J. (1990). "Antiandrogens: Clinical Aspects". <i>Hair and Hair Diseases</i>. pp.<span>&nbsp;</span>827–886. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-642-74612-3_35  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-642-74612-3_35'" tppabs="https://doi.org/10.1007%2F978-3-642-74612-3_35" class="external text external">10.1007/978-3-642-74612-3_35</a>. ISBN<span>&nbsp;</span><bdi>978-3-642-74614-7</bdi>.</cite></span></li><li id="cite_note-Nadakavukaren2011-39"> <span id="mw-reference-text-cite_note-Nadakavukaren2011-39" class="mw-reference-text"><cite id="CITEREFAnne_Nadakavukaren2011" class="citation book cs1">Anne Nadakavukaren (28 February 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=NXkbAAAAQBAJ&pg=PA63  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=NXkbAAAAQBAJ&pg=PA63'" tppabs="https://books.google.com/books?id=NXkbAAAAQBAJ&pg=PA63" class="external text external"><i>Our Global Environment: A Health Perspective, Seventh Edition</i></a>. Waveland Press. pp.<span>&nbsp;</span>63–. ISBN<span>&nbsp;</span><bdi>978-1-4786-0976-6</bdi>.</cite></span></li><li id="cite_note-Trussell_2011-40"> <span id="mw-reference-text-cite_note-Trussell_2011-40" class="mw-reference-text"><cite id="CITEREFTrussell2011" class="citation book cs1">Trussell J (2011). "Contraceptive efficacy".  In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS (eds.). <i>Contraceptive technology</i> (20th revised ed.). New York: Ardent Media. pp.<span>&nbsp;</span>779–863. ISBN<span>&nbsp;</span><bdi>978-1-59708-004-0</bdi>. OCLC<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/oclc/781956734  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/781956734'" tppabs="https://www.worldcat.org/oclc/781956734" class="external text external">781956734</a>.</cite> Table 26–1 = <span class=""><a href="javascript:if(confirm('http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf'" tppabs="http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf" class="external text external">Table 3–2 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception, and the percentage continuing use at the end of the first year. United States.</a> <a href="javascript:if(confirm('https://web.archive.org/web/20170215224018/http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170215224018/http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf'" tppabs="https://web.archive.org/web/20170215224018/http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf" class="external text external">Archived</a> 2017-02-15 at the Wayback Machine</span></span></li><li id="cite_note-pmid18470526-41"> <span id="mw-reference-text-cite_note-pmid18470526-41" class="mw-reference-text"><cite id="CITEREFBakryMerhiScaliseMahmoud2008" class="citation journal cs1">Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F (July 2008). "Depot-medroxyprogesterone acetate: an update". <i>Arch. Gynecol. Obstet</i>. <b>278</b> (1): 1–12. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00404-007-0497-z  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00404-007-0497-z'" tppabs="https://doi.org/10.1007%2Fs00404-007-0497-z" class="external text external">10.1007/s00404-007-0497-z</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18470526  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18470526'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18470526" class="external text external">18470526</a>.</cite></span></li><li id="cite_note-westhoff-42"> <span id="mw-reference-text-cite_note-westhoff-42" class="mw-reference-text"><cite id="CITEREFWesthoff2003" class="citation journal cs1">Westhoff C (August 2003). "Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety". <i>Contraception</i>. <b>68</b> (2): 75–87. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0010-7824%2803%2900136-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0010-7824%2803%2900136-7'" tppabs="https://doi.org/10.1016%2FS0010-7824%2803%2900136-7" class="external text external">10.1016/S0010-7824(03)00136-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12954518  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12954518'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12954518" class="external text external">12954518</a>.</cite></span></li><li id="cite_note-trussell_2004a-43"> <span id="mw-reference-text-cite_note-trussell_2004a-43" class="mw-reference-text"><cite id="CITEREFTrussell2004" class="citation book cs1">Trussell J (2004). "Contraceptive Efficacy".  In Hatcher RA, Trussell J, Stewart FH, Nelson AL, Cates Jr W, Guest F, Kowal D (eds.). <i>Contraceptive Technology</i> (18th rev. ed.). New York: Ardent Media. pp.<span>&nbsp;</span>773–845. ISBN<span>&nbsp;</span><bdi>0-9664902-5-8</bdi>.</cite></span></li><li id="cite_note-trussell_2004b-44"> <span id="mw-reference-text-cite_note-trussell_2004b-44" class="mw-reference-text"><cite class="citation journal cs1">Trussell J (August 2004). "Contraceptive failure in the United States". <i>Contraception</i>. <b>70</b> (2): 89–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.contraception.2004.03.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.contraception.2004.03.009'" tppabs="https://doi.org/10.1016%2Fj.contraception.2004.03.009" class="external text external">10.1016/j.contraception.2004.03.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15288211  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15288211'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15288211" class="external text external">15288211</a>.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite id="CITEREFTrussellHatcherCatesStewart1990" class="citation journal cs1">Trussell J, Hatcher RA, Cates W, Stewart FH, Kost K (September 1990). "A guide to interpreting contraceptive efficacy studies". <i>Obstetrics and Gynecology</i>. <b>76</b> (3 Pt 2): 558–67. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2199875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2199875'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2199875" class="external text external">2199875</a>.</cite></span></li><li id="cite_note-trussell_1994-46"> <span id="mw-reference-text-cite_note-trussell_1994-46" class="mw-reference-text"><cite id="CITEREFTrussell1994" class="citation book cs1">Trussell J (1994). "Contraceptive Failure Rates".  In Hatcher RA, Trussell J, Stewart F, Stewart GK, Kowal D, Guest F, Cates W, Policar MS (eds.). <span class="cs1-lock-registration"><a href="javascript:if(confirm('https://archive.org/details/isbn_9780829031713  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/isbn_9780829031713'" tppabs="https://archive.org/details/isbn_9780829031713" class="external text external"><i>Contraceptive Technology</i></a></span> (16th rev. ed.). New York: Irvington Publishers. pp.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/isbn_9780829031713/page/637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/isbn_9780829031713/page/637'" tppabs="https://archive.org/details/isbn_9780829031713/page/637" class="external text external">637</a>–688. ISBN<span>&nbsp;</span><bdi>0-8290-3171-5</bdi>.</cite></span></li><li id="cite_note-trussell_1998-47"> <span id="mw-reference-text-cite_note-trussell_1998-47" class="mw-reference-text"><cite id="CITEREFTrussell1998" class="citation book cs1">Trussell J (1998). <span class="cs1-lock-registration"><a href="javascript:if(confirm('https://archive.org/details/contraceptivetec00hatc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/contraceptivetec00hatc'" tppabs="https://archive.org/details/contraceptivetec00hatc" class="external text external">"Contraceptive Efficacy"</a></span>.  In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D (eds.). <i>Contraceptive Technology</i> (17th rev. ed.). New York: Ardent Media. pp.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/contraceptivetec00hatc/page/779  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/contraceptivetec00hatc/page/779'" tppabs="https://archive.org/details/contraceptivetec00hatc/page/779" class="external text external">779</a>–844. ISBN<span>&nbsp;</span><bdi>0-9664902-0-7</bdi>.</cite></span></li><li id="cite_note-fda_guidance-48"> <span id="mw-reference-text-cite_note-fda_guidance-48" class="mw-reference-text"><cite id="CITEREFFDA1998" class="citation web cs1">FDA (1998). <a href="javascript:if(confirm('https://web.archive.org/web/20070225182414/https://www.fda.gov/cdrh/ode/contrlab.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070225182414/https://www.fda.gov/cdrh/ode/contrlab.pdf'" tppabs="https://web.archive.org/web/20070225182414/https://www.fda.gov/cdrh/ode/contrlab.pdf" class="external text external">"Guidance for Industry - Uniform Contraceptive Labeling"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/cdrh/ode/contrlab.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cdrh/ode/contrlab.pdf'" tppabs="https://www.fda.gov/cdrh/ode/contrlab.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on February 25, 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-06-21</span></span>.</cite></span></li><li id="cite_note-trussell_2007-49"> <span id="mw-reference-text-cite_note-trussell_2007-49" class="mw-reference-text"><cite id="CITEREFTrussell2007" class="citation book cs1">Trussell J (2007). <a href="javascript:if(confirm('http://www.contraceptivetechnology.com/table.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.contraceptivetechnology.com/table.html'" tppabs="http://www.contraceptivetechnology.com/table.html" class="external text external">"Contraceptive Efficacy"</a>.  In Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D (eds.). <i>Contraceptive Technology</i> (19th rev. ed.). New York: Ardent Media. <a href="javascript:if(confirm('https://web.archive.org/web/20080531095926/http://www.contraceptivetechnology.com/table.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080531095926/http://www.contraceptivetechnology.com/table.html'" tppabs="https://web.archive.org/web/20080531095926/http://www.contraceptivetechnology.com/table.html" class="external text external">Archived</a> from the original on 2008-05-31<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-06-21</span></span>.</cite></span></li><li id="cite_note-trussell_1999-50"> <span id="mw-reference-text-cite_note-trussell_1999-50" class="mw-reference-text"><cite id="CITEREFTrussellVaughan1999" class="citation journal cs1">Trussell J, Vaughan B (1999). <a href="javascript:if(confirm('http://www.guttmacher.org/pubs/journals/3106499.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guttmacher.org/pubs/journals/3106499.pdf'" tppabs="http://www.guttmacher.org/pubs/journals/3106499.pdf" class="external text external">"Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth"</a> <span class="cs1-format">(PDF)</span>. <i>Family Planning Perspectives</i>. <b>31</b> (2): 64–72, 93. doi:<a href="javascript:if(confirm('https://doi.org/10.2307%2F2991641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2307%2F2991641'" tppabs="https://doi.org/10.2307%2F2991641" class="external text external">10.2307/2991641</a>. JSTOR<span>&nbsp;</span><a href="javascript:if(confirm('https://www.jstor.org/stable/2991641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.jstor.org/stable/2991641'" tppabs="https://www.jstor.org/stable/2991641" class="external text external">2991641</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10224544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10224544'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10224544" class="external text external">10224544</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20081202020036/https://www.guttmacher.org/pubs/journals/3106499.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20081202020036/https://www.guttmacher.org/pubs/journals/3106499.pdf'" tppabs="https://web.archive.org/web/20081202020036/https://www.guttmacher.org/pubs/journals/3106499.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 2008-12-02.</cite></span></li><li id="cite_note-hatcher-51"> <span id="mw-reference-text-cite_note-hatcher-51" class="mw-reference-text"><cite id="CITEREFHatcher2004" class="citation book cs1">Hatcher RA (2004). "Depo-Provera Injections, Implants, and Progestin-Only Pills (Minipills)".  In Hatcher RA, Trussell J, Stewart FH, Nelson AL, Cates Jr W, Guest F, Kowal D (eds.). <i>Contraceptive Technology</i> (18th rev. ed.). New York: Ardent Media. pp.<span>&nbsp;</span>461–494. ISBN<span>&nbsp;</span><bdi>0-9664902-5-8</bdi>.</cite></span></li><li id="cite_note-speroff-52"> <span id="mw-reference-text-cite_note-speroff-52" class="mw-reference-text"><cite id="CITEREFSperoffDarney2005" class="citation book cs1">Speroff L, Darney PD (2005). "Injectable Contraception". <i>A Clinical Guide for Contraception</i> (4th ed.). Philadelphia: Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>201–220. ISBN<span>&nbsp;</span><bdi>0-7817-6488-2</bdi>.</cite></span></li><li id="cite_note-mishell-53"> <span id="mw-reference-text-cite_note-mishell-53" class="mw-reference-text"><cite id="CITEREFMishell2004" class="citation book cs1">Mishell DR (2004). "Contraception".  In Strauss JF, Barbieri RL (eds.). <i>Yen and Jaffe's Reproductive Endocrinology</i> (5th ed.). Philadelphia: Elsevier Saunders. pp.<span>&nbsp;</span>899–938. ISBN<span>&nbsp;</span><bdi>0-7216-9546-9</bdi>.</cite></span></li><li id="cite_note-Kaunitz-54"> <span id="mw-reference-text-cite_note-Kaunitz-54" class="mw-reference-text"><cite id="CITEREFKaunitz2001" class="citation journal cs1">Kaunitz AM (December 2001). "Current options for injectable contraception in the United States". <i>Seminars in Reproductive Medicine</i>. <b>19</b> (4): 331–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1055%2Fs-2001-18641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1055%2Fs-2001-18641'" tppabs="https://doi.org/10.1055%2Fs-2001-18641" class="external text external">10.1055/s-2001-18641</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11727175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11727175'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11727175" class="external text external">11727175</a>.</cite></span></li><li id="cite_note-BrJFP_Bigrigg1999-55"> <span id="mw-reference-text-cite_note-BrJFP_Bigrigg1999-55" class="mw-reference-text"><cite id="CITEREFBigriggEvansGboladeNewton1999" class="citation journal cs1">Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M (July 1999). "Depo Provera. Position paper on clinical use, effectiveness and side effects". <i>The British Journal of Family Planning</i>. <b>25</b> (2): 69–76. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10454658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10454658'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10454658" class="external text external">10454658</a>.</cite></span></li><li id="cite_note-WHO_DMPA_EC-56"> <span id="mw-reference-text-cite_note-WHO_DMPA_EC-56" class="mw-reference-text"><cite class="citation journal cs1">"Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives". <i>International Journal of Cancer</i>. <b>49</b> (2): 186–90. September 1991. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fijc.2910490207  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fijc.2910490207'" tppabs="https://doi.org/10.1002%2Fijc.2910490207" class="external text external">10.1002/ijc.2910490207</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1831802  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1831802'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1831802" class="external text external">1831802</a>.</cite></span></li><li id="cite_note-Santen-57"> <span id="mw-reference-text-cite_note-Santen-57" class="mw-reference-text"><cite id="CITEREFSanten2004" class="citation book cs1">Santen RJ (2004). "Endocrinology of Breast and Endometrial Cancer".  In Strauss JF, Barbieri RL (eds.). <i>Yen and Jaffe's Reproductive Endocrinology</i> (5th ed.). Philadelphia: Elsevier Saunders. pp.<span>&nbsp;</span>787–809. ISBN<span>&nbsp;</span><bdi>0-7216-9546-9</bdi>.</cite></span></li><li id="cite_note-Bartz_2011-58"> <span id="mw-reference-text-cite_note-Bartz_2011-58" class="mw-reference-text"><cite id="CITEREFBartzGoldberg2011" class="citation book cs1">Bartz D, Goldberg AB (2011). "Injectable contraceptives".  In Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS (eds.). <i>Contraceptive technology</i> (20th revised ed.). New York: Ardent Media. pp.<span>&nbsp;</span>212–213. ISBN<span>&nbsp;</span><bdi>978-1-59708-004-0</bdi>. OCLC<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/oclc/781956734  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/781956734'" tppabs="https://www.worldcat.org/oclc/781956734" class="external text external">781956734</a>. <q>Advantages of DMPA Injectables. 5. Reduced risk of ectopic pregnancy. Compared with women who use no contraceptive at all, women who use DMPA have a reduced risk for having an ectopic pregnancy. Although the overall risk of pregnancy and thus ectopic pregnancy is lowered by DMPA, the possibility of an ectopic pregnancy should be excluded if a woman using DMPA becomes pregnant. One study showed that 1.5% of women who got pregnant on DMPA had an ectopic pregnancy, the same ectopic rate as women who conceived while not using contraception.<sup>27</sup></q></cite></span></li><li id="cite_note-59"> <span id="mw-reference-text-cite_note-59" class="mw-reference-text"><cite id="CITEREFBorgattaMurthyChuangBeardsley2002" class="citation journal cs1">Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill MS (September 2002). "Pregnancies diagnosed during Depo-Provera use". <i>Contraception</i>. <b>66</b> (3): 169–72. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0010-7824%2802%2900340-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0010-7824%2802%2900340-2'" tppabs="https://doi.org/10.1016%2FS0010-7824%2802%2900340-2" class="external text external">10.1016/S0010-7824(02)00340-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12384205  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12384205'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12384205" class="external text external">12384205</a>.</cite></span></li><li id="cite_note-obrien-60"> <span id="mw-reference-text-cite_note-obrien-60" class="mw-reference-text"><cite id="CITEREFO'BrienGuillebaud2006" class="citation journal cs1">O'Brien MD, Guillebaud J (September 2006). "Contraception for women with epilepsy". <i>Epilepsia</i>. <b>47</b> (9): 1419–22. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1528-1167.2006.00671.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1528-1167.2006.00671.x'" tppabs="https://doi.org/10.1111%2Fj.1528-1167.2006.00671.x" class="external text external">10.1111/j.1528-1167.2006.00671.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16981856  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16981856'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16981856" class="external text external">16981856</a>.</cite></span></li><li id="cite_note-61"> <span id="mw-reference-text-cite_note-61" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.nursingtimes.net/clinical-archive/sexual-health/increasing-use-of-long-acting-reversible-contraception-21-10-2008/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nursingtimes.net/clinical-archive/sexual-health/increasing-use-of-long-acting-reversible-contraception-21-10-2008/'" tppabs="https://www.nursingtimes.net/clinical-archive/sexual-health/increasing-use-of-long-acting-reversible-contraception-21-10-2008/" class="external text external">"Increasing use of long-acting reversible contraception"</a>. Nursing Times.net. 21 October 2008. <a href="javascript:if(confirm('https://web.archive.org/web/20090826233650/https://www.nursingtimes.net/clinical-archive/sexual-health/increasing-use-of-long-acting-reversible-contraception-21-10-2008/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090826233650/https://www.nursingtimes.net/clinical-archive/sexual-health/increasing-use-of-long-acting-reversible-contraception-21-10-2008/'" tppabs="https://web.archive.org/web/20090826233650/https://www.nursingtimes.net/clinical-archive/sexual-health/increasing-use-of-long-acting-reversible-contraception-21-10-2008/" class="external text external">Archived</a> from the original on 26 August 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-06-19</span></span>.</cite></span></li><li id="cite_note-62"> <span id="mw-reference-text-cite_note-62" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090920091647/http://www.nice.org.uk/nicemedia/pdf/cg030quickrefguide.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090920091647/http://www.nice.org.uk/nicemedia/pdf/cg030quickrefguide.pdf'" tppabs="https://web.archive.org/web/20090920091647/http://www.nice.org.uk/nicemedia/pdf/cg030quickrefguide.pdf" class="external text external">"CG30 Long-acting reversible contraception: quick reference guide"</a> <span class="cs1-format">(PDF)</span>. National Institute for Health and Clinical Excellence. Archived from <a href="javascript:if(confirm('http://www.nice.org.uk/nicemedia/pdf/cg030quickrefguide.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nice.org.uk/nicemedia/pdf/cg030quickrefguide.pdf'" tppabs="http://www.nice.org.uk/nicemedia/pdf/cg030quickrefguide.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2009-09-20<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-06-19</span></span>.</cite></span></li><li id="cite_note-63"> <span id="mw-reference-text-cite_note-63" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20v14/sexual_health_ruleset_r4_v14_0.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20v14/sexual_health_ruleset_r4_v14_0.pdf'" tppabs="http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20v14/sexual_health_ruleset_r4_v14_0.pdf" class="external text external">"Sexual Health Ruleset"</a> <span class="cs1-format">(PDF)</span>. <i>New GMS Contract Quality and Outcome Framework - Implementation Dataset and Business Rules</i>. Primary Care Commissioning. 1 May 2009. <a href="javascript:if(confirm('https://web.archive.org/web/20110810074228/http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20v14/sexual_health_ruleset_r4_v14_0.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110810074228/http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20v14/sexual_health_ruleset_r4_v14_0.pdf'" tppabs="https://web.archive.org/web/20110810074228/http://www.pcc.nhs.uk/uploads/QOF/Business%20Rules%20v14/sexual_health_ruleset_r4_v14_0.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 10 August 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-06-19</span></span>.</cite><br><b>Sumarized at</b><br>* <cite class="citation web cs1"><a href="javascript:if(confirm('http://cks.library.nhs.uk/contraception/management/goals_and_outcome_measures/qof_indicators  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://cks.library.nhs.uk/contraception/management/goals_and_outcome_measures/qof_indicators'" tppabs="http://cks.library.nhs.uk/contraception/management/goals_and_outcome_measures/qof_indicators" class="external text external">"Contraception - Management QOF indicators"</a>. <i>NHS Clinical Knowledge Summaries</i>. NHS Institute for Innovation and Improvement<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-06-19</span></span>.</cite></span></li><li id="cite_note-Holtorf2009-64"> <span id="mw-reference-text-cite_note-Holtorf2009-64" class="mw-reference-text"><cite id="CITEREFHoltorf2009" class="citation journal cs1">Holtorf K (January 2009). <a href="javascript:if(confirm('https://web.archive.org/web/20110708075449/http://www.bobmehrpharmacies.com/images/_content/bio-identical/The%20Bioidentical%20Hormone%20Debate-%20Ken%20Holtorf%20MD.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110708075449/http://www.bobmehrpharmacies.com/images/_content/bio-identical/The%20Bioidentical%20Hormone%20Debate-%20Ken%20Holtorf%20MD.pdf'" tppabs="https://web.archive.org/web/20110708075449/http://www.bobmehrpharmacies.com/images/_content/bio-identical/The%20Bioidentical%20Hormone%20Debate-%20Ken%20Holtorf%20MD.pdf" class="external text external">"The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?"</a> <span class="cs1-format">(PDF)</span>. <i>Postgraduate Medicine</i>. <b>121</b> (1): 73–85. doi:<a href="javascript:if(confirm('https://doi.org/10.3810%2Fpgm.2009.01.1949  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3810%2Fpgm.2009.01.1949'" tppabs="https://doi.org/10.3810%2Fpgm.2009.01.1949" class="external text external">10.3810/pgm.2009.01.1949</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19179815  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19179815'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19179815" class="external text external">19179815</a>. Archived from <a href="javascript:if(confirm('http://www.bobmehrpharmacies.com/images/_content/bio-identical/The%20Bioidentical%20Hormone%20Debate-%20Ken%20Holtorf%20MD.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.bobmehrpharmacies.com/images/_content/bio-identical/The%20Bioidentical%20Hormone%20Debate-%20Ken%20Holtorf%20MD.pdf'" tppabs="http://www.bobmehrpharmacies.com/images/_content/bio-identical/The%20Bioidentical%20Hormone%20Debate-%20Ken%20Holtorf%20MD.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2011-07-08.</cite></span></li><li id="cite_note-Cirigliano-65"> <span id="mw-reference-text-cite_note-Cirigliano-65" class="mw-reference-text"><cite id="CITEREFCirigliano2007" class="citation journal cs1">Cirigliano M (June 2007). <a href="javascript:if(confirm('https://web.archive.org/web/20110106204000/http://www.solaltech.com/doctors/3/Bioidentical%20Hormone%20Therapy--%20Cirigliano.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110106204000/http://www.solaltech.com/doctors/3/Bioidentical%20Hormone%20Therapy--%20Cirigliano.pdf'" tppabs="https://web.archive.org/web/20110106204000/http://www.solaltech.com/doctors/3/Bioidentical%20Hormone%20Therapy--%20Cirigliano.pdf" class="external text external">"Bioidentical hormone therapy: a review of the evidence"</a> <span class="cs1-format">(PDF)</span>. <i>Journal of Women's Health</i>. <b>16</b> (5): 600–31. doi:<a href="javascript:if(confirm('https://doi.org/10.1089%2Fjwh.2006.0311  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1089%2Fjwh.2006.0311'" tppabs="https://doi.org/10.1089%2Fjwh.2006.0311" class="external text external">10.1089/jwh.2006.0311</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17627398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17627398'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17627398" class="external text external">17627398</a>. Archived from <a href="javascript:if(confirm('http://www.solaltech.com/doctors/3/Bioidentical%20Hormone%20Therapy--%20Cirigliano.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.solaltech.com/doctors/3/Bioidentical%20Hormone%20Therapy--%20Cirigliano.pdf'" tppabs="http://www.solaltech.com/doctors/3/Bioidentical%20Hormone%20Therapy--%20Cirigliano.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2011-01-06.</cite></span></li><li id="cite_note-66"> <span id="mw-reference-text-cite_note-66" class="mw-reference-text"><cite id="CITEREFBoothbyDoering2008" class="citation journal cs1">Boothby LA, Doering PL (August 2008). "Bioidentical hormone therapy: a panacea that lacks supportive evidence". <i>Current Opinion in Obstetrics and Gynecology</i>. <b>20</b> (4): 400–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FGCO.0b013e3283081ae9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FGCO.0b013e3283081ae9'" tppabs="https://doi.org/10.1097%2FGCO.0b013e3283081ae9" class="external text external">10.1097/GCO.0b013e3283081ae9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18660693  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18660693'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18660693" class="external text external">18660693</a>.</cite></span></li><li id="cite_note-Drugs@FDA-67"> <span id="mw-reference-text-cite_note-Drugs@FDA-67" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/scripts/cder/daf/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/scripts/cder/daf/'" tppabs="http://www.accessdata.fda.gov/scripts/cder/daf/" class="external text external">"Drugs@FDA: FDA Approved Drug Products"</a>. United States Food and Drug Administration. <a href="javascript:if(confirm('https://web.archive.org/web/20161116164727/http://www.accessdata.fda.gov/scripts/cder/daf/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161116164727/http://www.accessdata.fda.gov/scripts/cder/daf/'" tppabs="https://web.archive.org/web/20161116164727/http://www.accessdata.fda.gov/scripts/cder/daf/" class="external text external">Archived</a> from the original on 16 November 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">31 March</span> 2018</span>.</cite></span></li><li id="cite_note-HospitalEngorn2014-68"> <span id="mw-reference-text-cite_note-HospitalEngorn2014-68" class="mw-reference-text"><cite id="CITEREFEngornFlerlage2014" class="citation book cs1">Engorn B, Flerlage J (1 May 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=6cSLAwAAQBAJ&pg=PA846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=6cSLAwAAQBAJ&pg=PA846'" tppabs="https://books.google.com/books?id=6cSLAwAAQBAJ&pg=PA846" class="external text external"><i>The Harriet Lane Handbook E-Book</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>846–. ISBN<span>&nbsp;</span><bdi>978-0-323-11246-8</bdi>.</cite></span></li><li id="cite_note-Tiziani2013-69"> <span id="mw-reference-text-cite_note-Tiziani2013-69" class="mw-reference-text"><cite id="CITEREFAdriana_P._Tiziani2013" class="citation book cs1">Adriana P. Tiziani (1 June 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=XpzQAgAAQBAJ&pg=PA989  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=XpzQAgAAQBAJ&pg=PA989'" tppabs="https://books.google.com/books?id=XpzQAgAAQBAJ&pg=PA989" class="external text external"><i>Havard's Nursing Guide to Drugs</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>989–. ISBN<span>&nbsp;</span><bdi>978-0-7295-8162-2</bdi>.</cite></span></li><li id="cite_note-Leidenberger2013-70"> <span id="mw-reference-text-cite_note-Leidenberger2013-70" class="mw-reference-text"><cite id="CITEREFFreimut_A._Leidenberger2013" class="citation book cs1">Freimut A. Leidenberger (17 April 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=YTiuBgAAQBAJ&pg=PA528  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=YTiuBgAAQBAJ&pg=PA528'" tppabs="https://books.google.com/books?id=YTiuBgAAQBAJ&pg=PA528" class="external text external"><i>Klinische Endokrinologie für Frauenärzte</i></a>. Springer-Verlag. pp.<span>&nbsp;</span>528–. ISBN<span>&nbsp;</span><bdi>978-3-662-08110-5</bdi>.</cite></span></li><li id="cite_note-Depo_Provera:_The_Birth_Control_Shot-71"> <span id="mw-reference-text-cite_note-Depo_Provera:_The_Birth_Control_Shot-71" class="mw-reference-text">Stacey, Dawn. <a href="javascript:if(confirm('http://contraception.about.com/od/prescriptionoptions/a/depoprovera.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://contraception.about.com/od/prescriptionoptions/a/depoprovera.htm'" tppabs="http://contraception.about.com/od/prescriptionoptions/a/depoprovera.htm" class="external text external"><i>Depo Provera: The Birth Control Shot</i></a> <a href="javascript:if(confirm('https://web.archive.org/web/20081010212054/http://contraception.about.com/od/prescriptionoptions/a/depoprovera.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20081010212054/http://contraception.about.com/od/prescriptionoptions/a/depoprovera.htm'" tppabs="https://web.archive.org/web/20081010212054/http://contraception.about.com/od/prescriptionoptions/a/depoprovera.htm" class="external text external">Archived</a><span> 2008-10-10 at the </span>Wayback Machine Accessed October 13, 2009</span></li><li id="cite_note-who_mec-72"> <span id="mw-reference-text-cite_note-who_mec-72" class="mw-reference-text"><cite id="CITEREFWHO2004" class="citation book cs1">WHO (2004). <a href="javascript:if(confirm('http://www.who.int/reproductive-health/publications/mec/pocs.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.who.int/reproductive-health/publications/mec/pocs.html'" tppabs="http://www.who.int/reproductive-health/publications/mec/pocs.html" class="external text external">"Progestogen-only contraceptives"</a>. <i>Medical Eligibility Criteria for Contraceptive Use</i> (3rd ed.). Geneva: Reproductive Health and Research, WHO. ISBN<span>&nbsp;</span><bdi>92-4-156266-8</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20090531160312/http://www.who.int/reproductive-health/publications/mec/pocs.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090531160312/http://www.who.int/reproductive-health/publications/mec/pocs.html'" tppabs="https://web.archive.org/web/20090531160312/http://www.who.int/reproductive-health/publications/mec/pocs.html" class="external text external">Archived</a> from the original on 2009-05-31.</cite></span></li><li id="cite_note-ffprhc_mec-73"> <span id="mw-reference-text-cite_note-ffprhc_mec-73" class="mw-reference-text"><cite id="CITEREFFFPRHC2006" class="citation web cs1">FFPRHC (2006). <a href="javascript:if(confirm('https://web.archive.org/web/20070619230102/http://www.ffprhc.org.uk/admin/uploads/UKMEC200506.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070619230102/http://www.ffprhc.org.uk/admin/uploads/UKMEC200506.pdf'" tppabs="https://web.archive.org/web/20070619230102/http://www.ffprhc.org.uk/admin/uploads/UKMEC200506.pdf" class="external text external">"The UK Medical Eligibility Criteria for Contraceptive Use (2005/2006)"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://www.ffprhc.org.uk/admin/uploads/UKMEC200506.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ffprhc.org.uk/admin/uploads/UKMEC200506.pdf'" tppabs="http://www.ffprhc.org.uk/admin/uploads/UKMEC200506.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on June 19, 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-01-11</span></span>.</cite></span></li><li id="cite_note-Merck-74"> <span id="mw-reference-text-cite_note-Merck-74" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.merck.com/mmpe/lexicomp/medroxyprogesterone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merck.com/mmpe/lexicomp/medroxyprogesterone.html'" tppabs="http://www.merck.com/mmpe/lexicomp/medroxyprogesterone.html" class="external text external">"MedroxyPROGESTERone: Drug Information Provided by Lexi-Comp"</a>. Merck Manual. 2009-12-01. <a href="javascript:if(confirm('https://web.archive.org/web/20100724182722/http://www.merck.com/mmpe/lexicomp/medroxyprogesterone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100724182722/http://www.merck.com/mmpe/lexicomp/medroxyprogesterone.html'" tppabs="https://web.archive.org/web/20100724182722/http://www.merck.com/mmpe/lexicomp/medroxyprogesterone.html" class="external text external">Archived</a> from the original on 2010-07-24<span class="reference-accessdate">. Retrieved <span class="nowrap">2010-07-08</span></span>.</cite></span></li><li id="cite_note-King2012-75"> <span id="mw-reference-text-cite_note-King2012-75" class="mw-reference-text"><cite id="CITEREFKing2012" class="citation book cs1">King SR (9 November 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=D1fOTC6CP3kC&pg=PA45  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=D1fOTC6CP3kC&pg=PA45'" tppabs="https://books.google.com/books?id=D1fOTC6CP3kC&pg=PA45" class="external text external"><i>Neurosteroids and the Nervous System</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>45–. ISBN<span>&nbsp;</span><bdi>978-1-4614-5559-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20171105200514/https://books.google.com/books?id=D1fOTC6CP3kC&pg=PA45  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20171105200514/https://books.google.com/books?id=D1fOTC6CP3kC&pg=PA45'" tppabs="https://web.archive.org/web/20171105200514/https://books.google.com/books?id=D1fOTC6CP3kC&pg=PA45" class="external text external">Archived</a> from the original on 5 November 2017.</cite></span></li><li id="cite_note-depo_us_patient_info-76"> <span id="mw-reference-text-cite_note-depo_us_patient_info-76" class="mw-reference-text"><cite id="CITEREFPfizer2004" class="citation web cs1">Pfizer (October 2004). <a href="javascript:if(confirm('https://web.archive.org/web/20070206044043/http://www.pfizer.com/pfizer/download/ppi_depo_provera_contraceptive.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070206044043/http://www.pfizer.com/pfizer/download/ppi_depo_provera_contraceptive.pdf'" tppabs="https://web.archive.org/web/20070206044043/http://www.pfizer.com/pfizer/download/ppi_depo_provera_contraceptive.pdf" class="external text external">"Depo-Provera Contraceptive Injection, US patient labeling"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://www.pfizer.com/pfizer/download/ppi_depo_provera_contraceptive.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pfizer.com/pfizer/download/ppi_depo_provera_contraceptive.pdf'" tppabs="http://www.pfizer.com/pfizer/download/ppi_depo_provera_contraceptive.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2007-02-06<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-02-21</span></span>.</cite></span></li><li id="cite_note-pmid720068-77"> <span id="mw-reference-text-cite_note-pmid720068-77" class="mw-reference-text"><cite id="CITEREFAmatayakulSivasomboonThanangkul1978" class="citation journal cs1">Amatayakul K, Sivasomboon B, Thanangkul O (September 1978). "Vitamin and trace mineral metabolism in medroxyprogesterone acetate users". <i>Contraception</i>. <b>18</b> (3): 253–69. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0010-7824%2878%2980019-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0010-7824%2878%2980019-5'" tppabs="https://doi.org/10.1016%2Fs0010-7824%2878%2980019-5" class="external text external">10.1016/s0010-7824(78)80019-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/720068  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/720068'" tppabs="https://pubmed.ncbi.nlm.nih.gov/720068" class="external text external">720068</a>.</cite></span></li><li id="cite_note-Nelson2014-78"> <span id="mw-reference-text-cite_note-Nelson2014-78" class="mw-reference-text"><cite id="CITEREFNelson2014" class="citation journal cs1">Nelson, Anita L (2014). "DMPA: battered and bruised but still needed and used in the USA". <i>Expert Review of Obstetrics &amp; Gynecology</i>. <b>5</b> (6): 673–686. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2Feog.10.60  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2Feog.10.60'" tppabs="https://doi.org/10.1586%2Feog.10.60" class="external text external">10.1586/eog.10.60</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1747-4108  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1747-4108'" tppabs="https://www.worldcat.org/issn/1747-4108" class="external text external">1747-4108</a>.</cite></span></li><li id="cite_note-Aronson2015-79"> <span id="mw-reference-text-cite_note-Aronson2015-79" class="mw-reference-text"><cite id="CITEREFJeffrey_K._Aronson2015" class="citation book cs1">Jeffrey K. Aronson (15 October 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=NOKoBAAAQBAJ&pg=RA2-PA836  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=NOKoBAAAQBAJ&pg=RA2-PA836'" tppabs="https://books.google.com/books?id=NOKoBAAAQBAJ&pg=RA2-PA836" class="external text external"><i>Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions</i></a>. Elsevier Science. pp.<span>&nbsp;</span>2–. ISBN<span>&nbsp;</span><bdi>978-0-444-53716-4</bdi>. <q>Perhaps surprisingly, a consensus seems to be emerging that depot medroxyprogesterone acetate implants do not in fact result in an increase in the incidence of depression or in the severity of pre-existing depression, even after 1 or 2 years, nor do they cause significant weight gain.</q></cite></span></li><li id="cite_note-80"> <span id="mw-reference-text-cite_note-80" class="mw-reference-text"><cite class="citation journal cs1">"Exposure to DMPA in pregnancy may cause low birth weight". <i>Progress in Human Reproduction Research</i> (23): 2–3. 1992. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12286194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12286194'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12286194" class="external text external">12286194</a>.</cite></span></li><li id="cite_note-Lobo2007-81"> <span id="mw-reference-text-cite_note-Lobo2007-81" class="mw-reference-text"><cite id="CITEREFRogerio_A._Lobo2007" class="citation book cs1">Rogerio A. Lobo (5 June 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=gywV9hkcyOMC&pg=PA211  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=gywV9hkcyOMC&pg=PA211'" tppabs="https://books.google.com/books?id=gywV9hkcyOMC&pg=PA211" class="external text external"><i>Treatment of the Postmenopausal Woman: Basic and Clinical Aspects</i></a>. Elsevier. pp.<span>&nbsp;</span>211–. ISBN<span>&nbsp;</span><bdi>978-0-08-055309-2</bdi>.</cite></span></li><li id="cite_note-pmid10338269-82"> <span id="mw-reference-text-cite_note-pmid10338269-82" class="mw-reference-text"><cite id="CITEREFKaunitz1999" class="citation journal cs1">Kaunitz AM (1999). "Long-acting hormonal contraception: assessing impact on bone density, weight, and mood". <i>Int J Fertil Womens Med</i>. <b>44</b> (2): 110–7. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10338269  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10338269'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10338269" class="external text external">10338269</a>. <q>Despite the efficacy and increasing acceptability of these long-term methods, some clinicians and women are reluctant to use them because of concerns regarding reduction in bone density with DMPA, and depressive symptoms and body weight issues with both injectables and implants. Recent multicenter experience showed no increase in depressive symptoms after 1 year's DMPA use and 2 years' Norplant use, even among users with the highest mean depressive symptom scores pre-therapy.</q></cite></span></li><li id="cite_note-pmid29496297-83"> <span id="mw-reference-text-cite_note-pmid29496297-83" class="mw-reference-text"><cite id="CITEREFWorlyGurSchaffir2018" class="citation journal cs1">Worly BL, Gur TL, Schaffir J (February 2018). "The relationship between progestin hormonal contraception and depression: a systematic review". <i>Contraception</i>. <b>97</b> (6): 478–489. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.contraception.2018.01.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.contraception.2018.01.010'" tppabs="https://doi.org/10.1016%2Fj.contraception.2018.01.010" class="external text external">10.1016/j.contraception.2018.01.010</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29496297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29496297'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29496297" class="external text external">29496297</a>.</cite></span></li><li id="cite_note-pmid12954518-84"> <span id="mw-reference-text-cite_note-pmid12954518-84" class="mw-reference-text"><cite class="citation journal cs1">Westhoff C (August 2003). "Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety". <i>Contraception</i>. <b>68</b> (2): 75–87. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0010-7824%2803%2900136-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0010-7824%2803%2900136-7'" tppabs="https://doi.org/10.1016%2Fs0010-7824%2803%2900136-7" class="external text external">10.1016/s0010-7824(03)00136-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12954518  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12954518'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12954518" class="external text external">12954518</a>. <q>Another common patient tolerability concern reported with hormonal contraception is the effect on mood [95]. The majority of published reports indicate that DMPA does not cause depressive symptoms. In a large, 1-year, clinical trial of DMPA in 3857 US women, fewer than 2% of users reported depression [15]. Other reports in various settings, including a private practice [96], adolescent clinics [97,98], a psychiatric hospital [99] and inner-city family-planning clinics [100,101], have not found an adverse effect of DMPA on depression. [...] Using a variety of objective indices for depressive symptoms, the overall data for both OCs and DMPA are supportive that these agents have no significant effect on mood. Although history of mood symptoms prior to OC use may predispose a subgroup of women to negative mood changes, the data for DMPA suggest that even women who have depressive symptoms prior to treatment can tolerate therapy with no exacerbation of these symptoms.</q></cite></span></li><li id="cite_note-pmid9649914-85"> <span id="mw-reference-text-cite_note-pmid9649914-85" class="mw-reference-text"><cite id="CITEREFWesthoffTrumanKalmussCushman1998" class="citation journal cs1">Westhoff C, Truman C, Kalmuss D, Cushman L, Davidson A, Rulin M, Heartwell S (April 1998). "Depressive symptoms and Depo-Provera". <i>Contraception</i>. <b>57</b> (4): 237–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0010-7824%2898%2900024-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0010-7824%2898%2900024-9'" tppabs="https://doi.org/10.1016%2Fs0010-7824%2898%2900024-9" class="external text external">10.1016/s0010-7824(98)00024-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9649914  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9649914'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9649914" class="external text external">9649914</a>.</cite></span></li><li id="cite_note-FinkPfaff2011-86"> <span id="mw-reference-text-cite_note-FinkPfaff2011-86" class="mw-reference-text"><cite id="CITEREFFinkPfaffLevine2011" class="citation book cs1">Fink G, Pfaff DW, Levine J (31 August 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=Disx7IryLxUC&pg=PA564  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Disx7IryLxUC&pg=PA564'" tppabs="https://books.google.com/books?id=Disx7IryLxUC&pg=PA564" class="external text external"><i>Handbook of Neuroendocrinology</i></a>. Academic Press. pp.<span>&nbsp;</span>564–. ISBN<span>&nbsp;</span><bdi>978-0-12-378554-1</bdi>.</cite></span></li><li id="cite_note-Ryden2009-87"> <span id="mw-reference-text-cite_note-Ryden2009-87" class="mw-reference-text"><cite id="CITEREFJanice_Ryden2009" class="citation book cs1">Janice Ryden (2009). <a href="javascript:if(confirm('https://books.google.com/books?id=Nxct2LPHIsEC&pg=PA379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Nxct2LPHIsEC&pg=PA379'" tppabs="https://books.google.com/books?id=Nxct2LPHIsEC&pg=PA379" class="external text external"><i>Practical Gynecology: A Guide for the Primary Care Physician</i></a>. ACP Press. pp.<span>&nbsp;</span>379–. ISBN<span>&nbsp;</span><bdi>978-1-934465-05-9</bdi>.</cite></span></li><li id="cite_note-pmid11829697-88"> <span id="mw-reference-text-cite_note-pmid11829697-88" class="mw-reference-text"><cite id="CITEREFHlatkyBoothroydVittinghoffSharp2002" class="citation journal cs1">Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA (February 2002). "Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial". <i>JAMA</i>. <b>287</b> (5): 591–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.287.5.591  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.287.5.591'" tppabs="https://doi.org/10.1001%2Fjama.287.5.591" class="external text external">10.1001/jama.287.5.591</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11829697  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11829697'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11829697" class="external text external">11829697</a>.</cite></span></li><li id="cite_note-pmid15358281-89"> <span id="mw-reference-text-cite_note-pmid15358281-89" class="mw-reference-text"><cite id="CITEREFWiegratzKuhl2004" class="citation journal cs1">Wiegratz I, Kuhl H (August 2004). "Progestogen therapies: differences in clinical effects?". <i>Trends Endocrinol. Metab</i>. <b>15</b> (6): 277–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.tem.2004.06.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.tem.2004.06.006'" tppabs="https://doi.org/10.1016%2Fj.tem.2004.06.006" class="external text external">10.1016/j.tem.2004.06.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15358281  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15358281'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15358281" class="external text external">15358281</a>.</cite></span></li><li id="cite_note-90"> <span id="mw-reference-text-cite_note-90" class="mw-reference-text"><cite id="CITEREFRossouwAndersonPrenticeLaCroix2002" class="citation journal cs1">Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). <a href="javascript:if(confirm('https://escholarship.org/content/qt3mr6f93p/qt3mr6f93p.pdf?t=prll4c  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://escholarship.org/content/qt3mr6f93p/qt3mr6f93p.pdf?t=prll4c'" tppabs="https://escholarship.org/content/qt3mr6f93p/qt3mr6f93p.pdf?t=prll4c" class="external text external">"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial"</a> <span class="cs1-format">(PDF)</span>. <i>JAMA</i>. <b>288</b> (3): 321–33. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.288.3.321  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.288.3.321'" tppabs="https://doi.org/10.1001%2Fjama.288.3.321" class="external text external">10.1001/jama.288.3.321</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12117397  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12117397'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12117397" class="external text external">12117397</a>.</cite></span></li><li id="cite_note-91"> <span id="mw-reference-text-cite_note-91" class="mw-reference-text"><cite id="CITEREFBethea2011" class="citation journal cs1">Bethea CL (February 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037166  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037166'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037166" class="external text external">"MPA: medroxy-progesterone acetate contributes to much poor advice for women"</a>. <i>Endocrinology</i>. <b>152</b> (2): 343–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fen.2010-1376  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fen.2010-1376'" tppabs="https://doi.org/10.1210%2Fen.2010-1376" class="external text external">10.1210/en.2010-1376</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037166  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037166'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037166" class="external text external">3037166</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21252179  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21252179'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21252179" class="external text external">21252179</a>.</cite></span></li><li id="cite_note-92"> <span id="mw-reference-text-cite_note-92" class="mw-reference-text"><cite id="CITEREFPrenticeAnderson2008" class="citation journal cs1">Prentice RL, Anderson GL (2008). "The women's health initiative: lessons learned". <i>Annual Review of Public Health</i>. <b>29</b>: 131–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1146%2Fannurev.publhealth.29.020907.090947  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1146%2Fannurev.publhealth.29.020907.090947'" tppabs="https://doi.org/10.1146%2Fannurev.publhealth.29.020907.090947" class="external text external">10.1146/annurev.publhealth.29.020907.090947</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18348708  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18348708'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18348708" class="external text external">18348708</a>.</cite></span></li><li id="cite_note-93"> <span id="mw-reference-text-cite_note-93" class="mw-reference-text"><cite id="CITEREFBuistNewtonMigliorettiBeverly2004" class="citation journal cs1">Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L (November 2004). "Hormone therapy prescribing patterns in the United States". <i>Obstetrics and Gynecology</i>. <b>104</b> (5 Pt 1): 1042–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F01.AOG.0000143826.38439.af  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F01.AOG.0000143826.38439.af'" tppabs="https://doi.org/10.1097%2F01.AOG.0000143826.38439.af" class="external text external">10.1097/01.AOG.0000143826.38439.af</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15516400  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15516400'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15516400" class="external text external">15516400</a>.</cite></span></li><li id="cite_note-pmid30008249-94"> <span id="mw-reference-text-cite_note-pmid30008249-94" class="mw-reference-text"><cite id="CITEREFBeyer-WestendorfBauersachsHach-WunderleZotz2018" class="citation journal cs1">Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H (October 2018). "Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy". <i>VASA</i>. <b>47</b> (6): 441–450. doi:<a href="javascript:if(confirm('https://doi.org/10.1024%2F0301-1526%2Fa000726  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1024%2F0301-1526%2Fa000726'" tppabs="https://doi.org/10.1024%2F0301-1526%2Fa000726" class="external text external">10.1024/0301-1526/a000726</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30008249  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30008249'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30008249" class="external text external">30008249</a>.</cite></span></li><li id="cite_note-pmid21559819-95"> <span id="mw-reference-text-cite_note-pmid21559819-95" class="mw-reference-text"><cite id="CITEREFDeLoughery2011" class="citation journal cs1">DeLoughery TG (June 2011). "Estrogen and thrombosis: controversies and common sense". <i>Rev Endocr Metab Disord</i>. <b>12</b> (2): 77–84. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11154-011-9178-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11154-011-9178-0'" tppabs="https://doi.org/10.1007%2Fs11154-011-9178-0" class="external text external">10.1007/s11154-011-9178-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21559819  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21559819'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21559819" class="external text external">21559819</a>.</cite></span></li><li id="cite_note-ManthaKarp2012-96"> <span id="mw-reference-text-cite_note-ManthaKarp2012-96" class="mw-reference-text"><cite id="CITEREFManthaKarpRaghavanTerrin2012" class="citation journal cs1">Mantha, S.; Karp, R.; Raghavan, V.; Terrin, N.; Bauer, K. A.; Zwicker, J. I. (2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580" class="external text external">"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis"</a>. <i>BMJ</i>. <b>345</b> (aug07 2): e4944. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.e4944  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.e4944'" tppabs="https://doi.org/10.1136%2Fbmj.e4944" class="external text external">10.1136/bmj.e4944</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1756-1833  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1756-1833'" tppabs="https://www.worldcat.org/issn/1756-1833" class="external text external">1756-1833</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580" class="external text external">3413580</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22872710  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22872710'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22872710" class="external text external">22872710</a>.</cite></span></li><li id="cite_note-pmid30741807-97"> <span id="mw-reference-text-cite_note-pmid30741807-97" class="mw-reference-text"><cite id="CITEREFTepperJengCurtisBoutot2019" class="citation journal cs1">Tepper NK, Jeng G, Curtis KM, Boutot ME, Boulet SL, Whiteman MK (March 2019). "Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum". <i>Obstet Gynecol</i>. <b>133</b> (3): 533–540. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FAOG.0000000000003135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FAOG.0000000000003135'" tppabs="https://doi.org/10.1097%2FAOG.0000000000003135" class="external text external">10.1097/AOG.0000000000003135</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30741807  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30741807'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30741807" class="external text external">30741807</a>.</cite></span></li><li id="cite_note-Van_Hylckama_VliegMiddeldorp2011-98"> <span id="mw-reference-text-cite_note-Van_Hylckama_VliegMiddeldorp2011-98" class="mw-reference-text"><cite id="CITEREFVan_Hylckama_VliegMiddeldorp2011" class="citation journal cs1">Van Hylckama Vlieg, A.; Middeldorp, S. (2011). "Hormone therapies and venous thromboembolism: where are we now?". <i>Journal of Thrombosis and Haemostasis</i>. <b>9</b> (2): 257–266. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1538-7836.2010.04148.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1538-7836.2010.04148.x'" tppabs="https://doi.org/10.1111%2Fj.1538-7836.2010.04148.x" class="external text external">10.1111/j.1538-7836.2010.04148.x</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1538-7933  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1538-7933'" tppabs="https://www.worldcat.org/issn/1538-7933" class="external text external">1538-7933</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21114755  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21114755'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21114755" class="external text external">21114755</a>.</cite></span></li><li id="cite_note-BenagianoPrimiero1983-99"> <span id="mw-reference-text-cite_note-BenagianoPrimiero1983-99" class="mw-reference-text"><cite id="CITEREFBenagianoPrimiero1983" class="citation journal cs1">Benagiano, G.; Primiero, F.M. (1983). "Long Acting Contraceptives Present Status". <i>Drugs</i>. <b>25</b> (6): 570–609. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-198325060-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-198325060-00003'" tppabs="https://doi.org/10.2165%2F00003495-198325060-00003" class="external text external">10.2165/00003495-198325060-00003</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0012-6667  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0012-6667'" tppabs="https://www.worldcat.org/issn/0012-6667" class="external text external">0012-6667</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6223801  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6223801'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6223801" class="external text external">6223801</a>.</cite></span></li><li id="cite_note-pmid30669160-100"> <span id="mw-reference-text-cite_note-pmid30669160-100" class="mw-reference-text"><cite id="CITEREFRott2019" class="citation journal cs1">Rott H (February 2019). "Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen". <i>Hamostaseologie</i>. <b>39</b> (1): 42–48. doi:<a href="javascript:if(confirm('https://doi.org/10.1055%2Fs-0039-1677806  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1055%2Fs-0039-1677806'" tppabs="https://doi.org/10.1055%2Fs-0039-1677806" class="external text external">10.1055/s-0039-1677806</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30669160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30669160'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30669160" class="external text external">30669160</a>.</cite></span></li><li id="cite_note-pmid29570359-101"> <span id="mw-reference-text-cite_note-pmid29570359-101" class="mw-reference-text"><cite id="CITEREFScarabin2018" class="citation journal cs1">Scarabin PY (August 2018). "Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis". <i>Climacteric</i>. <b>21</b> (4): 341–345. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F13697137.2018.1446931  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F13697137.2018.1446931'" tppabs="https://doi.org/10.1080%2F13697137.2018.1446931" class="external text external">10.1080/13697137.2018.1446931</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29570359  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29570359'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29570359" class="external text external">29570359</a>.</cite></span></li><li id="cite_note-pmid21538049-102"> <span id="mw-reference-text-cite_note-pmid21538049-102" class="mw-reference-text"><cite id="CITEREFSitruk-WareNath2011" class="citation journal cs1">Sitruk-Ware R, Nath A (June 2011). "Metabolic effects of contraceptive steroids". <i>Rev Endocr Metab Disord</i>. <b>12</b> (2): 63–75. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11154-011-9182-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11154-011-9182-4'" tppabs="https://doi.org/10.1007%2Fs11154-011-9182-4" class="external text external">10.1007/s11154-011-9182-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21538049  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21538049'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21538049" class="external text external">21538049</a>.</cite></span></li><li id="cite_note-Kuhl2011-103"> <span id="mw-reference-text-cite_note-Kuhl2011-103" class="mw-reference-text"><cite id="CITEREFKuhl2011" class="citation journal cs1">Kuhl H (2011). <a href="javascript:if(confirm('http://www.kup.at/kup/pdf/10168.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.kup.at/kup/pdf/10168.pdf'" tppabs="http://www.kup.at/kup/pdf/10168.pdf" class="external text external">"Pharmacology of Progestogens"</a> <span class="cs1-format">(PDF)</span>. <i>J Reproduktionsmed Endokrinol</i>. <b>8</b> (1): 157–177. <a href="javascript:if(confirm('https://web.archive.org/web/20161011060809/http://www.kup.at/kup/pdf/10168.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161011060809/http://www.kup.at/kup/pdf/10168.pdf'" tppabs="https://web.archive.org/web/20161011060809/http://www.kup.at/kup/pdf/10168.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 2016-10-11.</cite></span></li><li id="cite_note-104"> <span id="mw-reference-text-cite_note-104" class="mw-reference-text"><cite class="citation journal cs1"><a href="javascript:if(confirm('http://www.acog.org/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.acog.org/'" tppabs="http://www.acog.org/" class="external text external">"Depot medroxyprogesterone acetate and bone effects. Committee Opinion #602"</a>. June 2014. <a href="javascript:if(confirm('https://web.archive.org/web/20150430112715/http://www.acog.org/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150430112715/http://www.acog.org/'" tppabs="https://web.archive.org/web/20150430112715/http://www.acog.org/" class="external text external">Archived</a> from the original on 2015-04-30<span class="reference-accessdate">. Retrieved <span class="nowrap">2015-05-03</span></span>.</cite><span> </span><span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li><li id="cite_note-FDA2004-Warning-105"> <span id="mw-reference-text-cite_note-FDA2004-Warning-105" class="mw-reference-text"><cite id="CITEREFFDA2004" class="citation web cs1">FDA (November 17, 2004). <a href="javascript:if(confirm('https://web.archive.org/web/20051221195621/https://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20051221195621/https://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html'" tppabs="https://web.archive.org/web/20051221195621/https://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html" class="external text external">"Black Box Warning Added Concerning Long-Term Use of Depo-Provera Contraceptive Injection"</a>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html'" tppabs="https://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html" class="external text external">the original</a> on 2005-12-21<span class="reference-accessdate">. Retrieved <span class="nowrap">2006-05-12</span></span>.</cite></span></li><li id="cite_note-WHO2005-106"> <span id="mw-reference-text-cite_note-WHO2005-106" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2005" class="citation web cs1">World Health Organization (September 2005). <a href="javascript:if(confirm('http://www.who.int/reproductive-health/family_planning/bone_health.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.who.int/reproductive-health/family_planning/bone_health.html'" tppabs="http://www.who.int/reproductive-health/family_planning/bone_health.html" class="external text external">"Hormonal contraception and bone health"</a>. <i>Family Planning</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20060514022320/http://www.who.int/reproductive-health/family_planning/bone_health.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060514022320/http://www.who.int/reproductive-health/family_planning/bone_health.html'" tppabs="https://web.archive.org/web/20060514022320/http://www.who.int/reproductive-health/family_planning/bone_health.html" class="external text external">Archived</a> from the original on 2006-05-14<span class="reference-accessdate">. Retrieved <span class="nowrap">2006-05-12</span></span>.</cite></span></li><li id="cite_note-Contraception2006-Curtis-107"> <span id="mw-reference-text-cite_note-Contraception2006-Curtis-107" class="mw-reference-text"><cite id="CITEREFCurtisMartins2006" class="citation journal cs1">Curtis KM, Martins SL (May 2006). <a href="javascript:if(confirm('https://zenodo.org/record/1258855  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://zenodo.org/record/1258855'" tppabs="https://zenodo.org/record/1258855" class="external text external">"Progestogen-only contraception and bone mineral density: a systematic review"</a>. <i>Contraception</i>. <b>73</b> (5): 470–87. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.contraception.2005.12.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.contraception.2005.12.010'" tppabs="https://doi.org/10.1016%2Fj.contraception.2005.12.010" class="external text external">10.1016/j.contraception.2005.12.010</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16627031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16627031'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16627031" class="external text external">16627031</a>.</cite></span></li><li id="cite_note-108"> <span id="mw-reference-text-cite_note-108" class="mw-reference-text"><cite id="CITEREFCundyCornishEvansRoberts1994" class="citation journal cs1">Cundy T, Cornish J, Evans MC, Roberts H, Reid IR (January 1994). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539337  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539337'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539337" class="external text external">"Recovery of bone density in women who stop using medroxyprogesterone acetate"</a>. <i>BMJ</i>. <b>308</b> (6923): 247–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.308.6923.247  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.308.6923.247'" tppabs="https://doi.org/10.1136%2Fbmj.308.6923.247" class="external text external">10.1136/bmj.308.6923.247</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539337  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539337'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539337" class="external text external">2539337</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8111260  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8111260'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8111260" class="external text external">8111260</a>.</cite></span></li><li id="cite_note-Scholes2002-109"> <span id="mw-reference-text-cite_note-Scholes2002-109" class="mw-reference-text"><cite id="CITEREFScholesLaCroixIchikawaBarlow2002" class="citation journal cs1">Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM (September 2002). "Injectable hormone contraception and bone density: results from a prospective study". <i>Epidemiology</i>. <b>13</b> (5): 581–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00001648-200209000-00015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00001648-200209000-00015'" tppabs="https://doi.org/10.1097%2F00001648-200209000-00015" class="external text external">10.1097/00001648-200209000-00015</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12192229  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12192229'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12192229" class="external text external">12192229</a>.</cite></span></li><li id="cite_note-Scholes2005-110"> <span id="mw-reference-text-cite_note-Scholes2005-110" class="mw-reference-text"><cite id="CITEREFScholesLaCroixIchikawaBarlow2005" class="citation journal cs1">Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM (February 2005). "Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception". <i>Archives of Pediatrics &amp; Adolescent Medicine</i>. <b>159</b> (2): 139–44. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Farchpedi.159.2.139  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchpedi.159.2.139'" tppabs="https://doi.org/10.1001%2Farchpedi.159.2.139" class="external text external">10.1001/archpedi.159.2.139</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15699307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15699307'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15699307" class="external text external">15699307</a>.</cite></span></li><li id="cite_note-111"> <span id="mw-reference-text-cite_note-111" class="mw-reference-text"><cite id="CITEREFOrr-WalkerEvansAmesClearwater1998" class="citation journal cs1">Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR (November 1998). "The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women". <i>Clinical Endocrinology</i>. <b>49</b> (5): 615–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2265.1998.00582.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2265.1998.00582.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2265.1998.00582.x" class="external text external">10.1046/j.1365-2265.1998.00582.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10197077  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10197077'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10197077" class="external text external">10197077</a>.</cite></span></li><li id="cite_note-112"> <span id="mw-reference-text-cite_note-112" class="mw-reference-text"><cite id="CITEREFCundyCornishRobertsReid2002" class="citation journal cs1">Cundy T, Cornish J, Roberts H, Reid IR (May 2002). "Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception". <i>American Journal of Obstetrics and Gynecology</i>. <b>186</b> (5): 978–83. doi:<a href="javascript:if(confirm('https://doi.org/10.1067%2Fmob.2002.122420  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1067%2Fmob.2002.122420'" tppabs="https://doi.org/10.1067%2Fmob.2002.122420" class="external text external">10.1067/mob.2002.122420</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12015524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12015524'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12015524" class="external text external">12015524</a>.</cite></span></li><li id="cite_note-113"> <span id="mw-reference-text-cite_note-113" class="mw-reference-text"><cite id="CITEREFWalshEastellPeel2010" class="citation journal cs1">Walsh JS, Eastell R, Peel NF (February 2010). "Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density". <i>Fertility and Sterility</i>. <b>93</b> (3): 697–701. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.fertnstert.2008.10.004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.fertnstert.2008.10.004'" tppabs="https://doi.org/10.1016%2Fj.fertnstert.2008.10.004" class="external text external">10.1016/j.fertnstert.2008.10.004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19013564  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19013564'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19013564" class="external text external">19013564</a>.</cite></span></li><li id="cite_note-pmid18757687-114"> <span id="mw-reference-text-cite_note-pmid18757687-114" class="mw-reference-text"><cite id="CITEREFAmerican_College_of_Obstetricians_Gynecologists_Committee_on_Gynecologic_Practice2008" class="citation journal cs1">American College of Obstetricians Gynecologists Committee on Gynecologic Practice (September 2008). "ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects". <i>Obstetrics and Gynecology</i>. <b>112</b> (3): 727–30. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FAOG.0b013e318188d1ec  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FAOG.0b013e318188d1ec'" tppabs="https://doi.org/10.1097%2FAOG.0b013e318188d1ec" class="external text external">10.1097/AOG.0b013e318188d1ec</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18757687  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18757687'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18757687" class="external text external">18757687</a>.</cite></span></li><li id="cite_note-115"> <span id="mw-reference-text-cite_note-115" class="mw-reference-text"><cite id="CITEREFPolisPhillipsCurtisWestreich2014" class="citation journal cs1">Polis CB, Phillips SJ, Curtis KM, Westreich DJ, Steyn PS, Raymond E, Hannaford P, Turner AN (October 2014). <a href="javascript:if(confirm('http://www.contraceptionjournal.org/article/S0010-7824(14)00571-X/pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.contraceptionjournal.org/article/S0010-7824(14)00571-X/pdf'" tppabs="http://www.contraceptionjournal.org/article/S0010-7824(14)00571-X/pdf" class="external text external">"Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence"</a>. <i>Contraception</i>. <b>90</b> (4): 360–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.contraception.2014.07.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.contraception.2014.07.009'" tppabs="https://doi.org/10.1016%2Fj.contraception.2014.07.009" class="external text external">10.1016/j.contraception.2014.07.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25183264  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25183264'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25183264" class="external text external">25183264</a>.</cite></span></li><li id="cite_note-116"> <span id="mw-reference-text-cite_note-116" class="mw-reference-text"><cite id="CITEREFWHO_Department_of_Reproductive_Health_and_Research2012" class="citation web cs1">WHO Department of Reproductive Health and Research (February 16, 2012). <a href="javascript:if(confirm('http://www.who.int/reproductivehealth/publications/family_planning/rhr_12_8/en/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.who.int/reproductivehealth/publications/family_planning/rhr_12_8/en/'" tppabs="http://www.who.int/reproductivehealth/publications/family_planning/rhr_12_8/en/" class="external text external">"Technical Statement: Hormonal contraception and HIV"</a>. Geneva: World Health Organization. <a href="javascript:if(confirm('https://web.archive.org/web/20150130063224/http://www.who.int/reproductivehealth/publications/family_planning/rhr_12_8/en/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150130063224/http://www.who.int/reproductivehealth/publications/family_planning/rhr_12_8/en/'" tppabs="https://web.archive.org/web/20150130063224/http://www.who.int/reproductivehealth/publications/family_planning/rhr_12_8/en/" class="external text external">Archived</a> from the original on January 30, 2015.</cite></span></li><li id="cite_note-117"> <span id="mw-reference-text-cite_note-117" class="mw-reference-text"><cite id="CITEREFWHO_Department_of_Reproductive_Health_and_Research2014" class="citation web cs1">WHO Department of Reproductive Health and Research (July 23, 2014). <a href="javascript:if(confirm('http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf'" tppabs="http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf" class="external text external">"2014 Guidance Statement: Hormonal contraceptive methods for women at high risk of HIV and living with HIV"</a> <span class="cs1-format">(PDF)</span>. Geneva: World Health Organization. <a href="javascript:if(confirm('https://web.archive.org/web/20150130063143/http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150130063143/http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf'" tppabs="https://web.archive.org/web/20150130063143/http://apps.who.int/iris/bitstream/10665/128537/1/WHO_RHR_14.24_eng.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on January 30, 2015.</cite></span></li><li id="cite_note-118"> <span id="mw-reference-text-cite_note-118" class="mw-reference-text"><cite id="CITEREFAVAC2015" class="citation web cs1">AVAC (January 27, 2015). <a href="javascript:if(confirm('http://www.avac.org/blog/news-hc-hiv-front  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.avac.org/blog/news-hc-hiv-front'" tppabs="http://www.avac.org/blog/news-hc-hiv-front" class="external text external">"News from the HC-HIV front: it's raining meta (analyses)!"</a>. New York: AIDS Vaccine Advocacy Coalition. <a href="javascript:if(confirm('https://web.archive.org/web/20150130053427/http://www.avac.org/blog/news-hc-hiv-front  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150130053427/http://www.avac.org/blog/news-hc-hiv-front'" tppabs="https://web.archive.org/web/20150130053427/http://www.avac.org/blog/news-hc-hiv-front" class="external text external">Archived</a> from the original on January 30, 2015.</cite></span></li><li id="cite_note-119"> <span id="mw-reference-text-cite_note-119" class="mw-reference-text"><cite id="CITEREFRalphMcCoyShiuPadian2015" class="citation journal cs1">Ralph LJ, McCoy SI, Shiu K, Padian NS (February 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526270  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526270'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526270" class="external text external">"Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies"</a>. <i>The Lancet. Infectious Diseases</i>. <b>15</b> (2): 181–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1473-3099%2814%2971052-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1473-3099%2814%2971052-7'" tppabs="https://doi.org/10.1016%2FS1473-3099%2814%2971052-7" class="external text external">10.1016/S1473-3099(14)71052-7</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526270  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526270'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526270" class="external text external">4526270</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25578825  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25578825'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25578825" class="external text external">25578825</a>.</cite></span></li><li id="cite_note-120"> <span id="mw-reference-text-cite_note-120" class="mw-reference-text"><cite id="CITEREFMorrisonChenKwokBaeten2015" class="citation journal cs1">Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, Low N (January 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303292  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303292'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303292" class="external text external">"Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis"</a>. <i>PLOS Medicine</i>. <b>12</b> (1): e1001778. doi:<a href="javascript:if(confirm('https://doi.org/10.1371%2Fjournal.pmed.1001778  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1371%2Fjournal.pmed.1001778'" tppabs="https://doi.org/10.1371%2Fjournal.pmed.1001778" class="external text external">10.1371/journal.pmed.1001778</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303292  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303292'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303292" class="external text external">4303292</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25612136  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25612136'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25612136" class="external text external">25612136</a>.</cite></span></li><li id="cite_note-121"> <span id="mw-reference-text-cite_note-121" class="mw-reference-text"><cite id="CITEREFFaculty_of_Sexual_Reproductive_Healthcare2015" class="citation web cs1">Faculty of Sexual Reproductive Healthcare (January 2015). <a href="javascript:if(confirm('https://web.archive.org/web/20150130073139/http://www.fsrh.org/pdfs/CEUStatementDMPAandHIV.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150130073139/http://www.fsrh.org/pdfs/CEUStatementDMPAandHIV.pdf'" tppabs="https://web.archive.org/web/20150130073139/http://www.fsrh.org/pdfs/CEUStatementDMPAandHIV.pdf" class="external text external">"CEU Statement: Depot medroxyprogesterone acetate (DMPA, Depo-Provera) and risk of HIV acquisition"</a> <span class="cs1-format">(PDF)</span>. London: Royal College of Obstetricians and Gynaecologists. Archived from <a href="javascript:if(confirm('http://www.fsrh.org/pdfs/CEUStatementDMPAandHIV.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fsrh.org/pdfs/CEUStatementDMPAandHIV.pdf'" tppabs="http://www.fsrh.org/pdfs/CEUStatementDMPAandHIV.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2015-01-30.</cite></span></li><li id="cite_note-pmid26710371-122"> <span id="mw-reference-text-cite_note-pmid26710371-122" class="mw-reference-text"><cite id="CITEREFBrindCondlyMosherMorse2015" class="citation journal cs1">Brind J, Condly SJ, Mosher SW, Morse AR, Kimball J (2015). "Risk of HIV Infection in Depot-Medroxyprogesterone Acetate (DMPA) Users: A Systematic Review and Meta-analysis". <i>Issues Law Med</i>. <b>30</b> (2): 129–39. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26710371  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26710371'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26710371" class="external text external">26710371</a>.</cite></span></li><li id="cite_note-ECHO2019-123"> <span id="mw-reference-text-cite_note-ECHO2019-123" class="mw-reference-text"><cite id="CITEREFECHO_Trial_Consortium2019" class="citation journal cs1">ECHO Trial Consortium (13 June 2019). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675739'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675739" class="external text external">"HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial"</a>. <i>The Lancet</i>. <b>394</b> (10195): 303–313. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2819%2931288-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2819%2931288-7'" tppabs="https://doi.org/10.1016%2FS0140-6736%2819%2931288-7" class="external text external">10.1016/S0140-6736(19)31288-7</a></span>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675739'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675739" class="external text external">6675739</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31204114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31204114'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31204114" class="external text external">31204114</a>.</cite></span></li><li id="cite_note-124"> <span id="mw-reference-text-cite_note-124" class="mw-reference-text"><cite id="CITEREFDahlberg1982" class="citation journal cs1">Dahlberg K (February 1982). "Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user". <i>International Journal of Gynaecology and Obstetrics</i>. <b>20</b> (1): 43–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0020-7292%2882%2990044-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0020-7292%2882%2990044-3'" tppabs="https://doi.org/10.1016%2F0020-7292%2882%2990044-3" class="external text external">10.1016/0020-7292(82)90044-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6126406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6126406'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6126406" class="external text external">6126406</a>.</cite></span></li><li id="cite_note-125"> <span id="mw-reference-text-cite_note-125" class="mw-reference-text"><cite id="CITEREFPardthaisongYenchitGray1992" class="citation journal cs1">Pardthaisong T, Yenchit C, Gray R (April 1992). "The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation". <i>Contraception</i>. <b>45</b> (4): 313–24. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0010-7824%2892%2990053-V  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0010-7824%2892%2990053-V'" tppabs="https://doi.org/10.1016%2F0010-7824%2892%2990053-V" class="external text external">10.1016/0010-7824(92)90053-V</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1387602  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1387602'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1387602" class="external text external">1387602</a>.</cite></span></li><li id="cite_note-pmid1390312-126"> <span id="mw-reference-text-cite_note-pmid1390312-126" class="mw-reference-text"><cite id="CITEREFMussCruz1992" class="citation journal cs1">Muss HB, Cruz JM (August 1992). "High-dose progestin therapy for metastatic breast cancer". <i>Annals of Oncology</i>. 3 Suppl 3: 15–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Fannonc%2F3.suppl_3.S15  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fannonc%2F3.suppl_3.S15'" tppabs="https://doi.org/10.1093%2Fannonc%2F3.suppl_3.S15" class="external text external">10.1093/annonc/3.suppl_3.S15</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1390312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1390312'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1390312" class="external text external">1390312</a>.</cite></span></li><li id="cite_note-pmid350387-127"> <span id="mw-reference-text-cite_note-pmid350387-127" class="mw-reference-text"><cite id="CITEREFPannutiMartoniLenazPiana1978" class="citation journal cs1">Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P (April 1978). "A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate". <i>Cancer Treat Rep</i>. <b>62</b> (4): 499–504. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/350387  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/350387'" tppabs="https://pubmed.ncbi.nlm.nih.gov/350387" class="external text external">350387</a>.</cite></span></li><li id="cite_note-pmid9452274-128"> <span id="mw-reference-text-cite_note-pmid9452274-128" class="mw-reference-text"><cite id="CITEREFSimonsScholsHoefnagelsWesterterp1998" class="citation journal cs1">Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF (February 1998). "Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial". <i>Cancer</i>. <b>82</b> (3): 553–60. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F%28sici%291097-0142%2819980201%2982%3A3%3C553%3A%3Aaid-cncr18%3E3.0.co%3B2-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F%28sici%291097-0142%2819980201%2982%3A3%3C553%3A%3Aaid-cncr18%3E3.0.co%3B2-0'" tppabs="https://doi.org/10.1002%2F%28sici%291097-0142%2819980201%2982%3A3%3C553%3A%3Aaid-cncr18%3E3.0.co%3B2-0" class="external text external">10.1002/(sici)1097-0142(19980201)82:3<span>&lt;</span>553::aid-cncr18<span>&gt;</span>3.0.co;2-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9452274  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9452274'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9452274" class="external text external">9452274</a>.</cite></span></li><li id="cite_note-Organization2004-129"> <span id="mw-reference-text-cite_note-Organization2004-129" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2004" class="citation book cs1">World Health Organization (2004). <a href="javascript:if(confirm('https://books.google.com/books?id=4cmezxyAHGUC&pg=PA49  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4cmezxyAHGUC&pg=PA49'" tppabs="https://books.google.com/books?id=4cmezxyAHGUC&pg=PA49" class="external text external"><i>Residues of Some Veterinary Drugs in Animals and Food: Monographs Prepared by the Sixty-second Meeting of the Joint FAO/WHO Expert Committee on Food Additives, Rome, 4-12 February 2004</i></a>. Food &amp; Agriculture Org. p.<span>&nbsp;</span>49. ISBN<span>&nbsp;</span><bdi>978-92-5-105195-5</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20140617202257/http://books.google.com/books?id=4cmezxyAHGUC&pg=PA49  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140617202257/http://books.google.com/books?id=4cmezxyAHGUC&pg=PA49'" tppabs="https://web.archive.org/web/20140617202257/http://books.google.com/books?id=4cmezxyAHGUC&pg=PA49" class="external text external">Archived</a> from the original on 17 June 2014.</cite></span></li><li id="cite_note-pmid10509795-130"> <span id="mw-reference-text-cite_note-pmid10509795-130" class="mw-reference-text"><cite id="CITEREFBentelBirrellPickeringHolds1999" class="citation journal cs1">Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD (August 1999). "Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells". <i>Molecular and Cellular Endocrinology</i>. <b>154</b> (1–2): 11–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0303-7207%2899%2900109-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0303-7207%2899%2900109-4'" tppabs="https://doi.org/10.1016%2FS0303-7207%2899%2900109-4" class="external text external">10.1016/S0303-7207(99)00109-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10509795  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10509795'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10509795" class="external text external">10509795</a>.</cite></span></li><li id="cite_note-pmid16784762-131"> <span id="mw-reference-text-cite_note-pmid16784762-131" class="mw-reference-text"><cite id="CITEREFPullenLapingEdwardsBray2006" class="citation journal cs1">Pullen MA, Laping N, Edwards R, Bray J (September 2006). "Determination of conformational changes in the progesterone receptor using ELISA-like assays". <i>Steroids</i>. <b>71</b> (9): 792–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.steroids.2006.05.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.steroids.2006.05.009'" tppabs="https://doi.org/10.1016%2Fj.steroids.2006.05.009" class="external text external">10.1016/j.steroids.2006.05.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16784762  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16784762'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16784762" class="external text external">16784762</a>.</cite></span></li><li id="cite_note-pmid6233840-132"> <span id="mw-reference-text-cite_note-pmid6233840-132" class="mw-reference-text"><cite id="CITEREFWikströmGreenJohansson1984" class="citation journal cs1">Wikström A, Green B, Johansson ED (1984). "The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses". <i>Acta Obstetricia et Gynecologica Scandinavica</i>. <b>63</b> (2): 163–8. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F00016348409154654  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F00016348409154654'" tppabs="https://doi.org/10.3109%2F00016348409154654" class="external text external">10.3109/00016348409154654</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6233840  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6233840'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6233840" class="external text external">6233840</a>.</cite></span></li><li id="cite_note-Blum2013-133"> <span id="mw-reference-text-cite_note-Blum2013-133" class="mw-reference-text"><cite id="CITEREFBlum2013" class="citation book cs1">Blum RW (22 October 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=36PpAgAAQBAJ&pg=PA216  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=36PpAgAAQBAJ&pg=PA216'" tppabs="https://books.google.com/books?id=36PpAgAAQBAJ&pg=PA216" class="external text external"><i>Adolescent Health Care: Clinical Issues</i></a>. Elsevier Science. pp.<span>&nbsp;</span>216–. ISBN<span>&nbsp;</span><bdi>978-1-4832-7738-7</bdi>.</cite></span></li><li id="cite_note-SchindlerCampagnoli2003-134"> <span id="mw-reference-text-cite_note-SchindlerCampagnoli2003-134" class="mw-reference-text"><cite id="CITEREFSchindlerCampagnoliDruckmannHuber2003" class="citation journal cs1">Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (December 2003). "Classification and pharmacology of progestins". <i>Maturitas</i>. 46 Suppl 1: S7–S16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2003.09.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2003.09.014'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2003.09.014" class="external text external">10.1016/j.maturitas.2003.09.014</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14670641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14670641'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14670641" class="external text external">14670641</a>.</cite></span></li><li id="cite_note-glasier-135"> <span id="mw-reference-text-cite_note-glasier-135" class="mw-reference-text"><cite id="CITEREFGlasier2006" class="citation book cs1">Glasier A (2006). "Contraception".  In DeGroot LJ, Jameson JL (eds.). <i>Endocrinology</i> (5th ed.). Philadelphia: Elsevier Saunders. pp.<span>&nbsp;</span>2993–3003. ISBN<span>&nbsp;</span><bdi>978-0-7216-0376-6</bdi>.</cite></span></li><li id="cite_note-loose-136"> <span id="mw-reference-text-cite_note-loose-136" class="mw-reference-text"><cite id="CITEREFLooseStancel2006" class="citation book cs1">Loose DS, Stancel GM (2006). "Estrogens and Progestins".  In Brunton LL, Lazo JS, Parker KL (eds.). <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i> (11th ed.). New York: McGraw-Hill. pp.<span>&nbsp;</span>1541–1571. ISBN<span>&nbsp;</span><bdi>0-07-142280-3</bdi>.</cite></span></li><li id="cite_note-rivera-137"> <span id="mw-reference-text-cite_note-rivera-137" class="mw-reference-text"><cite id="CITEREFRiveraYacobsonGrimes1999" class="citation journal cs1">Rivera R, Yacobson I, Grimes D (November 1999). "The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices". <i>American Journal of Obstetrics and Gynecology</i>. <b>181</b> (5 Pt 1): 1263–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0002-9378%2899%2970120-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0002-9378%2899%2970120-1'" tppabs="https://doi.org/10.1016%2FS0002-9378%2899%2970120-1" class="external text external">10.1016/S0002-9378(99)70120-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10561657  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10561657'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10561657" class="external text external">10561657</a>.</cite></span></li><li id="cite_note-FritzSperoff2012-138"> <span id="mw-reference-text-cite_note-FritzSperoff2012-138" class="mw-reference-text"><cite id="CITEREFFritzSperoff2012" class="citation book cs1">Fritz MA, Speroff L (28 March 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=KZLubBxJEwEC&pg=PA761  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=KZLubBxJEwEC&pg=PA761'" tppabs="https://books.google.com/books?id=KZLubBxJEwEC&pg=PA761" class="external text external"><i>Clinical Gynecologic Endocrinology and Infertility</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>761–. ISBN<span>&nbsp;</span><bdi>978-1-4511-4847-3</bdi>.</cite></span></li><li id="cite_note-pmid2525057-139"> <span id="mw-reference-text-cite_note-pmid2525057-139" class="mw-reference-text"><cite id="CITEREFPoulinBakerPoirierLabrie1989" class="citation journal cs1">Poulin R, Baker D, Poirier D, Labrie F (March 1989). "Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells". <i>Breast Cancer Research and Treatment</i>. <b>13</b> (2): 161–72. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fbf01806528  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fbf01806528'" tppabs="https://doi.org/10.1007%2Fbf01806528" class="external text external">10.1007/bf01806528</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2525057  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2525057'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2525057" class="external text external">2525057</a>.</cite></span></li><li id="cite_note-pmid12641635-140"> <span id="mw-reference-text-cite_note-pmid12641635-140" class="mw-reference-text"><cite id="CITEREFBradyAndersonKinniburghBaird2003" class="citation journal cs1">Brady BM, Anderson RA, Kinniburgh D, Baird DT (April 2003). "Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male". <i>Clinical Endocrinology</i>. <b>58</b> (4): 506–12. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2265.2003.01751.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2265.2003.01751.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2265.2003.01751.x" class="external text external">10.1046/j.1365-2265.2003.01751.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12641635  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12641635'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12641635" class="external text external">12641635</a>.</cite></span></li><li id="cite_note-SalehGrudzinskas2009-141"> <span id="mw-reference-text-cite_note-SalehGrudzinskas2009-141" class="mw-reference-text"><cite id="CITEREFSalehGrudzinskasBradford2009" class="citation book cs1">Saleh FM, Grudzinskas AJ, Bradford JM (11 February 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=K2Tpk3qHkwcC&pg=PA44  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=K2Tpk3qHkwcC&pg=PA44'" tppabs="https://books.google.com/books?id=K2Tpk3qHkwcC&pg=PA44" class="external text external"><i>Sex Offenders: Identification, Risk Assessment, Treatment, and Legal Issues</i></a>. Oxford University Press. p.<span>&nbsp;</span>44. ISBN<span>&nbsp;</span><bdi>978-0-19-517704-6</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20140617204821/http://books.google.com/books?id=K2Tpk3qHkwcC&pg=PA44  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140617204821/http://books.google.com/books?id=K2Tpk3qHkwcC&pg=PA44'" tppabs="https://web.archive.org/web/20140617204821/http://books.google.com/books?id=K2Tpk3qHkwcC&pg=PA44" class="external text external">Archived</a> from the original on 17 June 2014.</cite></span></li><li id="cite_note-WHO2008-142"> <span id="mw-reference-text-cite_note-WHO2008-142" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2009" class="citation book cs1">World Health Organization (2009).  Stuart MC, Kouimtzi M, Hill SR (eds.). <i>WHO Model Formulary 2008</i>. World Health Organization. p.<span>&nbsp;</span>368. hdl:<a href="javascript:if(confirm('https://hdl.handle.net/10665%2F44053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F44053'" tppabs="https://hdl.handle.net/10665%2F44053" class="external text external">10665/44053</a>. ISBN<span>&nbsp;</span><bdi>9789241547659</bdi>.</cite></span></li><li id="cite_note-Lothstein1996-143"> <span id="mw-reference-text-cite_note-Lothstein1996-143" class="mw-reference-text"><cite id="CITEREFLothstein1996" class="citation journal cs1">Lothstein, Leslie M. (1996). "Antiandrogen treatment for sexual disorders: Guidelines for establishing a standard of care". <i>Sexual Addiction &amp; Compulsivity</i>. <b>3</b> (4): 313–331. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F10720169608400122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F10720169608400122'" tppabs="https://doi.org/10.1080%2F10720169608400122" class="external text external">10.1080/10720169608400122</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1072-0162  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1072-0162'" tppabs="https://www.worldcat.org/issn/1072-0162" class="external text external">1072-0162</a>.</cite></span></li><li id="cite_note-APA1999-144"> <span id="mw-reference-text-cite_note-APA1999-144" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=PbC8kWQ-n1sC&pg=PA112  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=PbC8kWQ-n1sC&pg=PA112'" tppabs="https://books.google.com/books?id=PbC8kWQ-n1sC&pg=PA112" class="external text external"><i>Dangerous Sex Offenders: A Task Force Report of the American Psychiatric Association</i></a>. American Psychiatric Pub. 1999. pp.<span>&nbsp;</span>112–144. ISBN<span>&nbsp;</span><bdi>978-0-89042-280-9</bdi>.</cite></span></li><li id="cite_note-pmid8891323-145"> <span id="mw-reference-text-cite_note-pmid8891323-145" class="mw-reference-text"><cite id="CITEREFKravitzHaywoodKellyLiles1996" class="citation journal cs1">Kravitz HM, Haywood TW, Kelly J, Liles S, Cavanaugh JL (1996). <a href="javascript:if(confirm('http://jaapl.org/content/24/1/73  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://jaapl.org/content/24/1/73'" tppabs="http://jaapl.org/content/24/1/73" class="external text external">"Medroxyprogesterone and paraphiles: do testosterone levels matter?"</a>. <i>Bull Am Acad Psychiatry Law</i>. <b>24</b> (1): 73–83. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8891323  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8891323'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8891323" class="external text external">8891323</a>.</cite></span></li><li id="cite_note-pmid6449127-146"> <span id="mw-reference-text-cite_note-pmid6449127-146" class="mw-reference-text"><cite id="CITEREFNovakHendrixChenSeckman1980" class="citation journal cs1">Novak E, Hendrix JW, Chen TT, Seckman CE, Royer GL, Pochi PE (October 1980). "Sebum production and plasma testosterone levels in man after high-dose medroxyprogesterone acetate treatment and androgen administration". <i>Acta Endocrinol</i>. <b>95</b> (2): 265–70. doi:<a href="javascript:if(confirm('https://doi.org/10.1530%2Facta.0.0950265  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2Facta.0.0950265'" tppabs="https://doi.org/10.1530%2Facta.0.0950265" class="external text external">10.1530/acta.0.0950265</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6449127  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6449127'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6449127" class="external text external">6449127</a>.</cite></span></li><li id="cite_note-pmid5066846-147"> <span id="mw-reference-text-cite_note-pmid5066846-147" class="mw-reference-text"><cite id="CITEREFKirschnerSchneider1972" class="citation journal cs1">Kirschner MA, Schneider G (February 1972). "Suppression of the pituitary-Leydig cell axis and sebum production in normal men by medroxyprogesterone acetate (provera)". <i>Acta Endocrinol</i>. <b>69</b> (2): 385–93. doi:<a href="javascript:if(confirm('https://doi.org/10.1530%2Facta.0.0690385  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2Facta.0.0690385'" tppabs="https://doi.org/10.1530%2Facta.0.0690385" class="external text external">10.1530/acta.0.0690385</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/5066846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/5066846'" tppabs="https://pubmed.ncbi.nlm.nih.gov/5066846" class="external text external">5066846</a>.</cite></span></li><li id="cite_note-AsschemanGooren1993-148"> <span id="mw-reference-text-cite_note-AsschemanGooren1993-148" class="mw-reference-text"><cite id="CITEREFAsschemanGooren1993" class="citation journal cs1">Asscheman H, Gooren LJ (1993). "Hormone Treatment in Transsexuals". <i>Journal of Psychology &amp; Human Sexuality</i>. <b>5</b> (4): 39–54. doi:<a href="javascript:if(confirm('https://doi.org/10.1300%2FJ056v05n04_03  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1300%2FJ056v05n04_03'" tppabs="https://doi.org/10.1300%2FJ056v05n04_03" class="external text external">10.1300/J056v05n04_03</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0890-7064  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0890-7064'" tppabs="https://www.worldcat.org/issn/0890-7064" class="external text external">0890-7064</a>.</cite></span></li><li id="cite_note-pmid25692882-149"> <span id="mw-reference-text-cite_note-pmid25692882-149" class="mw-reference-text"><cite id="CITEREFMeriggiolaGava2015" class="citation journal cs1">Meriggiola MC, Gava G (November 2015). "Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen". <i>Clin. Endocrinol. (Oxf)</i>. <b>83</b> (5): 607–15. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fcen.12754  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fcen.12754'" tppabs="https://doi.org/10.1111%2Fcen.12754" class="external text external">10.1111/cen.12754</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25692882  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25692882'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25692882" class="external text external">25692882</a>.</cite></span></li><li id="cite_note-pmid17986639-150"> <span id="mw-reference-text-cite_note-pmid17986639-150" class="mw-reference-text"><cite id="CITEREFGoorenGiltayBunck2008" class="citation journal cs1">Gooren LJ, Giltay EJ, Bunck MC (January 2008). "Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience". <i>J. Clin. Endocrinol. Metab</i>. <b>93</b> (1): 19–25. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2007-1809  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2007-1809'" tppabs="https://doi.org/10.1210%2Fjc.2007-1809" class="external text external">10.1210/jc.2007-1809</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17986639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17986639'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17986639" class="external text external">17986639</a>.</cite></span></li><li id="cite_note-Deutsch2016-151"> <span id="mw-reference-text-cite_note-Deutsch2016-151" class="mw-reference-text"><cite id="CITEREFDeutsch2016" class="citation web cs1">Deutsch M (17 June 2016). <a href="javascript:if(confirm('http://transhealth.ucsf.edu/pdf/Transgender-PGACG-6-17-16.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://transhealth.ucsf.edu/pdf/Transgender-PGACG-6-17-16.pdf'" tppabs="http://transhealth.ucsf.edu/pdf/Transgender-PGACG-6-17-16.pdf" class="external text external">"Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People"</a> <span class="cs1-format">(PDF)</span> (2nd ed.). University of California, San Francisco: Center of Excellence for Transgender Health. p.<span>&nbsp;</span>28.</cite></span></li><li id="cite_note-DahlFeldman2015-152"> <span id="mw-reference-text-cite_note-DahlFeldman2015-152" class="mw-reference-text"><cite id="CITEREFDahlFeldmanGoldbergJaberi2015" class="citation web cs1">Dahl M, Feldman JL, Goldberg J, Jaberi A (2015). <a href="javascript:if(confirm('http://www.phsa.ca/transcarebc/Documents/HealthProf/BC-Trans-Adult-Endocrine-Guidelines-2015.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.phsa.ca/transcarebc/Documents/HealthProf/BC-Trans-Adult-Endocrine-Guidelines-2015.pdf'" tppabs="http://www.phsa.ca/transcarebc/Documents/HealthProf/BC-Trans-Adult-Endocrine-Guidelines-2015.pdf" class="external text external">"Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines"</a> <span class="cs1-format">(PDF)</span>. Vancouver Coastal Health<span class="reference-accessdate">. Retrieved <span class="nowrap">15 August</span> 2018</span>.</cite></span></li><li id="cite_note-pmid29756046-153"> <span id="mw-reference-text-cite_note-pmid29756046-153" class="mw-reference-text"><cite id="CITEREFLeinungFeustelJoseph2018" class="citation journal cs1">Leinung MC, Feustel PJ, Joseph J (2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393" class="external text external">"Hormonal Treatment of Transgender Women with Oral Estradiol"</a>. <i>Transgend Health</i>. <b>3</b> (1): 74–81. doi:<a href="javascript:if(confirm('https://doi.org/10.1089%2Ftrgh.2017.0035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1089%2Ftrgh.2017.0035'" tppabs="https://doi.org/10.1089%2Ftrgh.2017.0035" class="external text external">10.1089/trgh.2017.0035</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393" class="external text external">5944393</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29756046  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29756046'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29756046" class="external text external">29756046</a>.</cite></span></li><li id="cite_note-MeyerWalker1985-154"> <span id="mw-reference-text-cite_note-MeyerWalker1985-154" class="mw-reference-text"><cite id="CITEREFMeyerWalkerEmorySmith1985" class="citation journal cs1">Meyer, Walter J.; Walker, Paul A.; Emory, Lee E.; Smith, Edward R. (1985). "Physical, metabolic, and hormonal effects on men of long-term therapy with medroxyprogesterone acetate". <i>Fertility and Sterility</i>. <b>43</b> (1): 102–109. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0015-0282%2816%2948326-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0015-0282%2816%2948326-3'" tppabs="https://doi.org/10.1016%2FS0015-0282%2816%2948326-3" class="external text external">10.1016/S0015-0282(16)48326-3</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0015-0282  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0015-0282'" tppabs="https://www.worldcat.org/issn/0015-0282" class="external text external">0015-0282</a>.</cite></span></li><li id="cite_note-pmid10819508-155"> <span id="mw-reference-text-cite_note-pmid10819508-155" class="mw-reference-text"><cite id="CITEREFBirrellHallTilley1998" class="citation journal cs1">Birrell SN, Hall RE, Tilley WD (January 1998). "Role of the androgen receptor in human breast cancer". <i>Journal of Mammary Gland Biology and Neoplasia</i>. <b>3</b> (1): 95–103. doi:<a href="javascript:if(confirm('https://doi.org/10.1023%2FA%3A1018730519839  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1023%2FA%3A1018730519839'" tppabs="https://doi.org/10.1023%2FA%3A1018730519839" class="external text external">10.1023/A:1018730519839</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10819508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10819508'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10819508" class="external text external">10819508</a>.</cite></span></li><li id="cite_note-pmid16166329-156"> <span id="mw-reference-text-cite_note-pmid16166329-156" class="mw-reference-text"><cite id="CITEREFBuchananBirrellPetersBianco-Miotto2005" class="citation journal cs1">Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD (September 2005). "Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate". <i>Cancer Research</i>. <b>65</b> (18): 8487–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1158%2F0008-5472.CAN-04-3077  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F0008-5472.CAN-04-3077'" tppabs="https://doi.org/10.1158%2F0008-5472.CAN-04-3077" class="external text external">10.1158/0008-5472.CAN-04-3077</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16166329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16166329'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16166329" class="external text external">16166329</a>.</cite></span></li><li id="cite_note-ReesHope2005-157"> <span id="mw-reference-text-cite_note-ReesHope2005-157" class="mw-reference-text"><cite id="CITEREFReesHopeRavnikar2005" class="citation book cs1">Rees MC, Hope S, Ravnikar V (12 August 2005). <a href="javascript:if(confirm('https://books.google.com/books?id=B6eFjomeMFcC&pg=PA213  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=B6eFjomeMFcC&pg=PA213'" tppabs="https://books.google.com/books?id=B6eFjomeMFcC&pg=PA213" class="external text external"><i>The Abnormal Menstrual Cycle</i></a>. Taylor &amp; Francis. p.<span>&nbsp;</span>213. ISBN<span>&nbsp;</span><bdi>978-1-84214-212-7</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20131231191143/http://books.google.com/books?id=B6eFjomeMFcC&pg=PA213  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131231191143/http://books.google.com/books?id=B6eFjomeMFcC&pg=PA213'" tppabs="https://web.archive.org/web/20131231191143/http://books.google.com/books?id=B6eFjomeMFcC&pg=PA213" class="external text external">Archived</a> from the original on 31 December 2013.</cite></span></li><li id="cite_note-Aronson2009-158"> <span id="mw-reference-text-cite_note-Aronson2009-158" class="mw-reference-text"><cite id="CITEREFAronson2009" class="citation book cs1">Aronson, JK (20 January 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA283'" tppabs="https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA283" class="external text external"><i>Meyler's Side Effects of Endocrine and Metabolic Drugs</i></a>. Elsevier. p.<span>&nbsp;</span>283. ISBN<span>&nbsp;</span><bdi>978-0-444-53271-8</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20131231191208/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131231191208/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA283'" tppabs="https://web.archive.org/web/20131231191208/http://books.google.com/books?id=BWMeSwVwfTkC&pg=PA283" class="external text external">Archived</a> from the original on 31 December 2013.</cite></span></li><li id="cite_note-pmid590535-159"> <span id="mw-reference-text-cite_note-pmid590535-159" class="mw-reference-text"><cite id="CITEREFEttingerGolditch1977" class="citation journal cs1">Ettinger B, Golditch IM (December 1977). "Medroxyprogesterone acetate for the evaluation of hypertestosteronism in hirsute women". <i>Fertility and Sterility</i>. <b>28</b> (12): 1285–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0015-0282%2816%2942970-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0015-0282%2816%2942970-5'" tppabs="https://doi.org/10.1016%2FS0015-0282%2816%2942970-5" class="external text external">10.1016/S0015-0282(16)42970-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/590535  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/590535'" tppabs="https://pubmed.ncbi.nlm.nih.gov/590535" class="external text external">590535</a>.</cite></span></li><li id="cite_note-pmid1200527-160"> <span id="mw-reference-text-cite_note-pmid1200527-160" class="mw-reference-text"><cite id="CITEREFCorrea_de_OliveiraNovaesLimaRodrigues1975" class="citation journal cs1">Correa de Oliveira RF, Novaes LP, Lima MB, Rodrigues J, Franco S, Khenaifes AI, Francalanci CP (December 1975). "A new treatment for hirsutism". <i>Annals of Internal Medicine</i>. <b>83</b> (6): 817–9. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-83-6-817  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-83-6-817'" tppabs="https://doi.org/10.7326%2F0003-4819-83-6-817" class="external text external">10.7326/0003-4819-83-6-817</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1200527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1200527'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1200527" class="external text external">1200527</a>.</cite></span></li><li id="cite_note-pmid4332067-161"> <span id="mw-reference-text-cite_note-pmid4332067-161" class="mw-reference-text"><cite id="CITEREFRichmanUnderwoodFrenchVan_Wyk1971" class="citation journal cs1">Richman RA, Underwood LE, French FS, Van Wyk JJ (December 1971). "Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity". <i>The Journal of Pediatrics</i>. <b>79</b> (6): 963–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0022-3476%2871%2980191-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0022-3476%2871%2980191-9'" tppabs="https://doi.org/10.1016%2Fs0022-3476%2871%2980191-9" class="external text external">10.1016/s0022-3476(71)80191-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4332067  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4332067'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4332067" class="external text external">4332067</a>.</cite></span></li><li id="cite_note-Luciano1992-162"> <span id="mw-reference-text-cite_note-Luciano1992-162" class="mw-reference-text"><cite id="CITEREFLuciano1992" class="citation journal cs1">Luciano, A. A. (1992). "Endometriosis—the role of medroxyprogesterone acetate". <i>Journal of Obstetrics and Gynaecology</i>. <b>12</b> (sup2): S38–S44. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F01443619209045611  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F01443619209045611'" tppabs="https://doi.org/10.3109%2F01443619209045611" class="external text external">10.3109/01443619209045611</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0144-3615  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0144-3615'" tppabs="https://www.worldcat.org/issn/0144-3615" class="external text external">0144-3615</a>.</cite></span></li><li id="cite_note-pmid10914617-163"> <span id="mw-reference-text-cite_note-pmid10914617-163" class="mw-reference-text"><cite id="CITEREFNachtigallRajuBanerjeeWan2000" class="citation journal cs1">Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M (2000). "Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels". <i>Menopause</i>. <b>7</b> (4): 243–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00042192-200007040-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00042192-200007040-00006'" tppabs="https://doi.org/10.1097%2F00042192-200007040-00006" class="external text external">10.1097/00042192-200007040-00006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10914617  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10914617'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10914617" class="external text external">10914617</a>.</cite></span></li><li id="cite_note-164"> <span id="mw-reference-text-cite_note-164" class="mw-reference-text"><cite id="CITEREFMerrinAlexander1990" class="citation journal cs1">Merrin PK, Alexander WD (August 1990). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1663616  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1663616'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1663616" class="external text external">"Cushing's syndrome induced by medroxyprogesterone"</a>. <i>BMJ</i>. <b>301</b> (6747): 345. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.301.6747.345-a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.301.6747.345-a'" tppabs="https://doi.org/10.1136%2Fbmj.301.6747.345-a" class="external text external">10.1136/bmj.301.6747.345-a</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1663616  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1663616'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1663616" class="external text external">1663616</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2144198  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2144198'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2144198" class="external text external">2144198</a>.</cite></span></li><li id="cite_note-165"> <span id="mw-reference-text-cite_note-165" class="mw-reference-text"><cite class="citation cs2"><a href="javascript:if(confirm('http://www.medscape.org/viewarticle/549746  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medscape.org/viewarticle/549746'" tppabs="http://www.medscape.org/viewarticle/549746" class="external text external"><i>Systemic Effects of Oral Glucocorticoids</i></a>, <a href="javascript:if(confirm('https://web.archive.org/web/20140128153658/http://www.medscape.org/viewarticle/549746  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140128153658/http://www.medscape.org/viewarticle/549746'" tppabs="https://web.archive.org/web/20140128153658/http://www.medscape.org/viewarticle/549746" class="external text external">archived</a> from the original on 2014-01-28</cite></span></li><li id="cite_note-pmid12181616-166"> <span id="mw-reference-text-cite_note-pmid12181616-166" class="mw-reference-text"><cite id="CITEREFIshidaIshidaHeersche2002" class="citation journal cs1">Ishida Y, Ishida Y, Heersche JN (August 2002). "Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis". <i>Osteoporos Int</i>. <b>13</b> (8): 601–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs001980200080  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs001980200080'" tppabs="https://doi.org/10.1007%2Fs001980200080" class="external text external">10.1007/s001980200080</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12181616  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12181616'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12181616" class="external text external">12181616</a>.</cite></span></li><li id="cite_note-pmid6213817-167"> <span id="mw-reference-text-cite_note-pmid6213817-167" class="mw-reference-text"><cite id="CITEREFSundeRosnessEik-Nes1982" class="citation journal cs1">Sunde A, Rosness PA, Eik-Nes KB (August 1982). "Effects in vitro of medroxyprogesterone acetate on steroid metabolizing enzymes in the rat: selective inhibition of 3 alpha-hydroxysteroid oxidoreductase activity". <i>Journal of Steroid Biochemistry</i>. <b>17</b> (2): 197–203. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2882%2990122-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2882%2990122-4'" tppabs="https://doi.org/10.1016%2F0022-4731%2882%2990122-4" class="external text external">10.1016/0022-4731(82)90122-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6213817  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6213817'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6213817" class="external text external">6213817</a>.</cite></span></li><li id="cite_note-pmid2933398-168"> <span id="mw-reference-text-cite_note-pmid2933398-168" class="mw-reference-text"><cite id="CITEREFPenningSharpKrieger1985" class="citation journal cs1">Penning TM, Sharp RB, Krieger NR (December 1985). "Purification and properties of 3 alpha-hydroxysteroid dehydrogenase from rat brain cytosol. Inhibition by nonsteroidal anti-inflammatory drugs and progestins". <i>The Journal of Biological Chemistry</i>. <b>260</b> (28): 15266–72. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2933398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2933398'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2933398" class="external text external">2933398</a>.</cite></span></li><li id="cite_note-pmid15181090-169"> <span id="mw-reference-text-cite_note-pmid15181090-169" class="mw-reference-text"><cite id="CITEREFPazolWilsonWallen2004" class="citation journal cs1">Pazol K, Wilson ME, Wallen K (June 2004). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440328  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440328'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440328" class="external text external">"Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques"</a>. <i>The Journal of Clinical Endocrinology and Metabolism</i>. <b>89</b> (6): 2998–3006. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2003-032086  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2003-032086'" tppabs="https://doi.org/10.1210%2Fjc.2003-032086" class="external text external">10.1210/jc.2003-032086</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440328  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440328'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440328" class="external text external">1440328</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15181090  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15181090'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15181090" class="external text external">15181090</a>.</cite></span></li><li id="cite_note-pmid18291663-170"> <span id="mw-reference-text-cite_note-pmid18291663-170" class="mw-reference-text"><cite id="CITEREFMeyerVenardSchaefferPatte-Mensah2008" class="citation journal cs1">Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG (April 2008). "The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury". <i>Neurobiology of Disease</i>. <b>30</b> (1): 30–41. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.nbd.2007.12.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.nbd.2007.12.001'" tppabs="https://doi.org/10.1016%2Fj.nbd.2007.12.001" class="external text external">10.1016/j.nbd.2007.12.001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18291663  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18291663'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18291663" class="external text external">18291663</a>.</cite></span></li><li id="cite_note-pmid11750861-171"> <span id="mw-reference-text-cite_note-pmid11750861-171" class="mw-reference-text"><cite id="CITEREFMellonGriffin2002" class="citation journal cs1">Mellon SH, Griffin LD (2002). "Neurosteroids: biochemistry and clinical significance". <i>Trends in Endocrinology and Metabolism</i>. <b>13</b> (1): 35–43. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs1043-2760%2801%2900503-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs1043-2760%2801%2900503-3'" tppabs="https://doi.org/10.1016%2Fs1043-2760%2801%2900503-3" class="external text external">10.1016/s1043-2760(01)00503-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11750861  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11750861'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11750861" class="external text external">11750861</a>.</cite></span></li><li id="cite_note-pmid10372718-172"> <span id="mw-reference-text-cite_note-pmid10372718-172" class="mw-reference-text"><cite id="CITEREFLeeMillerAuchus1999" class="citation journal cs1">Lee TC, Miller WL, Auchus RJ (June 1999). "Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes". <i>The Journal of Clinical Endocrinology and Metabolism</i>. <b>84</b> (6): 2104–10. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem.84.6.5646  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem.84.6.5646'" tppabs="https://doi.org/10.1210%2Fjcem.84.6.5646" class="external text external">10.1210/jcem.84.6.5646</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10372718  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10372718'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10372718" class="external text external">10372718</a>.</cite></span></li><li id="cite_note-pmid14644065-173"> <span id="mw-reference-text-cite_note-pmid14644065-173" class="mw-reference-text"><cite id="CITEREFSöderpalmLindseyPurdyHauger2004" class="citation journal cs1">Söderpalm AH, Lindsey S, Purdy RH, Hauger R, Wit de H (April 2004). "Administration of progesterone produces mild sedative-like effects in men and women". <i>Psychoneuroendocrinology</i>. <b>29</b> (3): 339–54. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0306-4530%2803%2900033-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0306-4530%2803%2900033-7'" tppabs="https://doi.org/10.1016%2Fs0306-4530%2803%2900033-7" class="external text external">10.1016/s0306-4530(03)00033-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14644065  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14644065'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14644065" class="external text external">14644065</a>.</cite></span></li><li id="cite_note-pmid8516376-174"> <span id="mw-reference-text-cite_note-pmid8516376-174" class="mw-reference-text"><cite id="CITEREFMcAuleyKrobothStiffReynolds1993" class="citation journal cs1">McAuley JW, Kroboth PD, Stiff DD, Reynolds IJ (May 1993). "Modulation of [3H]flunitrazepam binding by natural and synthetic progestational agents". <i>Pharmacology Biochemistry and Behavior</i>. <b>45</b> (1): 77–83. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0091-3057%2893%2990089-c  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0091-3057%2893%2990089-c'" tppabs="https://doi.org/10.1016%2F0091-3057%2893%2990089-c" class="external text external">10.1016/0091-3057(93)90089-c</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8516376  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8516376'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8516376" class="external text external">8516376</a>.</cite></span></li><li id="cite_note-Weizman2008-175"> <span id="mw-reference-text-cite_note-Weizman2008-175" class="mw-reference-text"><cite id="CITEREFWeizman2008" class="citation book cs1">Weizman A (1 February 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=uABKkFdPjhkC&pg=PA104  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=uABKkFdPjhkC&pg=PA104'" tppabs="https://books.google.com/books?id=uABKkFdPjhkC&pg=PA104" class="external text external"><i>Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>104, 107, 112. ISBN<span>&nbsp;</span><bdi>978-1-4020-6854-6</bdi>.</cite></span></li><li id="cite_note-HofbauerAnker2005-176"> <span id="mw-reference-text-cite_note-HofbauerAnker2005-176" class="mw-reference-text"><cite id="CITEREFHofbauerAnkerInuiNicholson2005" class="citation book cs1">Hofbauer KG, Anker SD, Inui A, Nicholson JR (22 December 2005). <a href="javascript:if(confirm('https://books.google.com/books?id=I6cf05LaCakC&pg=PA292  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=I6cf05LaCakC&pg=PA292'" tppabs="https://books.google.com/books?id=I6cf05LaCakC&pg=PA292" class="external text external"><i>Pharmacotherapy of Cachexia</i></a>. CRC Press. pp.<span>&nbsp;</span>292–. ISBN<span>&nbsp;</span><bdi>978-1-4200-4895-7</bdi>. <q>Medroxyprogesterone [acetate] has similarly been shown to increase appetite and food intake with stabilization of body weight at a dose of 1000 mg (500 mg twice daily).13 Although the drug may be used at 500 to 4000 mg daily, side effects increase above oral doses of 1000 mg daily.16</q></cite></span></li><li id="cite_note-DoyleHanks2005-177"> <span id="mw-reference-text-cite_note-DoyleHanks2005-177" class="mw-reference-text"><cite id="CITEREFDoyleHanksCherny2005" class="citation book cs1">Doyle D, Hanks G, Cherny NI (3 February 2005). <a href="javascript:if(confirm('https://books.google.com/books?id=1n93PGjL0IMC&pg=PA553  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=1n93PGjL0IMC&pg=PA553'" tppabs="https://books.google.com/books?id=1n93PGjL0IMC&pg=PA553" class="external text external"><i>Oxford Textbook Of Palliative Medicine</i></a>. Oxford University Press. p.<span>&nbsp;</span>553. ISBN<span>&nbsp;</span><bdi>978-0-19-856698-4</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20130618070049/http://books.google.com/books?id=1n93PGjL0IMC&pg=PA553  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130618070049/http://books.google.com/books?id=1n93PGjL0IMC&pg=PA553'" tppabs="https://web.archive.org/web/20130618070049/http://books.google.com/books?id=1n93PGjL0IMC&pg=PA553" class="external text external">Archived</a> from the original on 18 June 2013.</cite></span></li><li id="cite_note-pmid23758160-178"> <span id="mw-reference-text-cite_note-pmid23758160-178" class="mw-reference-text"><cite id="CITEREFNeubauerMaZhouYu2013" class="citation journal cs1">Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, Fehm T, Mueck AO (October 2013). "Possible role of PGRMC1 in breast cancer development". <i>Climacteric</i>. <b>16</b> (5): 509–13. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F13697137.2013.800038  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F13697137.2013.800038'" tppabs="https://doi.org/10.3109%2F13697137.2013.800038" class="external text external">10.3109/13697137.2013.800038</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23758160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23758160'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23758160" class="external text external">23758160</a>.</cite></span></li><li id="cite_note-pmid31512725-179"> <span id="mw-reference-text-cite_note-pmid31512725-179" class="mw-reference-text"><cite id="CITEREFTrabertShermanKannanStanczyk2019" class="citation journal cs1">Trabert B, Sherman ME, Kannan N, Stanczyk FZ (September 2019). "Progesterone and breast cancer". <i>Endocr. Rev</i>. <b>41</b> (2). doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fendrev%2Fbnz001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fendrev%2Fbnz001'" tppabs="https://doi.org/10.1210%2Fendrev%2Fbnz001" class="external text external">10.1210/endrev/bnz001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31512725  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31512725'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31512725" class="external text external">31512725</a>.</cite></span></li><li id="cite_note-pmid24291402-180"> <span id="mw-reference-text-cite_note-pmid24291402-180" class="mw-reference-text"><cite id="CITEREFStanczykBhavnani2014" class="citation journal cs1">Stanczyk, Frank Z.; Bhavnani, Bhagu R. (2014). "Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?". <i>The Journal of Steroid Biochemistry and Molecular Biology</i>. <b>142</b>: 30–38. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jsbmb.2013.11.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jsbmb.2013.11.011'" tppabs="https://doi.org/10.1016%2Fj.jsbmb.2013.11.011" class="external text external">10.1016/j.jsbmb.2013.11.011</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0960-0760  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0960-0760'" tppabs="https://www.worldcat.org/issn/0960-0760" class="external text external">0960-0760</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24291402  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24291402'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24291402" class="external text external">24291402</a>.</cite></span></li><li id="cite_note-VictorJohansson1976-181"> <span id="mw-reference-text-cite_note-VictorJohansson1976-181" class="mw-reference-text"><cite id="CITEREFVictorJohansson1976" class="citation journal cs1">Victor, Arne; Johansson, Elof D.B. (1976). "Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally". <i>Contraception</i>. <b>14</b> (3): 319–329. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0010-7824%2876%2990099-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0010-7824%2876%2990099-8'" tppabs="https://doi.org/10.1016%2F0010-7824%2876%2990099-8" class="external text external">10.1016/0010-7824(76)90099-8</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0010-7824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0010-7824'" tppabs="https://www.worldcat.org/issn/0010-7824" class="external text external">0010-7824</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/975821  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/975821'" tppabs="https://pubmed.ncbi.nlm.nih.gov/975821" class="external text external">975821</a>.</cite></span></li><li id="cite_note-HiroiStanczyk1975-182"> <span id="mw-reference-text-cite_note-HiroiStanczyk1975-182" class="mw-reference-text"><cite id="CITEREFHiroiStanczykGoebelsmannBrenner1975" class="citation journal cs1">Hiroi, M.; Stanczyk, F.Z.; Goebelsmann, U.; Brenner, P.F.; Lumkin, M.E.; Mishell, D.R. (1975). "Radioimmunoassay of serum medroxyprogesterone acetate (Provera ®) in women following oral and intravaginal administration". <i>Steroids</i>. <b>26</b> (3): 373–386. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0039-128X%2875%2990082-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0039-128X%2875%2990082-3'" tppabs="https://doi.org/10.1016%2F0039-128X%2875%2990082-3" class="external text external">10.1016/0039-128X(75)90082-3</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0039-128X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0039-128X'" tppabs="https://www.worldcat.org/issn/0039-128X" class="external text external">0039-128X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1198624  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1198624'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1198624" class="external text external">1198624</a>.</cite></span></li><li id="cite_note-SvenssonJohnson1994-183"> <span id="mw-reference-text-cite_note-SvenssonJohnson1994-183" class="mw-reference-text"><cite id="CITEREFSvenssonJohnsonOlsson1994" class="citation journal cs1">Svensson, L.-O.; Johnson, S.Hedman; Olsson, S.-E. (1994). "Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence® / Provera® and Divina®. A randomized, single-blind, triple cross-over bioavailability study in menopausal women". <i>Maturitas</i>. <b>18</b> (3): 229–238. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0378-5122%2894%2990129-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0378-5122%2894%2990129-5'" tppabs="https://doi.org/10.1016%2F0378-5122%2894%2990129-5" class="external text external">10.1016/0378-5122(94)90129-5</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0378-5122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0378-5122'" tppabs="https://www.worldcat.org/issn/0378-5122" class="external text external">0378-5122</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8015506  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8015506'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8015506" class="external text external">8015506</a>.</cite></span></li><li id="cite_note-JärvinenKainulainen2004-184"> <span id="mw-reference-text-cite_note-JärvinenKainulainen2004-184" class="mw-reference-text"><cite id="CITEREFJärvinenKainulainenNissiläNikkanen2004" class="citation journal cs1">Järvinen, Asko; Kainulainen, Petri; Nissilä, Minna; Nikkanen, Hanna; Kela, Marjo (2004). "Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women". <i>Maturitas</i>. <b>47</b> (3): 209–217. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2003.01.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2003.01.001'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2003.01.001" class="external text external">10.1016/j.maturitas.2003.01.001</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0378-5122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0378-5122'" tppabs="https://www.worldcat.org/issn/0378-5122" class="external text external">0378-5122</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15036491  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15036491'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15036491" class="external text external">15036491</a>.</cite></span></li><li id="cite_note-PDR-MPA-185"> <span id="mw-reference-text-cite_note-PDR-MPA-185" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20181007065946/https://www.pdr.net/drug-summary/Provera-medroxyprogesterone-acetate-1015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20181007065946/https://www.pdr.net/drug-summary/Provera-medroxyprogesterone-acetate-1015'" tppabs="https://web.archive.org/web/20181007065946/https://www.pdr.net/drug-summary/Provera-medroxyprogesterone-acetate-1015" class="external text external">"Medroxyprogesterone Acetate - Drug Summary"</a>. <i>Prescribers' Digital Reference (PDR)</i>. ConnectiveRx. Archived from <a href="javascript:if(confirm('https://www.pdr.net/drug-summary/Provera-medroxyprogesterone-acetate-1015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.pdr.net/drug-summary/Provera-medroxyprogesterone-acetate-1015'" tppabs="https://www.pdr.net/drug-summary/Provera-medroxyprogesterone-acetate-1015" class="external text external">the original</a> on 2018-10-07<span class="reference-accessdate">. Retrieved <span class="nowrap">2019-06-17</span></span>. <q>When needed, tablets may be administered sublingually†; absorption is adequate by this route.</q></cite></span></li><li id="cite_note-pmid1101759-186"> <span id="mw-reference-text-cite_note-pmid1101759-186" class="mw-reference-text"><cite id="CITEREFSutton1975" class="citation journal cs1">Sutton, Frank D. (1975). "Progesterone for Outpatient Treatment of Pickwickian Syndrome". <i>Annals of Internal Medicine</i>. <b>83</b> (4): 476–9. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-83-4-476  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-83-4-476'" tppabs="https://doi.org/10.7326%2F0003-4819-83-4-476" class="external text external">10.7326/0003-4819-83-4-476</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0003-4819  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0003-4819'" tppabs="https://www.worldcat.org/issn/0003-4819" class="external text external">0003-4819</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1101759  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1101759'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1101759" class="external text external">1101759</a>. <q>The sublingual route was chosen to avoid any irregular absorption that might result from simultaneous food intake.</q></cite></span></li><li id="cite_note-pmid31127826-187"> <span id="mw-reference-text-cite_note-pmid31127826-187" class="mw-reference-text"><cite id="CITEREFJainKwanForcier2019" class="citation journal cs1">Jain J, Kwan D, Forcier M (April 2019). "Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results from a Retrospective Study". <i>The Journal of Clinical Endocrinology &amp; Metabolism</i>. <b>104</b> (11): 5148–5156. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2018-02253  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2018-02253'" tppabs="https://doi.org/10.1210%2Fjc.2018-02253" class="external text external">10.1210/jc.2018-02253</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0021-972X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0021-972X'" tppabs="https://www.worldcat.org/issn/0021-972X" class="external text external">0021-972X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31127826  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31127826'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31127826" class="external text external">31127826</a>.</cite></span></li><li id="cite_note-pmid1884566-188"> <span id="mw-reference-text-cite_note-pmid1884566-188" class="mw-reference-text"><cite id="CITEREFvan_Hoogdalemde_BoerBreimer1991" class="citation journal cs1">van Hoogdalem EJ, de Boer AG, Breimer DD (August 1991). "Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions". <i>Clin Pharmacokinet</i>. <b>21</b> (2): 110–28. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-199121020-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-199121020-00003'" tppabs="https://doi.org/10.2165%2F00003088-199121020-00003" class="external text external">10.2165/00003088-199121020-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1884566  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1884566'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1884566" class="external text external">1884566</a>.</cite></span></li><li id="cite_note-Mishell-189"> <span id="mw-reference-text-cite_note-Mishell-189" class="mw-reference-text"><cite id="CITEREFMishell1996" class="citation journal cs1">Mishell DR (May 1996). <a href="javascript:if(confirm('http://www.reproductivemedicine.com/toc/auto_abstract.php?id=540  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.reproductivemedicine.com/toc/auto_abstract.php?id=540'" tppabs="http://www.reproductivemedicine.com/toc/auto_abstract.php?id=540" class="external text external">"Pharmacokinetics of depot medroxyprogesterone acetate contraception"</a>. <i>The Journal of Reproductive Medicine</i>. <b>41</b> (5 Suppl): 381–90. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8725700  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8725700'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8725700" class="external text external">8725700</a>.</cite></span></li><li id="cite_note-pmid8013220-190"> <span id="mw-reference-text-cite_note-pmid8013220-190" class="mw-reference-text"><cite id="CITEREFSang1994" class="citation journal cs1">Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". <i>Contraception</i>. <b>49</b> (4): 361–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0010-7824%2894%2990033-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0010-7824%2894%2990033-7'" tppabs="https://doi.org/10.1016%2F0010-7824%2894%2990033-7" class="external text external">10.1016/0010-7824(94)90033-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8013220  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8013220'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8013220" class="external text external">8013220</a>.</cite></span></li><li id="cite_note-pmid1958567-191"> <span id="mw-reference-text-cite_note-pmid1958567-191" class="mw-reference-text"><cite id="CITEREFGarza-FloresHallPerez-Palacios1991" class="citation journal cs1">Garza-Flores J, Hall PE, Perez-Palacios G (1991). "Long-acting hormonal contraceptives for women". <i>J. Steroid Biochem. Mol. Biol</i>. <b>40</b> (4–6): 697–704. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0960-0760%2891%2990293-e  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0960-0760%2891%2990293-e'" tppabs="https://doi.org/10.1016%2F0960-0760%2891%2990293-e" class="external text external">10.1016/0960-0760(91)90293-e</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1958567  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1958567'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1958567" class="external text external">1958567</a>.</cite></span></li><li id="cite_note-GabelnickHall1987-192"> <span id="mw-reference-text-cite_note-GabelnickHall1987-192" class="mw-reference-text"><cite id="CITEREFGabelnickHall1987" class="citation journal cs1">Gabelnick, Henry L.; Hall, Peter E. (1987). "Long-acting methods for fertility regulation". <i>Journal of Controlled Release</i>. <b>6</b> (1): 387–394. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0168-3659%2887%2990092-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0168-3659%2887%2990092-7'" tppabs="https://doi.org/10.1016%2F0168-3659%2887%2990092-7" class="external text external">10.1016/0168-3659(87)90092-7</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0168-3659  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0168-3659'" tppabs="https://www.worldcat.org/issn/0168-3659" class="external text external">0168-3659</a>.</cite></span></li><li id="cite_note-AntalDick1989-193"> <span id="mw-reference-text-cite_note-AntalDick1989-193" class="mw-reference-text"><cite id="CITEREFAntalDickWrightiiiWelshman1989" class="citation journal cs1">Antal, E; Dick, C; Wrightiii, C; Welshman, I; Block, E (1989). "Comparative bioavailability of two medroxyprogesterone acetate suspensions". <i>International Journal of Pharmaceutics</i>. <b>54</b> (1): 33–39. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0378-5173%2889%2990162-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0378-5173%2889%2990162-2'" tppabs="https://doi.org/10.1016%2F0378-5173%2889%2990162-2" class="external text external">10.1016/0378-5173(89)90162-2</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0378-5173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0378-5173'" tppabs="https://www.worldcat.org/issn/0378-5173" class="external text external">0378-5173</a>.</cite></span></li><li id="cite_note-pmid1271819-194"> <span id="mw-reference-text-cite_note-pmid1271819-194" class="mw-reference-text"><cite id="CITEREFIshiharaKirdaniOsawaSandberg1976" class="citation journal cs1">Ishihara M, Kirdani Y, Osawa Y, Sandberg AA (January 1976). "The metabolic fate of medroxyprogesterone acetate in the baboon". <i>Journal of Steroid Biochemistry</i>. <b>7</b> (1): 65–70. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2876%2990167-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2876%2990167-9'" tppabs="https://doi.org/10.1016%2F0022-4731%2876%2990167-9" class="external text external">10.1016/0022-4731(76)90167-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1271819  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1271819'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1271819" class="external text external">1271819</a>.</cite></span></li><li id="cite_note-Jr.Lawrence2015-195"> <span id="mw-reference-text-cite_note-Jr.Lawrence2015-195" class="mw-reference-text"><cite id="CITEREFDeVitaLawrenceRosenberg2015" class="citation book cs1">DeVita VT, Lawrence TS, Rosenberg SA (7 January 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1149  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1149'" tppabs="https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1149" class="external text external"><i>DeVita, Hellman, and Rosenberg's Cancer: Principles &amp; Practice of Oncology</i></a>. Wolters Kluwer Health. pp.<span>&nbsp;</span>1149–. ISBN<span>&nbsp;</span><bdi>978-1-4698-9455-3</bdi>.</cite></span></li><li id="cite_note-196"> <span id="mw-reference-text-cite_note-196" class="mw-reference-text"><cite class="citation journal cs1">Järvinen, Asko; Kainulainen, Petri; Nissilä, Minna; Nikkanen, Hanna; Kela, Marjo (2004). "Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women". <i>Maturitas</i>. <b>47</b> (3): 209–217. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2003.01.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2003.01.001'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2003.01.001" class="external text external">10.1016/j.maturitas.2003.01.001</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0378-5122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0378-5122'" tppabs="https://www.worldcat.org/issn/0378-5122" class="external text external">0378-5122</a>.</cite></span></li><li id="cite_note-Goebelsmann1986-197"> <span id="mw-reference-text-cite_note-Goebelsmann1986-197" class="mw-reference-text"><cite id="CITEREFGoebelsmann1986" class="citation book cs1">Goebelsmann, Uwe (1986). <a href="javascript:if(confirm('https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67'" tppabs="https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67" class="external text external">"Pharmacokinetics of Contraceptive Steroids in Humans"</a>.  In A. T. Gregoire; Richard P. Blye (eds.). <i>Contraceptive Steroids: Pharmacology and Safety</i>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>67–111. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-1-4613-2241-2_4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-1-4613-2241-2_4'" tppabs="https://doi.org/10.1007%2F978-1-4613-2241-2_4" class="external text external">10.1007/978-1-4613-2241-2_4</a>. ISBN<span>&nbsp;</span><bdi>978-1-4613-2241-2</bdi>.</cite></span></li><li id="cite_note-pmid833262-198"> <span id="mw-reference-text-cite_note-pmid833262-198" class="mw-reference-text"><cite id="CITEREFOrtizHirolStanczykGoebelsmann1977" class="citation journal cs1">Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR (January 1977). "Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA". <i>J. Clin. Endocrinol. Metab</i>. <b>44</b> (1): 32–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem-44-1-32  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem-44-1-32'" tppabs="https://doi.org/10.1210%2Fjcem-44-1-32" class="external text external">10.1210/jcem-44-1-32</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/833262  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/833262'" tppabs="https://pubmed.ncbi.nlm.nih.gov/833262" class="external text external">833262</a>.</cite></span></li><li id="cite_note-pmid6451351-199"> <span id="mw-reference-text-cite_note-pmid6451351-199" class="mw-reference-text"><cite id="CITEREFFotherbyKoetsawangMathrubutham1980" class="citation journal cs1">Fotherby K, Koetsawang S, Mathrubutham M (November 1980). "Pharmacokinetic study of different doses of Depo Provera". <i>Contraception</i>. <b>22</b> (5): 527–36. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0010-7824%2880%2990105-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0010-7824%2880%2990105-5'" tppabs="https://doi.org/10.1016%2F0010-7824%2880%2990105-5" class="external text external">10.1016/0010-7824(80)90105-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6451351  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6451351'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6451351" class="external text external">6451351</a>.</cite></span></li><li id="cite_note-Elks2014-200"> <span id="mw-reference-text-cite_note-Elks2014-200" class="mw-reference-text"><cite id="CITEREFElks2014" class="citation book cs1">Elks J (14 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA187  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA187'" tppabs="https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA187" class="external text external"><i>The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies</i></a>. Springer. p.<span>&nbsp;</span>657. ISBN<span>&nbsp;</span><bdi>978-1-4757-2085-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20171105200514/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA187  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20171105200514/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA187'" tppabs="https://web.archive.org/web/20171105200514/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA187" class="external text external">Archived</a> from the original on 5 November 2017.</cite></span></li><li id="cite_note-pmid19158035-201"> <span id="mw-reference-text-cite_note-pmid19158035-201" class="mw-reference-text"><cite id="CITEREFAdemuyiwaMiller2008" class="citation journal cs1">Ademuyiwa FO, Miller KD (December 2008). "Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer". <i>Clin. Breast Cancer</i>. 8 Suppl 4: S151–6. doi:<a href="javascript:if(confirm('https://doi.org/10.3816%2FCBC.2008.s.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3816%2FCBC.2008.s.011'" tppabs="https://doi.org/10.3816%2FCBC.2008.s.011" class="external text external">10.3816/CBC.2008.s.011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19158035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19158035'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19158035" class="external text external">19158035</a>.</cite></span></li><li id="cite_note-AdisInsight-FMPA-202"> <span id="mw-reference-text-cite_note-AdisInsight-FMPA-202" class="mw-reference-text"><a href="javascript:if(confirm('https://adisinsight.springer.com/drugs/800011224  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://adisinsight.springer.com/drugs/800011224'" tppabs="https://adisinsight.springer.com/drugs/800011224" class="external free external">https://adisinsight.springer.com/drugs/800011224</a></span></li><li id="cite_note-FR1295307-203"> <span id="mw-reference-text-cite_note-FR1295307-203" class="mw-reference-text"><span class="citation patent"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=FR1295307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=FR1295307'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=FR1295307" class="external text external">FR 1295307</a>,<span> </span>"Procédé de préparation de dérivés cyclopentano-phénanthréniques",<span> </span>published 1962-06-08,<span> </span> assigned to Syntex SA</span></span></li><li id="cite_note-US3377364-204"> <span id="mw-reference-text-cite_note-US3377364-204" class="mw-reference-text"><span class="citation patent" id="CITEREFSpero_G2020"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US3377364  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US3377364'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US3377364" class="external text external">US<span> </span>granted 3377364</a>,<span> </span>Spero G,<span> </span>"6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same",<span> </span>published 1968-04-09,<span> </span> assigned to Upjohn Company</span></span></li><li id="cite_note-Green1987-205"> <span id="mw-reference-text-cite_note-Green1987-205" class="mw-reference-text"><cite id="CITEREFGreen1987" class="citation journal cs1">Green W (1987). "Odyssey of Depo-Provera: Contraceptives, Carcinogenic Drugs, and Risk-Management Analyses". <i>The. Food Drug Cosm. LJ</i>. Chicago (42): 567–587. <q>Depo-Provera is a drug, manufactured by The Upjohn Co., whose active ingredient is medroxyprogesterone acetate (MPA). FDA first approved the drug in 1959 to treat amenorrhea,5 irregular uterine bleeding, and threatened and habitual abortion.</q></cite></span></li><li id="cite_note-pmid23617013-206"> <span id="mw-reference-text-cite_note-pmid23617013-206" class="mw-reference-text"><cite id="CITEREFHartmannJeromeLindegrenPotter2013" class="citation book cs1">Hartmann KE, Jerome RN, Lindegren ML, Potter SA, Shields TC, Surawicz TS, Andrews JC (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK132498/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK132498/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK132498/" class="external text external"><i>Primary Care Management of Abnormal Uterine Bleeding</i></a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23617013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23617013'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23617013" class="external text external">23617013</a>.</cite></span></li><li id="cite_note-Gelijns1991-207"> <span id="mw-reference-text-cite_note-Gelijns1991-207" class="mw-reference-text"><cite id="CITEREFGelijns1991" class="citation book cs1">Gelijns A (1991). <a href="javascript:if(confirm('https://books.google.com/books?id=MZkrAAAAYAAJ&pg=PA167  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=MZkrAAAAYAAJ&pg=PA167'" tppabs="https://books.google.com/books?id=MZkrAAAAYAAJ&pg=PA167" class="external text external"><i>Innovation in Clinical Practice: The Dynamics of Medical Technology Development</i></a>. National Academies. pp.<span>&nbsp;</span>167–. NAP:13513.</cite></span></li><li id="cite_note-Publishing2013-208"> <span id="mw-reference-text-cite_note-Publishing2013-208" class="mw-reference-text"><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1501  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1501'" tppabs="https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1501" class="external text external"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. Elsevier. pp.<span>&nbsp;</span>1501–. ISBN<span>&nbsp;</span><bdi>978-0-8155-1856-3</bdi>.</cite></span></li><li id="cite_note-209"> <span id="mw-reference-text-cite_note-209" class="mw-reference-text"><cite id="CITEREFKolbe1976" class="citation book cs1">Kolbe HK (1976). <a href="javascript:if(confirm('http://pdf.usaid.gov/pdf_docs/pnaap426.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://pdf.usaid.gov/pdf_docs/pnaap426.pdf'" tppabs="http://pdf.usaid.gov/pdf_docs/pnaap426.pdf" class="external text external"><i>Population/fertility control thesaurus</i></a> <span class="cs1-format">(PDF)</span>. Population Information Program, Science Communication Division, Dept. of Medical and Public Affairs, George Washington University. <a href="javascript:if(confirm('https://web.archive.org/web/20161009213403/http://pdf.usaid.gov/pdf_docs/pnaap426.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161009213403/http://pdf.usaid.gov/pdf_docs/pnaap426.pdf'" tppabs="https://web.archive.org/web/20161009213403/http://pdf.usaid.gov/pdf_docs/pnaap426.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 2016-10-09.</cite></span></li><li id="cite_note-Lee1966-210"> <span id="mw-reference-text-cite_note-Lee1966-210" class="mw-reference-text"><cite id="CITEREFBolivar_De_Lee1966" class="citation book cs1">Bolivar De Lee J (1966). <a href="javascript:if(confirm('https://books.google.com/books?id=hBU-AQAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=hBU-AQAAIAAJ'" tppabs="https://books.google.com/books?id=hBU-AQAAIAAJ" class="external text external"><i>The ... Year Book of Obstetrics and Gynecology</i></a>. Year Book Publishers. p.<span>&nbsp;</span>339. <q>One of these is medroxyprogesterone acetate, which is sold in the United States by Upjohn as Provest, and is obtainable abroad as Provestral, Provestrol, Cyclo-Farlutal, and the more frankly suggestive Nogest.</q></cite></span></li><li id="cite_note-211"> <span id="mw-reference-text-cite_note-211" class="mw-reference-text"><cite id="CITEREFFínkelstein1966" class="citation book cs1">Fínkelstein M (1966). <a href="javascript:if(confirm('https://books.google.com/books?id=Hg5rAAAAMAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Hg5rAAAAMAAJ'" tppabs="https://books.google.com/books?id=Hg5rAAAAMAAJ" class="external text external"><i>Research on Steroids</i></a>. Pergamon. pp.<span>&nbsp;</span>469, 542.</cite></span></li><li id="cite_note-Li2009-212"> <span id="mw-reference-text-cite_note-Li2009-212" class="mw-reference-text"><cite id="CITEREFChristopher_Li2009" class="citation book cs1">Christopher Li (11 November 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=m3MtuTKbkbUC&pg=PA110  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=m3MtuTKbkbUC&pg=PA110'" tppabs="https://books.google.com/books?id=m3MtuTKbkbUC&pg=PA110" class="external text external"><i>Breast Cancer Epidemiology</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>110–. ISBN<span>&nbsp;</span><bdi>978-1-4419-0685-4</bdi>.</cite></span></li><li id="cite_note-Levitt2015-213"> <span id="mw-reference-text-cite_note-Levitt2015-213" class="mw-reference-text"><cite id="CITEREFLevitt2015" class="citation book cs1">Levitt JI (30 April 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=emwaCAAAQBAJ&pg=PA231  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=emwaCAAAQBAJ&pg=PA231'" tppabs="https://books.google.com/books?id=emwaCAAAQBAJ&pg=PA231" class="external text external"><i>Black Women and International Law: Deliberate Interactions, Movements and Actions</i></a>. Cambridge University Press. pp.<span>&nbsp;</span>230–231. ISBN<span>&nbsp;</span><bdi>978-1-316-29840-4</bdi>.</cite></span></li><li id="cite_note-Women1998-214"> <span id="mw-reference-text-cite_note-Women1998-214" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=ItQcAQAAMAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=ItQcAQAAMAAJ'" tppabs="https://books.google.com/books?id=ItQcAQAAMAAJ" class="external text external"><i>Documentation on Women's Concerns</i></a>. Library and Documentation Centre, All India Association for Christian Higher Education. January 1998. <q>Upjohn meanwhile, had been repeatedly seeking FDA approval for use of DMPA as a contraceptive, but applications were rejected in 1967, 1978 and yet again in 1983, [...]</q></cite></span></li><li id="cite_note-ShoupeJr.2015-215"> <span id="mw-reference-text-cite_note-ShoupeJr.2015-215" class="mw-reference-text"><cite id="CITEREFShoupeMishell2015" class="citation book cs1">Shoupe D, Mishell DR (28 September 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=ZQehCgAAQBAJ&pg=PA126  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=ZQehCgAAQBAJ&pg=PA126'" tppabs="https://books.google.com/books?id=ZQehCgAAQBAJ&pg=PA126" class="external text external"><i>The Handbook of Contraception: A Guide for Practical Management</i></a>. Humana Press. pp.<span>&nbsp;</span>126–. ISBN<span>&nbsp;</span><bdi>978-3-319-20185-6</bdi>.</cite></span></li><li id="cite_note-MortonHall1999-216"> <span id="mw-reference-text-cite_note-MortonHall1999-216" class="mw-reference-text"><cite id="CITEREFMortonHall1999" class="citation book cs1">Morton I, Hall JM (31 October 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=mqaOMOtk61IC&pg=PA173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=mqaOMOtk61IC&pg=PA173'" tppabs="https://books.google.com/books?id=mqaOMOtk61IC&pg=PA173" class="external text external"><i>Concise Dictionary of Pharmacological Agents: Properties and Synonyms</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>173–. ISBN<span>&nbsp;</span><bdi>978-0-7514-0499-9</bdi>.</cite></span></li><li id="cite_note-217"> <span id="mw-reference-text-cite_note-217" class="mw-reference-text"><cite id="CITEREFLouisiana_State_Legislature" class="citation web cs1">Louisiana State Legislature. <a href="javascript:if(confirm('http://www.legis.la.gov/legis/Law.aspx?d=508441  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.legis.la.gov/legis/Law.aspx?d=508441'" tppabs="http://www.legis.la.gov/legis/Law.aspx?d=508441" class="external text external">"§43.6. Administration of medroxyprogesterone acetate (MPA) to certain sex offenders"</a>. <i>Louisiana Revised Statutes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">8 July</span> 2019</span>.</cite></span></li><li id="cite_note-UnzeitigLunsen2000-218"> <span id="mw-reference-text-cite_note-UnzeitigLunsen2000-218" class="mw-reference-text"><cite id="CITEREFUnzeitigvan_Lunsen2000" class="citation book cs1">Unzeitig V, van Lunsen RH (15 February 2000). <a href="javascript:if(confirm('https://books.google.com/books?id=-FliV0TxtEEC&pg=PA73  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=-FliV0TxtEEC&pg=PA73'" tppabs="https://books.google.com/books?id=-FliV0TxtEEC&pg=PA73" class="external text external"><i>Contraceptive Choices and Realities: Proceedings of the 5th Congress of the European Society of Contraception</i></a>. CRC Press. pp.<span>&nbsp;</span>73–. ISBN<span>&nbsp;</span><bdi>978-1-85070-067-8</bdi>.</cite></span></li><li id="cite_note-HumansOrganization2007-219"> <span id="mw-reference-text-cite_note-HumansOrganization2007-219" class="mw-reference-text"><cite id="CITEREFIARC_Working_Group_on_the_Evaluation_of_Carcinogenic_Risks_to_HumansWorld_Health_OrganizationInternational_Agency_for_Research_on_Cancer2007" class="citation book cs1">IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). <a href="javascript:if(confirm('https://books.google.com/books?id=aGDU5xibtNgC&pg=PA434  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=aGDU5xibtNgC&pg=PA434'" tppabs="https://books.google.com/books?id=aGDU5xibtNgC&pg=PA434" class="external text external"><i>Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy</i></a>. World Health Organization. p.<span>&nbsp;</span>44. ISBN<span>&nbsp;</span><bdi>978-92-832-1291-1</bdi>.</cite></span></li><li id="cite_note-Gordon2007-220"> <span id="mw-reference-text-cite_note-Gordon2007-220" class="mw-reference-text"><cite id="CITEREFJohn_David_Gordon2007" class="citation book cs1">John David Gordon (2007). <a href="javascript:if(confirm('https://books.google.com/books?id=2JLC6yiA7fcC&pg=PA228  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2JLC6yiA7fcC&pg=PA228'" tppabs="https://books.google.com/books?id=2JLC6yiA7fcC&pg=PA228" class="external text external"><i>Obstetrics, Gynecology &amp; Infertility: Handbook for Clinicians</i></a>. Scrub Hill Press, Inc. pp.<span>&nbsp;</span>228–. ISBN<span>&nbsp;</span><bdi>978-0-9645467-7-6</bdi>.</cite></span></li><li id="cite_note-221"> <span id="mw-reference-text-cite_note-221" class="mw-reference-text"><cite class="citation journal cs1">"Contraceptives. Case for public enquiry". <i>Economic and Political Weekly</i>. <b>29</b> (15): 825–6. 1994. Popline database document number 096527.</cite></span></li><li id="cite_note-222"> <span id="mw-reference-text-cite_note-222" class="mw-reference-text"><cite id="CITEREFSorojini,_NB2005" class="citation journal cs1">Sorojini, NB (January–March 2005). <a href="javascript:if(confirm('https://web.archive.org/web/20060506074850/http://www.issuesinmedicalethics.org/131di008.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060506074850/http://www.issuesinmedicalethics.org/131di008.html'" tppabs="https://web.archive.org/web/20060506074850/http://www.issuesinmedicalethics.org/131di008.html" class="external text external">"Why women's groups oppose injectable contraceptives"</a>. <i>Indian Journal of Medical Ethics</i>. <b>13</b> (1). Archived from <a href="javascript:if(confirm('http://www.issuesinmedicalethics.org/131di008.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.issuesinmedicalethics.org/131di008.html'" tppabs="http://www.issuesinmedicalethics.org/131di008.html" class="external text external">the original</a> <span class="cs1-format">(– <sup><a href="javascript:if(confirm('https://scholar.google.co.uk/scholar?hl=en&lr=&q=intitle%3AWhy+women%27s+groups+oppose+injectable+contraceptives&as_publication=Indian+Journal+of+Medical+Ethics&as_ylo=2005&as_yhi=2005&btnG=Search  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://scholar.google.co.uk/scholar?hl=en&lr=&q=intitle%3AWhy+women%27s+groups+oppose+injectable+contraceptives&as_publication=Indian+Journal+of+Medical+Ethics&as_ylo=2005&as_yhi=2005&btnG=Search'" tppabs="https://scholar.google.co.uk/scholar?hl=en&lr=&q=intitle%3AWhy+women%27s+groups+oppose+injectable+contraceptives&as_publication=Indian+Journal+of+Medical+Ethics&as_ylo=2005&as_yhi=2005&btnG=Search" class="external text external">Scholar search</a></sup>)</span> on May 6, 2006.</cite></span></li><li id="cite_note-223"> <span id="mw-reference-text-cite_note-223" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://nhm.gov.in/New_Updates_2018/NHM_Components/RMNCHA/Family_planning/Schemes_&_Guidelines/Injectable_Contraceptive_MPA.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://nhm.gov.in/New_Updates_2018/NHM_Components/RMNCHA/Family_planning/Schemes_&_Guidelines/Injectable_Contraceptive_MPA.pdf'" tppabs="https://nhm.gov.in/New_Updates_2018/NHM_Components/RMNCHA/Family_planning/Schemes_&_Guidelines/Injectable_Contraceptive_MPA.pdf" class="external text external">"Reference Manual for Injectable Contraceptive (MPA)"</a> <span class="cs1-format">(pdf)</span>. <i>nhm.gov.in</i><span class="reference-accessdate">. Retrieved <span class="nowrap">26 February</span> 2020</span>.</cite></span></li><li id="cite_note-224"> <span id="mw-reference-text-cite_note-224" class="mw-reference-text"><cite id="CITEREFMadeline_Boscoe1991" class="citation web cs1">Madeline Boscoe (December 6, 1991). <a href="javascript:if(confirm('https://web.archive.org/web/20070205105907/http://www.cwhn.ca/resources/birth_control/depoLetter.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070205105907/http://www.cwhn.ca/resources/birth_control/depoLetter.html'" tppabs="https://web.archive.org/web/20070205105907/http://www.cwhn.ca/resources/birth_control/depoLetter.html" class="external text external">"Canadian Coalition on Depo-Provera letter to The Honorable Benoit Bouchard, National Minister of Health and Welfare"</a>. Canadian Women's Health Network. Archived from <a href="javascript:if(confirm('http://www.cwhn.ca/resources/birth_control/depoLetter.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cwhn.ca/resources/birth_control/depoLetter.html'" tppabs="http://www.cwhn.ca/resources/birth_control/depoLetter.html" class="external text external">the original</a> on 5 February 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">2006-08-22</span></span>.</cite></span></li><li id="cite_note-225"> <span id="mw-reference-text-cite_note-225" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20051219/depo_provera_051219/20051219?hub=TopStories  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20051219/depo_provera_051219/20051219?hub=TopStories'" tppabs="http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20051219/depo_provera_051219/20051219?hub=TopStories" class="external text external">"Class action suit filed over birth control drug"</a>. CTV.ca. December 19, 2005. <a href="javascript:if(confirm('https://web.archive.org/web/20060813180129/http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20051219/depo_provera_051219/20051219?hub=TopStories  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060813180129/http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20051219/depo_provera_051219/20051219?hub=TopStories'" tppabs="https://web.archive.org/web/20060813180129/http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20051219/depo_provera_051219/20051219?hub=TopStories" class="external text external">Archived</a> from the original on August 13, 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">2006-08-22</span></span>.</cite></span></li><li id="cite_note-226"> <span id="mw-reference-text-cite_note-226" class="mw-reference-text">"<cite class="citation web cs1"><a href="javascript:if(confirm('http://www.haaretz.com/news/israel/israeli-minister-appointing-team-to-probe-ethiopian-birth-control-shot-controversy-1.506266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.haaretz.com/news/israel/israeli-minister-appointing-team-to-probe-ethiopian-birth-control-shot-controversy-1.506266'" tppabs="http://www.haaretz.com/news/israel/israeli-minister-appointing-team-to-probe-ethiopian-birth-control-shot-controversy-1.506266" class="external text external">"Archived copy"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20150620062920/http://www.haaretz.com/news/israel/israeli-minister-appointing-team-to-probe-ethiopian-birth-control-shot-controversy-1.506266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150620062920/http://www.haaretz.com/news/israel/israeli-minister-appointing-team-to-probe-ethiopian-birth-control-shot-controversy-1.506266'" tppabs="https://web.archive.org/web/20150620062920/http://www.haaretz.com/news/israel/israeli-minister-appointing-team-to-probe-ethiopian-birth-control-shot-controversy-1.506266" class="external text external">Archived</a> from the original on 2015-06-20<span class="reference-accessdate">. Retrieved <span class="nowrap">2015-06-20</span></span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li><li id="cite_note-Leary1992-227"> <span id="mw-reference-text-cite_note-Leary1992-227" class="mw-reference-text"><cite id="CITEREFLeary1992" class="citation journal cs1">Leary WE (October 1992). <a href="javascript:if(confirm('https://query.nytimes.com/gst/fullpage.html?sec=health&res=9E0CE1DD123BF933A05753C1A964958260  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://query.nytimes.com/gst/fullpage.html?sec=health&res=9E0CE1DD123BF933A05753C1A964958260'" tppabs="https://query.nytimes.com/gst/fullpage.html?sec=health&res=9E0CE1DD123BF933A05753C1A964958260" class="external text external">"U.S. approves injectable drug as birth control"</a>. <i>The New York Times on the Web</i>: A1, A14. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11646958  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11646958'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11646958" class="external text external">11646958</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20081208133159/http://query.nytimes.com/gst/fullpage.html?sec=health&res=9E0CE1DD123BF933A05753C1A964958260  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20081208133159/http://query.nytimes.com/gst/fullpage.html?sec=health&res=9E0CE1DD123BF933A05753C1A964958260'" tppabs="https://web.archive.org/web/20081208133159/http://query.nytimes.com/gst/fullpage.html?sec=health&res=9E0CE1DD123BF933A05753C1A964958260" class="external text external">Archived</a> from the original on 2008-12-08.</cite></span></li><li id="cite_note-228"> <span id="mw-reference-text-cite_note-228" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.inchem.org/documents/iarc/suppl7/progestins.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.inchem.org/documents/iarc/suppl7/progestins.html'" tppabs="http://www.inchem.org/documents/iarc/suppl7/progestins.html" class="external text external">"Progestins (IARC Summary &amp; Evaluation, Supplement7, 1987)"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20171107030422/http://www.inchem.org/documents/iarc/suppl7/progestins.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20171107030422/http://www.inchem.org/documents/iarc/suppl7/progestins.html'" tppabs="https://web.archive.org/web/20171107030422/http://www.inchem.org/documents/iarc/suppl7/progestins.html" class="external text external">Archived</a> from the original on 7 November 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2016</span>.</cite></span></li><li id="cite_note-MM_Goodman1985-229"> <span id="mw-reference-text-cite_note-MM_Goodman1985-229" class="mw-reference-text"><cite id="CITEREFAmy_Goodman1985" class="citation journal cs1">Amy Goodman (February–March 1985). <a href="javascript:if(confirm('http://www.multinationalmonitor.org/hyper/issues/1985/02/problems-us.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.multinationalmonitor.org/hyper/issues/1985/02/problems-us.html'" tppabs="http://www.multinationalmonitor.org/hyper/issues/1985/02/problems-us.html" class="external text external">"The Case Against Depo-Provera - Problems in the U.S"</a>. <i>Multinational Monitor</i>. <b>6</b> (2 &amp; 3). <a href="javascript:if(confirm('https://web.archive.org/web/20061003000448/http://www.multinationalmonitor.org/hyper/issues/1985/02/problems-us.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20061003000448/http://www.multinationalmonitor.org/hyper/issues/1985/02/problems-us.html'" tppabs="https://web.archive.org/web/20061003000448/http://www.multinationalmonitor.org/hyper/issues/1985/02/problems-us.html" class="external text external">Archived</a> from the original on 2006-10-03.</cite></span></li><li id="cite_note-230"> <span id="mw-reference-text-cite_note-230" class="mw-reference-text"><cite class="citation journal cs1">"Controversy over Depo-Provera". <i>Washington Drug &amp; Device Letter</i>. <b>9</b> (1): 2. January 1977. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12335988  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12335988'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12335988" class="external text external">12335988</a>.</cite></span></li><li id="cite_note-231"> <span id="mw-reference-text-cite_note-231" class="mw-reference-text"><cite id="CITEREFThomasYeRay1995" class="citation journal cs1">Thomas DB, Ye Z, Ray RM (January 1995). "Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives". <i>Contraception</i>. <b>51</b> (1): 25–31. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0010-7824%2894%2900007-J  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0010-7824%2894%2900007-J'" tppabs="https://doi.org/10.1016%2F0010-7824%2894%2900007-J" class="external text external">10.1016/0010-7824(94)00007-J</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7750280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7750280'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7750280" class="external text external">7750280</a>.</cite></span></li><li id="cite_note-232"> <span id="mw-reference-text-cite_note-232" class="mw-reference-text"><cite class="citation journal cs1">"Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives". <i>Contraception</i>. <b>45</b> (4): 299–312. April 1992. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0010-7824%2892%2990052-U  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0010-7824%2892%2990052-U'" tppabs="https://doi.org/10.1016%2F0010-7824%2892%2990052-U" class="external text external">10.1016/0010-7824(92)90052-U</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1387601  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1387601'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1387601" class="external text external">1387601</a>.</cite></span></li><li id="cite_note-233"> <span id="mw-reference-text-cite_note-233" class="mw-reference-text"><cite id="CITEREFThomasRay1995" class="citation journal cs1">Thomas DB, Ray RM (November 1995). "Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives". <i>Contraception</i>. <b>52</b> (5): 307–12. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0010-7824%2895%2900215-V  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0010-7824%2895%2900215-V'" tppabs="https://doi.org/10.1016%2F0010-7824%2895%2900215-V" class="external text external">10.1016/0010-7824(95)00215-V</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8585888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8585888'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8585888" class="external text external">8585888</a>.</cite></span></li><li id="cite_note-234"> <span id="mw-reference-text-cite_note-234" class="mw-reference-text"><cite id="CITEREFShapiroRosenbergHoffmanKelly2003" class="citation journal cs1">Shapiro S, Rosenberg L, Hoffman M, Kelly JP, Cooper DD, Carrara H, Denny LE, du Toit G, Allan BR, Stander IA, Williamson AL (June 2003). "Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa)". <i>Cancer Causes &amp; Control</i>. <b>14</b> (5): 485–95. doi:<a href="javascript:if(confirm('https://doi.org/10.1023%2FA%3A1024910808307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1023%2FA%3A1024910808307'" tppabs="https://doi.org/10.1023%2FA%3A1024910808307" class="external text external">10.1023/A:1024910808307</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12946044  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12946044'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12946044" class="external text external">12946044</a>.</cite></span></li><li id="cite_note-235"> <span id="mw-reference-text-cite_note-235" class="mw-reference-text"><cite id="CITEREFKaunitz1996" class="citation journal cs1">Kaunitz AM (May 1996). "Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer". <i>The Journal of Reproductive Medicine</i>. <b>41</b> (5 Suppl): 419–27. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8725705  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8725705'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8725705" class="external text external">8725705</a>.</cite></span></li><li id="cite_note-albion-236"> <span id="mw-reference-text-cite_note-albion-236" class="mw-reference-text"><cite id="CITEREFHawkinsElliott1996" class="citation web cs1">Hawkins K, Elliott J (5 May 1996). <a href="javascript:if(confirm('https://web.archive.org/web/20151121180041/http://www.monitor.net/monitor/controlled/bc-depohearing.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151121180041/http://www.monitor.net/monitor/controlled/bc-depohearing.html'" tppabs="https://web.archive.org/web/20151121180041/http://www.monitor.net/monitor/controlled/bc-depohearing.html" class="external text external">"Seeking Approval"</a>. <i>Albion Monitor</i>. Archived from <a href="javascript:if(confirm('http://www.monitor.net/monitor/controlled/bc-depohearing.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.monitor.net/monitor/controlled/bc-depohearing.html'" tppabs="http://www.monitor.net/monitor/controlled/bc-depohearing.html" class="external text external">the original</a> on 21 November 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">20 November</span> 2006</span>.</cite></span></li><li id="cite_note-237"> <span id="mw-reference-text-cite_note-237" class="mw-reference-text"><cite class="citation journal cs1">"Sterilization of minors leads to controversy". <i>Family Planning/Population Reporter; A Review of State Laws and Policies</i>. <b>2</b> (4): 77–8. August 1973. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12257656  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12257656'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12257656" class="external text external">12257656</a>.</cite></span></li><li id="cite_note-238"> <span id="mw-reference-text-cite_note-238" class="mw-reference-text"><cite id="CITEREFEganSiegertFairley1993" class="citation journal cs1">Egan TM, Siegert RJ, Fairley NA (August 1993). "Use of hormonal contraceptives in an institutional setting: reasons for use, consent and safety in women with psychiatric and intellectual disabilities". <i>The New Zealand Medical Journal</i>. <b>106</b> (961): 338–41. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8341476  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8341476'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8341476" class="external text external">8341476</a>.</cite></span></li><li id="cite_note-239"> <span id="mw-reference-text-cite_note-239" class="mw-reference-text"><cite id="CITEREFSingh1995" class="citation journal cs1">Singh S (May 1995). "Adolescent knowledge and use of injectable contraceptives in developing countries". <i>The Journal of Adolescent Health</i>. <b>16</b> (5): 396–404. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1054-139X%2894%2900060-R  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1054-139X%2894%2900060-R'" tppabs="https://doi.org/10.1016%2FS1054-139X%2894%2900060-R" class="external text external">10.1016/S1054-139X(94)00060-R</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7662691  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7662691'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7662691" class="external text external">7662691</a>.</cite></span></li><li id="cite_note-240"> <span id="mw-reference-text-cite_note-240" class="mw-reference-text"><cite class="citation journal cs1">"Clinicians clash with consumer groups over possible Depo ban". <i>Contraceptive Technology Update</i>. <b>16</b> (1): 11–4. January 1995. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12319319  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12319319'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12319319" class="external text external">12319319</a>.</cite></span></li><li id="cite_note-pmid865726-241"> <span id="mw-reference-text-cite_note-pmid865726-241" class="mw-reference-text"><cite id="CITEREFToppozada1977" class="citation journal cs1">Toppozada M (June 1977). "The clinical use of monthly injectable contraceptive preparations". <i>Obstet Gynecol Surv</i>. <b>32</b> (6): 335–47. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00006254-197706000-00001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00006254-197706000-00001'" tppabs="https://doi.org/10.1097%2F00006254-197706000-00001" class="external text external">10.1097/00006254-197706000-00001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/865726  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/865726'" tppabs="https://pubmed.ncbi.nlm.nih.gov/865726" class="external text external">865726</a>.</cite></span></li><li id="cite_note-GoldzieherFotherby1994-242"> <span id="mw-reference-text-cite_note-GoldzieherFotherby1994-242" class="mw-reference-text"><cite id="CITEREFJoseph_William_GoldzieherKenneth_Fotherby1994" class="citation book cs1">Joseph William Goldzieher; Kenneth Fotherby (1994). <a href="javascript:if(confirm('https://books.google.com/books?id=bJRsAAAAMAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=bJRsAAAAMAAJ'" tppabs="https://books.google.com/books?id=bJRsAAAAMAAJ" class="external text external"><i>Pharmacology of the contraceptive steroids</i></a>. Raven Press. p.<span>&nbsp;</span>154. ISBN<span>&nbsp;</span><bdi>978-0-7817-0097-9</bdi>.</cite></span></li><li id="cite_note-pmid5925038-243"> <span id="mw-reference-text-cite_note-pmid5925038-243" class="mw-reference-text"><cite id="CITEREFZañartuRice-WrayGoldzieher1966" class="citation journal cs1">Zañartu J, Rice-Wray E, Goldzieher JW (October 1966). <a href="javascript:if(confirm('https://journals.lww.com/greenjournal/citation/1966/10000/fertility_control_with_long_acting_injectable.11.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://journals.lww.com/greenjournal/citation/1966/10000/fertility_control_with_long_acting_injectable.11.aspx'" tppabs="https://journals.lww.com/greenjournal/citation/1966/10000/fertility_control_with_long_acting_injectable.11.aspx" class="external text external">"Fertility control with long-acting injectable steroids. A preliminary report"</a>. <i>Obstet Gynecol</i>. <b>28</b> (4): 513–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00006250-196610000-00011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00006250-196610000-00011'" tppabs="https://doi.org/10.1097%2F00006250-196610000-00011" class="external text external">10.1097/00006250-196610000-00011</a> (inactive 2020-03-23). PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/5925038  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/5925038'" tppabs="https://pubmed.ncbi.nlm.nih.gov/5925038" class="external text external">5925038</a>.</cite></span></li><li id="cite_note-Beckman1967-244"> <span id="mw-reference-text-cite_note-Beckman1967-244" class="mw-reference-text"><cite id="CITEREFHarry_Beckman1967" class="citation book cs1">Harry Beckman (1967). <a href="javascript:if(confirm('https://books.google.com/books?id=sRc-AQAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=sRc-AQAAIAAJ'" tppabs="https://books.google.com/books?id=sRc-AQAAIAAJ" class="external text external"><i>The Year Book of Drug Therapy</i></a>. Year Book Publishers.</cite></span></li><li id="cite_note-PiotrowskiGreenberg2016-245"> <span id="mw-reference-text-cite_note-PiotrowskiGreenberg2016-245" class="mw-reference-text"><cite id="CITEREFPiotrowskiGreenberg2016" class="citation book cs1">Piotrowski Z, Greenberg RE (2016). "Antiandrogen Monotherapy in the Treatment of Prostate Cancer". <i>Prostate Cancer</i>. pp.<span>&nbsp;</span>515–521. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FB978-0-12-800077-9.00055-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FB978-0-12-800077-9.00055-4'" tppabs="https://doi.org/10.1016%2FB978-0-12-800077-9.00055-4" class="external text external">10.1016/B978-0-12-800077-9.00055-4</a>. ISBN<span>&nbsp;</span><bdi>9780128000779</bdi>.</cite></span></li><li id="cite_note-pmid11842755-246"> <span id="mw-reference-text-cite_note-pmid11842755-246" class="mw-reference-text"><cite id="CITEREFForsterStoffelGasser2002" class="citation journal cs1">Forster TH, Stoffel F, Gasser TC (2002). "Hormone therapy in advanced prostate cancer". <i>Front Radiat Ther Oncol</i>. Frontiers of Radiation Therapy and Oncology. <b>36</b>: 49–65. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000061329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000061329'" tppabs="https://doi.org/10.1159%2F000061329" class="external text external">10.1159/000061329</a>. ISBN<span>&nbsp;</span><bdi>3-8055-7217-4</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11842755  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11842755'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11842755" class="external text external">11842755</a>.</cite></span></li><li id="cite_note-pmid9088277-247"> <span id="mw-reference-text-cite_note-pmid9088277-247" class="mw-reference-text"><cite id="CITEREFNewling1997" class="citation journal cs1">Newling DW (March 1997). "The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials". <i>Br J Urol</i>. 79 Suppl 1: 72–81. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1464-410X.1997.tb00805.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1464-410X.1997.tb00805.x'" tppabs="https://doi.org/10.1111%2Fj.1464-410X.1997.tb00805.x" class="external text external">10.1111/j.1464-410X.1997.tb00805.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9088277  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9088277'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9088277" class="external text external">9088277</a>.</cite></span></li><li id="cite_note-DenisGriffiths1999-248"> <span id="mw-reference-text-cite_note-DenisGriffiths1999-248" class="mw-reference-text"><cite id="CITEREFDenisGriffithsKaisaryMurphy1999" class="citation book cs1">Denis LJ, Griffiths K, Kaisary AV, Murphy GP (1 March 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=GreZlojD-tYC&pg=PA296  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=GreZlojD-tYC&pg=PA296'" tppabs="https://books.google.com/books?id=GreZlojD-tYC&pg=PA296" class="external text external"><i>Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment</i></a>. CRC Press. pp.<span>&nbsp;</span>296–. ISBN<span>&nbsp;</span><bdi>978-1-85317-422-3</bdi>.</cite></span></li><li id="cite_note-pmid20933120-249"> <span id="mw-reference-text-cite_note-pmid20933120-249" class="mw-reference-text"><cite id="CITEREFNieschlag2010" class="citation journal cs1">Nieschlag E (2010). <a href="javascript:if(confirm('http://www.kup.at/kup/pdf/10172.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.kup.at/kup/pdf/10172.pdf'" tppabs="http://www.kup.at/kup/pdf/10172.pdf" class="external text external">"Clinical trials in male hormonal contraception"</a> <span class="cs1-format">(PDF)</span>. <i>Contraception</i>. <b>82</b> (5): 457–70. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.contraception.2010.03.020  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.contraception.2010.03.020'" tppabs="https://doi.org/10.1016%2Fj.contraception.2010.03.020" class="external text external">10.1016/j.contraception.2010.03.020</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20933120  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20933120'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20933120" class="external text external">20933120</a>.</cite></span></li><li id="cite_note-AdisInsight-MPA-AI-250"> <span id="mw-reference-text-cite_note-AdisInsight-MPA-AI-250" class="mw-reference-text"><a href="javascript:if(confirm('https://adisinsight.springer.com/drugs/800008646  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://adisinsight.springer.com/drugs/800008646'" tppabs="https://adisinsight.springer.com/drugs/800008646" class="external free external">https://adisinsight.springer.com/drugs/800008646</a></span></li><li id="cite_note-pmid15102587-251"> <span id="mw-reference-text-cite_note-pmid15102587-251" class="mw-reference-text"><cite id="CITEREFSrinivasanLichtenstein2004" class="citation journal cs1">Srinivasan R, Lichtenstein GR (April 2004). "Recent developments in the pharmacological treatment of Crohn's disease". <i>Expert Opin Investig Drugs</i>. <b>13</b> (4): 373–91. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F13543784.13.4.373  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F13543784.13.4.373'" tppabs="https://doi.org/10.1517%2F13543784.13.4.373" class="external text external">10.1517/13543784.13.4.373</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15102587  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15102587'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15102587" class="external text external">15102587</a>.</cite></span></li><li id="cite_note-SaxenaScaini2017-252"> <span id="mw-reference-text-cite_note-SaxenaScaini2017-252" class="mw-reference-text"><cite id="CITEREFSaxenaScainiBavarescoLeite2017" class="citation journal cs1">Saxena, Ashwini; Scaini, Giselli; Bavaresco, Daniela V.; Leite, Camila; Valvassoria, Samira S.; Carvalho, André F.; Quevedo, João (2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701269  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701269'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701269" class="external text external">"Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature"</a>. <i>Molecular Neuropsychiatry</i>. <b>3</b> (2): 108–124. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000480349  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000480349'" tppabs="https://doi.org/10.1159%2F000480349" class="external text external">10.1159/000480349</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2296-9209  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2296-9209'" tppabs="https://www.worldcat.org/issn/2296-9209" class="external text external">2296-9209</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701269  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701269'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701269" class="external text external">5701269</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29230399  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29230399'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29230399" class="external text external">29230399</a>.</cite></span></li><li id="cite_note-pmid12701517-253"> <span id="mw-reference-text-cite_note-pmid12701517-253" class="mw-reference-text"><cite id="CITEREFSimpsonPapich2003" class="citation journal cs1">Simpson BS, Papich MG (March 2003). "Pharmacologic management in veterinary behavioral medicine". <i>Vet. Clin. North Am. Small Anim. Pract</i>. <b>33</b> (2): 365–404, vii. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0195-5616%2802%2900130-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0195-5616%2802%2900130-4'" tppabs="https://doi.org/10.1016%2FS0195-5616%2802%2900130-4" class="external text external">10.1016/S0195-5616(02)00130-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12701517  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12701517'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12701517" class="external text external">12701517</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/medroxyprogesterone%20acetate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/medroxyprogesterone%20acetate'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/medroxyprogesterone%20acetate" class="external text external">"Medroxyprogesterone acetate"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Appetite_stimulants_(A15)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Appetite_stimulants_(A15)" style="font-size:114%;margin:0 4em">Appetite stimulants (A15)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Exogenous</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li><a href="Clonidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clonidine" title="Clonidine">Clonidine</a></li>
<li><a href="Cyproheptadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproheptadine" title="Cyproheptadine">Cyproheptadine</a></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><a href="Tetrahydrocannabinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetrahydrocannabinol" title="Tetrahydrocannabinol">Dronabinol/Tetrahydrocannabinol</a> (<i>Cannabis</i>)</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Megestrol acetate</li>
<li><a href="Mirtazapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mirtazapine" title="Mirtazapine">Mirtazapine</a></li>
<li><a href="Nabilone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nabilone" title="Nabilone">Nabilone</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a></li>
<li><a href="Olanzapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Olanzapine" title="Olanzapine">Olanzapine</a></li>
<li>Omega-3 fatty acid</li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Pentoxifylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Pentoxifylline" title="Pentoxifylline">Pentoxifylline</a></li>
<li><a href="Prednisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisone" title="Prednisone">Prednisone</a></li>
<li>Sugars</li>
<li>Testosterone</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Endogenous</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Adrenocorticotropic_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenocorticotropic_hormone" title="Adrenocorticotropic hormone">ACTH/Corticotropin</a></li>
<li>Adiponectin</li>
<li>Agouti-related peptide</li>
<li><a href="Anandamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Anandamide" title="Anandamide">Anandamide</a></li>
<li><a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">Cortisol/Hydrocortisone</a></li>
<li><a href="Cortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisone" title="Cortisone">Cortisone</a></li>
<li>Ghrelin</li>
<li>Melanin-concentrating hormone</li>
<li><a href="Melatonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Melatonin" title="Melatonin">Melatonin</a></li>
<li>Neuropeptide Y</li>
<li>Orexin/Hypocretin</li></ul>
</div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Progestogens_and_antiprogestogens" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Progestogens_and_antiprogestogens" style="font-size:114%;margin:0 4em">Progestogens and antiprogestogens</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Progestogens<br>(and progestins)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="PR_agonists" scope="row" class="navbox-group" style="width:8em;;text-align:center;"><abbr>PR</abbr> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Progesterone derivatives:</i> Progesterone</li>
<li>Quingestrone</li></ul>

<ul><li><i>Retroprogesterone derivatives:</i> <a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li>Trengestone</li></ul>

<ul><li><i>17α-Hydroxyprogesterone (and closely related) derivatives:</i> <i>17α-Hydroxylated:</i> Acetomepregenol (mepregenol diacetate)</li>
<li>Algestone acetophenide (dihydroxyprogesterone acetophenide)</li>
<li>Anagestone acetate</li>
<li>Chlormadinone acetate</li>
<li>Chlormethenmadinone acetate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone acetate</li>
<li>Flugestone acetate (flurogestone acetate)</li>
<li>Flumedroxone acetate</li>
<li>Hydroxyprogesterone acetate</li>
<li>Hydroxyprogesterone caproate</li>
<li>Hydroxyprogesterone heptanoate</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a><sup>#</sup></li>
<li>Megestrol acetate</li>
<li>Melengestrol acetate</li>
<li>Methenmadinone acetate</li>
<li>Osaterone acetate</li>
<li>Pentagestrone acetate</li>
<li>Proligestone; <i>17α-Methylated:</i> Medrogestone; <i>Others:</i> Haloprogesterone</li></ul>

<ul><li><i>19-Norprogesterone derivatives:</i> <i>17α-Hydroxylated:</i> Gestonorone caproate (gestronol hexanoate)</li>
<li>Nomegestrol acetate</li>
<li>Norgestomet</li>
<li>Segesterone acetate (nestorone, elcometrine); <i>17α-Methylated:</i> Demegestone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Trimegestone</li></ul>

<ul><li><i>Testosterone derivatives:</i> <i>Estranes:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Dimethisterone</li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone</a></li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> <i>Estranes:</i> <a href="Allylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Allylestrenol" title="Allylestrenol">Allylestrenol</a></li>
<li>Altrenogest</li>
<li>Dienogest</li>
<li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li>
<li>Lynestrenol</li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone (norethindrone)</a><sup>#</sup></li>
<li>Norethisterone acetate</li>
<li>Norethisterone enanthate</li>
<li>Noretynodrel</li>
<li>Norgesterone</li>
<li>Norgestrienone</li>
<li>Normethandrone (methylestrenolone)</li>
<li>Norvinisterone</li>
<li>Oxendolone</li>
<li>Quingestanol acetate</li>
<li>Tibolone; <i>Gonanes:</i> <a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a><sup>#</sup></li>
<li>Norelgestromin</li>
<li><a href="Norgestimate.htm" tppabs="https://ptable.com/wiki/compounds/A/Norgestimate" title="Norgestimate">Norgestimate</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li></ul>

<ul><li><i>Spirolactone derivatives:</i> <a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li></ul>

<ul><li><i>Others:</i> Anabolic–androgenic steroids (e.g., <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">nandrolone</a> and esters, trenbolone and esters, <a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">ethylestrenol</a>, norethandrolone, others)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antiprogestogens</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:8em;;text-align:center;"><abbr>SPRMs</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Telapristone<sup>§</sup></li>
<li>Ulipristal acetate</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:8em;;text-align:center;"><abbr>PR</abbr> antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aglepristone</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div>
<dl><dt>See also</dt>
<dd>Progesterone receptor modulators</dd>
<dd>Androgens and antiandrogens</dd>
<dd>Estrogens and antiestrogens</dd>
<dd>List of progestogens</dd></dl></div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Pharmacodynamics" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="background:#e8e8ff;background:#ccccff"><div id="Pharmacodynamics" style="font-size:114%;margin:0 4em">Pharmacodynamics</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;font-size:114%"><div style="padding:0px">
<div role="navigation" class="navbox" aria-labelledby="Androgen_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgen_receptor_modulators" style="font-size:114%;margin:0 4em">Androgen receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>AR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> <a href="4-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenediol" title="4-Androstenediol">4-Androstenediol</a></li>
<li>4-Dehydroepiandrosterone (4-DHEA)</li>
<li>4-Hydroxytestosterone</li>
<li><span class="new">4,17α-Dimethyltestosterone</span></li>
<li>5-Androstenedione</li>
<li>11-Ketotestosterone</li>
<li>11β-Hydroxyandrostenedione</li>
<li><a href="Adrenosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenosterone" title="Adrenosterone">Adrenosterone (11-ketoandrostenedione, 11-oxoandrostenedione)</a></li>
<li><a href="5-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Androstenediol" title="5-Androstenediol" class="mw-redirect">Androstenediol (5-androstenediol)</a>
<ul><li>Androstenediol 3β-acetate</li>
<li>Androstenediol 17β-acetate</li>
<li>Androstenediol diacetate</li>
<li>Androstenediol dipropionate</li></ul></li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenedione" title="4-Androstenedione" class="mw-redirect">Androstenedione (4-androstenedione)</a></li>
<li>Atamestane</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Boldenone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Boldenone'" tppabs="https://ptable.com/wiki/compounds/A/Boldenone" title="Boldenone">Boldenone</a>
<ul><li>Boldenone undecylenate</li></ul></li>
<li>Boldione (1,4-androstadienedione)</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a>
<ul><li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li></ul></li>
<li>Cloxotestosterone
<ul><li>Cloxotestosterone acetate</li></ul></li>
<li>Dehydroandrosterone</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA (androstenolone, prasterone; 5-DHEA)</a>
<ul><li>DHEA enanthate (prasterone enanthate)</li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA sulfate</a></li></ul></li>
<li><a href="Exemestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Exemestane" title="Exemestane">Exemestane</a></li>
<li><a href="Formestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Formestane" title="Formestane">Formestane</a></li>
<li>Plomestane</li>
<li>Quinbolone</li>
<li>Silandrone</li>
<li>Testosterone<sup>#</sup> (+dutasteride)
<ul><li>Testosterone esters</li>
<li>Polytestosterone phloretin phosphate</li></ul></li></ul>

<ul><li><i>5α-Dihydrotestosterone derivatives:</i> 1-Androstenediol</li>
<li>1-Androstenedione</li>
<li>1-Androsterone (1-andro, 1-DHEA)</li>
<li>1-Testosterone</li>
<li>3α-Androstanediol</li>
<li>5α-Androst-2-en-17-one</li>
<li>7β-Hydroxyepiandrosterone</li>
<li>11-Ketodihydrotestosterone</li>
<li><a href="Androsterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Androsterone" title="Androsterone">Androsterone</a></li>
<li>Bolazine
<ul><li>Bolazine capronate</li></ul></li>
<li><span class="new">Dihydroethyltestosterone</span></li>
<li>Dihydrofluoxymesterone</li>
<li><span class="new">Dihydromethylandrostenediol</span></li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone (DHT)</a> (androstanolone, stanolone)
<ul><li>Dihydrotestosterone esters</li></ul></li>
<li><a href="Drostanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drostanolone" title="Drostanolone">Drostanolone</a>
<ul><li>Drostanolone propionate</li></ul></li>
<li><a href="Epiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Epiandrosterone" title="Epiandrosterone">Epiandrosterone</a></li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li>Mesabolone</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a>
<ul><li>Mesterolone cipionate</li></ul></li>
<li>Methyldiazinol</li>
<li>Nisterime
<ul><li>Nisterime acetate</li></ul></li>
<li>Prostanozol</li>
<li>Stenbolone
<ul><li>Stenbolone acetate</li></ul></li>
<li>Testifenon (testiphenon, testiphenone)</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> 7α-Methyl-19-norandrostenedione (MENT dione, trestione)</li>
<li>11β-Methyl-19-nortestosterone
<ul><li>11β-Methyl-19-nortestosterone dodecylcarbonate</li></ul></li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol
<ul><li>Bolandiol dipropionate</li></ul></li>
<li>Bolandione (19-nor-4-androstenedione)</li>
<li>Bolmantalate (nandrolone adamantoate)</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone
<ul><li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li></ul></li>
<li>LS-1727 (nandrolone 17β-<i>N</i>-(2-chloroethyl)-<i>N</i>-nitrosocarbamate)</li>
<li>Methoxydienone (methoxygonadiene)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a>
<ul><li>Nandrolone esters</li></ul></li>
<li>Norclostebol
<ul><li>Norclostebol acetate</li></ul></li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li><a href="Oxabolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone" title="Oxabolone">Oxabolone</a>
<ul><li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li></ul></li>
<li>Trenbolone
<ul><li>Trenbolone acetate</li>
<li>Trenbolone enanthate</li>
<li>Trenbolone hexahydrobenzylcarbonate</li>
<li>Trenbolone undecanoate</li></ul></li>
<li>Trendione</li>
<li>Trestolone (MENT)
<ul><li>Trestolone acetate</li>
<li>Trestolone enanthate</li></ul></li></ul>

<ul><li><i>5α-Dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronandrolone</li>
<li><span class="new">5α-Dihydrotrestolone</span></li>
<li>19-Norandrosterone</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethylandrostenediol (CDMA)</li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li>Chloromethylandrostenediol (CMA)</li>
<li>Enestebol</li>
<li>Ethyltestosterone</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Hydroxystenozole</li>
<li>Metandienone (methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)
<ul><li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol diacetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li></ul></li>
<li>Methylclostebol (chloromethyltestosterone)</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a> (+esterified estrogens)
<ul><li>Methyltestosterone 3-hexyl ether</li></ul></li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li>Desoxymethyltestosterone</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li>Metenolone
<ul><li>Metenolone acetate</li>
<li>Metenolone enanthate</li></ul></li>
<li>Methasterone</li>
<li>Methyl-1-testosterone</li>
<li>Methylepitiostanol</li>
<li>Methylstenbolone</li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> Bolenol</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Methyldienolone</li>
<li>Methylhydroxynandrolone (MOHN, MHN)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Mibolerone</li>
<li>Norboletone</li>
<li>Norethandrolone</li>
<li>Propetandrol</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronorethandrolone</li>
<li>5α-Dihydronormethandrone</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Vinyl-19-nortestosterone derivatives:</i> Vinyltestosterone</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone (ethynyltestosterone)</a></li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyltestosterone derivatives:</i> 17α-Ethynyl-3α-androstanediol</li>
<li>17α-Ethynyl-3β-androstanediol</li>
<li>Dihydroethisterone</li></ul>

<ul><li><i>17α-Ethynyl-19-nortestosterone derivatives:</i> Δ<sup>4</sup>-Tibolone</li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol
<ul><li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li></ul></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol
<ul><li>Lynestrenol phenylpropionate</li></ul></li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Quingestanol
<ul><li>Quingestanol acetate</li></ul></li>
<li>Tibolone</li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyl-19-nortestosterone derivatives:</i> 5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li></ul>

<ul><li><i>Progesterone derivatives:</i> 6α-Methylprogesterone</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Megestrol acetate</li></ul>

<ul><li><i>Others/unsorted:</i> 3-Keto-5α-abiraterone</li>
<li><a href="Androstane.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Androstane" title="5α-Androstane" class="mw-redirect">5α-Androstane</a></li>
<li>Alternariol</li>
<li>Cl-4AS-1</li>
<li>Drupanol</li>
<li><a href="Trilostane.htm" tppabs="https://ptable.com/wiki/compounds/A/Trilostane" title="Trilostane">Trilostane</a></li>
<li>ZM-182345</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SARMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Nonsteroidal:</i> <span class="new">198RL26</span></li>
<li><span class="new">ACP-105</span></li>
<li><span class="new">AC-262536</span></li>
<li>Acetothiolutamide</li>
<li>Andarine (acetamidoxolutamide, androxolutamide, GTx-007, S-4)</li>
<li><span class="new">BMS-564929</span></li>
<li><span class="new">DTIB</span></li>
<li>Enobosarm (ostarine, MK-2866, GTx-024, S-22)</li>
<li><span class="new">FTBU-1</span></li>
<li>GSK2881078</li>
<li><span class="new">GSK-4336A</span></li>
<li><span class="new">GSK-8698</span></li>
<li>LG-121071 (LGD-121071)</li>
<li>LGD-2226</li>
<li><span class="new">LGD-2941 (LGD-122941)</span></li>
<li>LGD-3303</li>
<li>LGD-4033</li>
<li>LY-2452473</li>
<li><span class="new">JNJ-26146900</span></li>
<li>JNJ-28330835</li>
<li><span class="new">JNJ-37654032</span></li>
<li><span class="new">ORM-11984</span></li>
<li><span class="new">R-1</span></li>
<li>RAD140</li>
<li>RU-59063</li>
<li><span class="new">S-1</span></li>
<li>S-23</li>
<li>S-40503</li>
<li><span class="new">S-101479</span></li>
<li>Triclosan</li></ul>

<ul><li><i>Steroidal:</i> <span class="new">EM-9017</span></li>
<li>MK-0773</li>
<li>TFM-4AS-1</li>
<li>YK-11</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 7α-Thioprogesterone</li>
<li>7α-Thiospironolactone</li>
<li>7α-Thiomethylspironolactone</li>
<li>11α-Hydroxyprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>Abiraterone</li>
<li>Abiraterone acetate</li>
<li>Allyltestosterone</li>
<li>Benorterone</li>
<li>BOMT</li>
<li>Canrenoic acid</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Clascoterone</li>
<li>Clometerone</li>
<li><a href="Cyproheptadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproheptadine" title="Cyproheptadine">Cyproheptadine</a></li>
<li><a href="Cyproterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproterone" title="Cyproterone">Cyproterone</a></li>
<li>Cyproterone acetate</li>
<li>Delanterone</li>
<li>Delmadinone acetate</li>
<li>Dicirenone</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>DU-41165</li>
<li>Edogestrone</li>
<li><span class="new">EM-4350</span></li>
<li>EM-5854</li>
<li><span class="new">EM-5855</span></li>
<li><span class="new">EM-6537</span></li>
<li>Epitestosterone</li>
<li>Galeterone</li>
<li>Guggulsterone</li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Mespirenone</li>
<li>Metogest</li>
<li>Mexrenone</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li>Nomegestrol acetate</li>
<li>Nordinone</li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Prorenone</li>
<li>Rosterolone</li>
<li><span class="new">RU-15328</span></li>
<li>SC-5233 (spirolactone)</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li>
<li>Spiroxasone</li>
<li>Topterone</li>
<li>Trimegestone</li>
<li>Trimethyltrienolone (R-2956)</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> 5<i>N</i>-Bicalutamide</li>
<li>AA560</li>
<li><span class="new">Antarlides</span></li>
<li><span class="new">Arabilin</span></li>
<li>Apalutamide</li>
<li>Atraric acid</li>
<li><span class="new">AZD-3514</span></li>
<li>Bakuchiol</li>
<li><span class="new">BAY-1024767</span></li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Bisphenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol" title="Bisphenol">Bisphenols</a> (e.g., <a href="Bisphenol_A_diglycidyl_ether.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A_diglycidyl_ether" title="Bisphenol A diglycidyl ether">BADGE</a>, <span class="new">BFDGE</span>, <a href="Bisphenol_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A" title="Bisphenol A">bisphenol A</a>, bisphenol F, <a href="Bisphenol_S.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_S" title="Bisphenol S">bisphenol S</a>)</li>
<li><span class="new">BMS-501949</span></li>
<li><span class="new">BMS-570511</span></li>
<li>BMS-641988</li>
<li><span class="new">CH5137291</span></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Cioteronel</li>
<li>Cyanonilutamide</li>
<li>Darolutamide</li>
<li>DDT (via metabolite p,p’-DDE)</li>
<li><a href="Dieldrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dieldrin" title="Dieldrin">Dieldrin</a></li>
<li>DIMP</li>
<li><a href="Endosulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Endosulfan" title="Endosulfan">Endosulfan</a></li>
<li>Enzalutamide</li>
<li>EPI-001</li>
<li>EPI-7386</li>
<li><a href="Fenarimol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenarimol" title="Fenarimol">Fenarimol</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li>Hydroxyflutamide</li>
<li>Inocoterone</li>
<li>Inocoterone acetate</li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Ketodarolutamide</li>
<li>Lavender oil</li>
<li><span class="new">LG-105</span></li>
<li>LG-120907</li>
<li><span class="new">LGD-1331</span></li>
<li>Linuron</li>
<li><a href="Methiocarb.htm" tppabs="https://ptable.com/wiki/compounds/A/Methiocarb" title="Methiocarb">Methiocarb</a></li>
<li><span class="new"><i>N</i>-Butylbenzenesulfonamide</span></li>
<li><i>N</i>-Desmethylapalutamide</li>
<li><i>N</i>-Desmethylenzalutamide</li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li><span class="new">ONC1-13B</span></li>
<li>Pentomone</li>
<li><span class="new">PF-998425</span></li>
<li><a href="Phenothrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenothrin" title="Phenothrin">Phenothrin</a></li>
<li>Prochloraz</li>
<li><a href="Procymidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Procymidone" title="Procymidone">Procymidone</a></li>
<li>Proxalutamide</li>
<li>Ralaniten (EPI-002)</li>
<li>Ralaniten acetate (EPI-506)</li>
<li>RD-162</li>
<li><span class="new">Ro 2-7239</span></li>
<li><span class="new">Ro 5-2537</span></li>
<li>RU-22930</li>
<li>RU-56187</li>
<li>RU-57073</li>
<li>RU-58642</li>
<li>RU-58841</li>
<li>Seviteronel</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li>Topilutamide (fluridil)</li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li>Vinclozolin</li>
<li><span class="new">YM-580</span></li>
<li><span class="new">YM-92088</span></li>
<li><span class="new">YM-175735</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GPRC6A</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center;">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cations (incl. aluminum, <a href="Calcium.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium" title="Calcium">calcium</a>, <a href="Gadolinium.htm" tppabs="https://ptable.com/wiki/compounds/A/Gadolinium" title="Gadolinium">gadolinium</a>, <a href="Magnesium.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium" title="Magnesium">magnesium</a>, <a href="Strontium.htm" tppabs="https://ptable.com/wiki/compounds/A/Strontium" title="Strontium">strontium</a>, <a href="Zinc.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc" title="Zinc">zinc</a>)</li>
<li>Dehydroandrosterone</li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone</a></li>
<li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li><small>L</small>-α-Amino acids (incl. <a href="Arginine.htm" tppabs="https://ptable.com/wiki/compounds/A/Arginine" title="Arginine"><small>L</small>-arginine</a>, <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>, <a href="Ornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ornithine" title="Ornithine"><small>L</small>-ornithine</a>)</li>
<li>Osteocalcin</li>
<li><abbr>SHBG</abbr></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Androgens and antiandrogens</dd>
<dd>Estrogen receptor modulators</dd>
<dd>Progesterone receptor modulators</dd>
<dd>List of androgens/anabolic steroids</dd></dl>
</div></td></tr></tbody></table></div>

<div role="navigation" class="navbox" aria-labelledby="Glucocorticoid_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Glucocorticoid_receptor_modulators" style="font-size:114%;margin:0 4em">Glucocorticoid receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Cortisol-like and related (16-unsubstituted):</i> 3α,5α-Tetrahydrocorticosterone</li>
<li>5α-Dihydrocorticosterone</li>
<li>9α-Fluorocortisone (alfluorone)</li>
<li>11-Dehydrocorticosterone (11-oxocorticosterone, 17-deoxycortisone)
<ul><li><span class="new">11-Dehydrocorticosterone acetate</span></li></ul></li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycorticosterone (desoxycortone, deoxycortone, desoxycorticosterone)</a>
<ul><li>Desoxycortone esters</li></ul></li>
<li>11-Deoxycortisol (cortodoxone, cortexolone)
<ul><li>Cortifen (cortiphen, kortifen)</li>
<li><span class="new">Cortodoxone acetate</span></li></ul></li>
<li>21-Deoxycortisol</li>
<li>Δ<sup>7</sup>-Prednisolone
<ul><li><span class="new">Δ<sup>7</sup>-Prednisolone 21-acetate</span></li></ul></li>
<li>Amebucort</li>
<li>Chloroprednisone
<ul><li>Chloroprednisone acetate</li></ul></li>
<li>Cloprednol
<ul><li><span class="new">Cloprednol acetate</span></li></ul></li>
<li><a href="Corticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Corticosterone" title="Corticosterone">Corticosterone</a>
<ul><li><span class="new">Corticosterone acetate</span></li>
<li><span class="new">Corticosterone benzoate</span></li></ul></li>
<li><a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">Cortisol</a> (hydrocortisone)
<ul><li>Benzodrocortisone (hydrocortisone benzoate)</li>
<li><a href="Hydrocortamate.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrocortamate" title="Hydrocortamate">Hydrocortamate (hydrocortisone diethylaminoacetate)</a></li>
<li>Hydrocortisone esters</li></ul></li>
<li><a href="Cortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisone" title="Cortisone">Cortisone</a>
<ul><li>Cortisone acetate</li></ul></li>
<li>Deprodone
<ul><li><span class="new">Deprodone propionate</span></li></ul></li>
<li>Dichlorisone
<ul><li><span class="new">Dichlorisone acetate</span></li>
<li><span class="new">Dichlorisone diacetate</span></li></ul></li>
<li><a href="Difluprednate.htm" tppabs="https://ptable.com/wiki/compounds/A/Difluprednate" title="Difluprednate">Difluprednate</a></li>
<li>Endrisone (endrysone)</li>
<li>Etiprednol
<ul><li><span class="new">Etiprednol dicloacetate (etiprednol dichloroacetate)</span></li></ul></li>
<li><a href="Fludrocortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fludrocortisone" title="Fludrocortisone">Fludrocortisone (fludrocortone)</a>
<ul><li>Fludrocortisone acetate</li></ul></li>
<li><a href="Fluorometholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorometholone" title="Fluorometholone">Fluorometholone</a>
<ul><li>Fluorometholone acetate</li></ul></li>
<li>Fluperolone
<ul><li>Fluperolone acetate</li></ul></li>
<li><a href="Fluprednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluprednisolone" title="Fluprednisolone">Fluprednisolone</a>
<ul><li>Fluprednisolone esters</li></ul></li>
<li>Halopredone
<ul><li><span class="new">Halopredone acetate (halopredone diacetate)</span></li></ul></li>
<li>Isoflupredone (9α-fluoroprednisolone)
<ul><li><span class="new">Isoflupredone acetate</span></li></ul></li>
<li><a href="Loteprednol.htm" tppabs="https://ptable.com/wiki/compounds/A/Loteprednol" title="Loteprednol">Loteprednol</a></li>
<li>Mazipredone (depersolone)</li>
<li><a href="Medrysone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medrysone" title="Medrysone">Medrysone</a></li>
<li><a href="Methylprednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylprednisolone" title="Methylprednisolone">Methylprednisolone</a>
<ul><li>Methylprednisolone esters</li></ul></li>
<li>Prebediolone
<ul><li>Prebediolone acetate</li></ul></li>
<li><a href="Prednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisolone" title="Prednisolone">Prednisolone</a>
<ul><li>Prednazate</li>
<li>Prednazoline</li>
<li><a href="Prednicarbate.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednicarbate" title="Prednicarbate">Prednicarbate (prednisolone ethylcarbonate propionate)</a></li>
<li><a href="Prednimustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednimustine" title="Prednimustine">Prednimustine</a></li>
<li>Prednisolamate (prednisolone diethylaminoacetate)</li>
<li>Prednisolone esters</li></ul></li>
<li><a href="Prednisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisone" title="Prednisone">Prednisone</a>
<ul><li>Prednisone esters</li></ul></li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a>
<ul><li>Pregnenolone acetate</li>
<li>Pregnenolone succinate (pregnenolone hemisuccinate)</li></ul></li>
<li>Resocortol</li>
<li>Tipredane</li>
<li>Tixocortol
<ul><li>Butixocort (tixocortol butyrate)
<ul><li><span class="new">Butixocort propionate</span></li></ul></li>
<li><a href="Tixocortol_pivalate.htm" tppabs="https://ptable.com/wiki/compounds/A/Tixocortol_pivalate" title="Tixocortol pivalate">Tixocortol pivalate</a></li></ul></li></ul>

<ul><li><i>Methasones and related (16-substituted):</i> 16α-Methyl-11-oxoprednisolone</li>
<li><a href="Alclometasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Alclometasone" title="Alclometasone">Alclometasone</a>
<ul><li>Alclometasone dipropionate</li></ul></li>
<li>Amelometasone</li>
<li>Beclometasone (beclomethasone)
<ul><li>Beclometasone esters</li></ul></li>
<li><a href="Betamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Betamethasone" title="Betamethasone">Betamethasone (betametasone)</a>
<ul><li>Betamethasone esters</li>
<li>Cortobenzolone (betamethasone salicylate)</li></ul></li>
<li>Ciclometasone (ciclomethasone, cyclomethasone)</li>
<li>Clobetasol
<ul><li><a href="Clobetasol_propionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Clobetasol_propionate" title="Clobetasol propionate">Clobetasol propionate</a></li></ul></li>
<li>Clobetasone
<ul><li>Clobetasone butyrate</li></ul></li>
<li><a href="Clocortolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Clocortolone" title="Clocortolone">Clocortolone</a>
<ul><li>Clocortolone esters</li></ul></li>
<li>Cloticasone
<ul><li><span class="new">Cloticasone propionate</span></li></ul></li>
<li>Cormetasone (cormethasone)
<ul><li><span class="new">Cormetasone acetate</span></li></ul></li>
<li>Descinolone</li>
<li><a href="Desoximetasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Desoximetasone" title="Desoximetasone">Desoximetasone (desoxymethasone)</a></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone (dexametasone)</a>
<ul><li>Dexamethasone esters</li></ul></li>
<li><a href="Diflorasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Diflorasone" title="Diflorasone">Diflorasone</a>
<ul><li>Diflorasone diacetate</li></ul></li>
<li>Diflucortolone
<ul><li><span class="new">Diflucortolone pivalate</span></li>
<li>Diflucortolone valerate</li></ul></li>
<li>Dimesone
<ul><li><span class="new">Dimesone acetate</span></li></ul></li>
<li>Doxibetasol (doxybetasol)</li>
<li>Fluclorolone</li>
<li>Flumetasone (flumethasone)
<ul><li><span class="new">Flumetasone acetate</span></li>
<li>Flumetasone pivalate</li></ul></li>
<li>Fluocinolone</li>
<li>Fluocortin
<ul><li>Fluocortin butyl (fluocortin butylate)</li></ul></li>
<li>Fluocortolone
<ul><li>Fluocortolone esters</li></ul></li>
<li>Fluprednidene (fluprednylidene)
<ul><li>Fluprednidene acetate</li></ul></li>
<li>Fluticasone
<ul><li>Fluticasone furoate</li>
<li><a href="Fluticasone_propionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluticasone_propionate" title="Fluticasone propionate">Fluticasone propionate</a></li></ul></li>
<li>Halocortolone</li>
<li><a href="Halometasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Halometasone" title="Halometasone">Halometasone</a></li>
<li>Icometasone
<ul><li><span class="new">Icometasone enbutate (icometasone butyrate acetate)</span></li></ul></li>
<li>Isoprednidene</li>
<li>Locicortolone (locicortone)
<ul><li><span class="new">Locicortolone dicibate (locicortone dicibate)</span></li></ul></li>
<li>Meclorisone
<ul><li><span class="new">Meclorisone dibutyrate</span></li></ul></li>
<li>Meprednisone (methylprednisone)
<ul><li><span class="new">Meprednisone acetate</span></li>
<li><span class="new">Meprednisone hydrogen succinate (methylprednisone hemisuccinate)</span></li></ul></li>
<li>Mometasone
<ul><li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone furoate</a></li></ul></li>
<li><a href="Paramethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Paramethasone" title="Paramethasone">Paramethasone</a>
<ul><li>Paramethasone acetate</li>
<li><span class="new">Paramethasone disodium phosphate</span></li>
<li><span class="new">Paramethasone phosphate</span></li></ul></li>
<li>Prednylidene
<ul><li><span class="new">Prednylidene diethylaminoacetate</span></li></ul></li>
<li><a href="Rimexolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Rimexolone" title="Rimexolone">Rimexolone</a></li>
<li>Ticabesone
<ul><li><span class="new">Ticabesone propionate</span></li></ul></li>
<li>Timobesone
<ul><li><span class="new">Timobesone acetate</span></li></ul></li>
<li><a href="Triamcinolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Triamcinolone" title="Triamcinolone">Triamcinolone</a>
<ul><li>Triamcinolone diacetate</li></ul></li>
<li><a href="Ulobetasol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ulobetasol" title="Ulobetasol">Ulobetasol (halobetasol)</a>
<ul><li>Ulobetasol propionate</li></ul></li>
<li>Vamorolone</li></ul>

<ul><li><i>Cyclic ketals (16,17-cyclized):</i> Acrocinonide (triamcinolone acroleinide)</li>
<li>Amcinafal (triamcinolone pentanonide)</li>
<li>Amcinafide (triamcinolone acetophenide)</li>
<li><a href="Amcinonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Amcinonide" title="Amcinonide">Amcinonide (triamcinolone acetate cyclopentanonide)</a></li>
<li><a href="Budesonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Budesonide" title="Budesonide">Budesonide</a></li>
<li><a href="Ciclesonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclesonide" title="Ciclesonide">Ciclesonide</a></li>
<li>Cicortonide</li>
<li>Deflazacort (azacort)</li>
<li>Descinolone acetonide</li>
<li><a href="Desonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Desonide" title="Desonide">Desonide (hydroxyprednisolone acetonide)</a>
<ul><li><span class="new">Desonide disodium phosphate</span></li>
<li><span class="new">Desonide pivalate</span></li></ul></li>
<li>Dexbudesonide</li>
<li>Drocinonide
<ul><li><span class="new">Drocinonide phosphate</span></li></ul></li>
<li>Fluazacort</li>
<li>Fluclorolone acetonide (flucloronide)</li>
<li><a href="Fludroxycortide.htm" tppabs="https://ptable.com/wiki/compounds/A/Fludroxycortide" title="Fludroxycortide">Fludroxycortide (flurandrenolone, flurandrenolide)</a></li>
<li>Flumoxonide</li>
<li><a href="Flunisolide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flunisolide" title="Flunisolide">Flunisolide</a>
<ul><li><span class="new">Flunisolide acetate</span></li></ul></li>
<li><a href="Fluocinolone_acetonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluocinolone_acetonide" title="Fluocinolone acetonide">Fluocinolone acetonide</a>
<ul><li>Ciprocinonide (fluocinolone acetonide cyclopropylcarboxylate)</li>
<li><a href="Fluocinonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluocinonide" title="Fluocinonide">Fluocinonide (fluocinolide, fluocinolone acetonide acetate)</a></li>
<li>Procinonide (fluocinolone acetonide propionate)</li></ul></li>
<li>Formocortal</li>
<li><a href="Halcinonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Halcinonide" title="Halcinonide">Halcinonide</a></li>
<li>Itrocinonide</li>
<li>Rofleponide
<ul><li>Rofleponide palmitate</li></ul></li>
<li>Tralonide</li>
<li><a href="Triamcinolone_acetonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Triamcinolone_acetonide" title="Triamcinolone acetonide">Triamcinolone acetonide</a>
<ul><li>Flupamesone (triamcinolone acetonide metembonate)</li>
<li>Triamcinolone acetonide esters</li></ul></li>
<li>Triamcinolone aminobenzal benzamidoisobutyrate (TBI-PAB)</li>
<li>Triclonide</li></ul>

<ul><li><i>Others/atypical (other expanded steroid ring systems, homosteroids, and non-pregnane steroids):</i> Cortisuzol</li>
<li>Cortivazol</li>
<li>Domoprednate</li>
<li>Naflocort</li>
<li>Nicocortonide
<ul><li><span class="new">Nicocortonide acetate</span></li></ul></li>
<li>Nivacortol (nivazol)</li>
<li>Oxisopred</li>
<li><span class="new">RU-26988</span></li>
<li>RU-28362</li></ul>

<ul><li><i>Non-corticosteroids with some glucocorticoid activity:</i> 15β-Hydroxycyproterone acetate</li>
<li>17α-Hydroxyprogesterone</li>
<li>Bromoketoprogesterone</li>
<li>Chlormadinone acetate</li>
<li><a href="Cyproterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproterone" title="Cyproterone">Cyproterone</a></li>
<li>Cyproterone acetate</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Delmadinone acetate</li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li>DU-41165</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Flugestone</li>
<li>Flugestone acetate (flurogestone acetate)</li>
<li>Fluoromedroxyprogesterone acetate</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li>Medrogestone</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Megestrol acetate</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Norgestomet</li>
<li>Osaterone acetate</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>RU-2309</li>
<li>Quingestrone</li>
<li>Segesterone acetate (nestorone)</li>
<li>Tetrahydrogestrinone</li></ul>

<ul><li><i>Nonsteroidal glucocorticoids:</i> AZD-5423</li>
<li><span class="new">GSK-9027</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SEGRMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Dagrocorat</li>
<li>Fosdagrocorat</li>
<li>Mapracorat</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>7α-Hydroxy-DHEA</li>
<li>17α-Methylprogesterone</li>
<li>Aglepristone</li>
<li>Asoprisnil</li>
<li>Asoprisnil ecamate</li>
<li><span class="new">C108297</span></li>
<li><span class="new">C113176</span></li>
<li><span class="new">CORT-108297</span></li>
<li>Cyproterone acetate</li>
<li><span class="new">Exicorilant (CORT-125281)</span></li>
<li>Guggulsterone</li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Lilopristone</li>
<li><span class="new">LLY-2707</span></li>
<li>Metapristone (RU-42633)</li>
<li><a href="Miconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Miconazole" title="Miconazole">Miconazole</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone (RU-486)</a></li>
<li><span class="new">Miricorilant (CORT-118335)</span></li>
<li>Onapristone</li>
<li><span class="new">ORG-34116</span></li>
<li><span class="new">ORG-34517 (SCH-900636)</span></li>
<li><span class="new">ORG-34850</span></li>
<li>Pregnenolone 16α-carbonitrile</li>
<li>Relacorilant (CORT-125134)</li>
<li>RTI 3021–012</li>
<li><span class="new">RTI 3021–022</span></li>
<li>Telapristone</li>
<li>Tibolone</li>
<li>Toripristone</li>
<li>Ulipristal acetate</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Others</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Antisense oligonucleotides:</i> IONIS-GCCR<sub>Rx</sub> (ISIS-426115)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Glucocorticoids and antiglucocorticoids</dd>
<dd>Mineralocorticoid receptor modulators</dd>
<dd>List of corticosteroids</dd></dl>
</div></td></tr></tbody></table></div>

<div role="navigation" class="navbox" aria-labelledby="Progesterone_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Progesterone_receptor_modulators" style="font-size:114%;margin:0 4em">Progesterone receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Progesterone derivatives:</i> 3β-Dihydroprogesterone</li>
<li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>6α-Methylprogesterone</li>
<li>9α-Bromo-11-ketoprogesterone</li>
<li>11-Dehydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycorticosterone</a></li>
<li>16α-Hydroxyprogesterone</li>
<li><span class="new">17α-Methyl-11-deoxycorticosterone acetate</span></li>
<li>20α-Dihydroprogesterone</li>
<li>20β-Dihydroprogesterone</li>
<li>Dimepregnen</li>
<li><a href="Diosgenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Diosgenin" title="Diosgenin">Diosgenin</a></li>
<li>P1-185</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Progesterone 3-acetyl enol ether</li>
<li>Quingestrone</li></ul>

<ul><li><i>Retroprogesterone derivatives:</i> 20α-Dihydrodydrogesterone</li>
<li>20α-Dihydrotrengestone</li>
<li>DU-41164</li>
<li>DU-41165</li>
<li><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li>Retroprogesterone</li>
<li>Ro 6-3129</li>
<li>Trengestone</li></ul>

<ul><li><i>17α-Substituted progesterone derivatives:</i> 6α-Methyl-17α-bromoprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>16-Methylene-17α-hydroxyprogesterone acetate</li>
<li>17α-Bromoprogesterone</li>
<li>17α-Hydroxyprogesterone (hydroxyprogesterone)</li>
<li>17α-Methylprogesterone</li>
<li>Acetomepregenol (mepregenol diacetate)</li>
<li>Algestone</li>
<li>Algestone acetonide</li>
<li>Algestone acetophenide</li>
<li>Anagestone</li>
<li>Anagestone acetate</li>
<li><span class="new">Bromethenmadinone</span></li>
<li>Bromethenmadinone acetate</li>
<li>Butagest (buterol)</li>
<li>Chlormadinone</li>
<li>Chlormadinone acetate</li>
<li>Chlormadinone caproate</li>
<li><span class="new">Chlormethenmadinone</span></li>
<li>Chlormethenmadinone acetate</li>
<li>Cismadinone</li>
<li>Cismadinone acetate</li>
<li>Clogestone</li>
<li>Clogestone acetate</li>
<li>Clomegestone</li>
<li>Clomegestone acetate</li>
<li>Cymegesolate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone</li>
<li>Delmadinone acetate</li>
<li>Edogestrone</li>
<li>Flugestone</li>
<li>Flugestone acetate</li>
<li><a href="Fluorometholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorometholone" title="Fluorometholone">Fluorometholone</a></li>
<li>Fluorometholone acetate</li>
<li>Flumedroxone</li>
<li>Flumedroxone acetate</li>
<li>Fluoromedroxyprogesterone acetate</li>
<li>Gestaclone</li>
<li>Haloprogesterone</li>
<li>Hydromadinone</li>
<li>Hydromadinone acetate</li>
<li>Hydroxyprogesterone acetate</li>
<li>Hydroxyprogesterone caproate (hydroxyprogesterone hexanoate)</li>
<li>Hydroxyprogesterone heptanoate (hydroxyprogesterone enanthate)</li>
<li>Hydroxyprogesterone heptanoate benzilic acid hydrazone</li>
<li>Mecigestone (pentarane B)</li>
<li>Medrogestone</li>
<li><a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">Medroxyprogesterone</a></li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Medroxyprogesterone caproate</li>
<li><a href="Megestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Megestrol" title="Megestrol">Megestrol</a></li>
<li>Megestrol acetate</li>
<li>Megestrol caproate</li>
<li>Melengestrol</li>
<li>Melengestrol acetate</li>
<li>Methenmadinone</li>
<li>Methenmadinone acetate</li>
<li>Methenmadinone caproate</li>
<li>Mometasone</li>
<li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone furoate</a></li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Pentagestrone</li>
<li>Pentagestrone acetate</li>
<li>Pentarane A</li>
<li>Proligestone</li></ul>

<ul><li><i>19-Norprogesterone derivatives:</i> 17α-Methyl-19-norprogesterone</li>
<li>18-Methylsegesterone acetate</li>
<li>19-Norprogesterone</li>
<li>Amadinone</li>
<li>Amadinone acetate</li>
<li>Demegestone</li>
<li><span class="new">Fluoro ethyl norprogesterone</span></li>
<li><span class="new">Fluoro furanyl norprogesterone</span></li>
<li>Gestadienol</li>
<li>Gestadienol acetate</li>
<li>Gestonorone acetate (gestronol acetate)</li>
<li>Gestonorone caproate (gestronol hexanoate)</li>
<li>Gestronol (gestonorone)</li>
<li>Nomegestrol</li>
<li>Nomegestrol acetate</li>
<li>Norgestomet</li>
<li>ORG-2058</li>
<li>Oxogestone</li>
<li>Oxogestone phenpropionate (xinogestone)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Segesterone</li>
<li>Segesterone acetate (nestorone)</li>
<li>Trimegestone</li></ul>

<ul><li><i>Testosterone derivatives:</i> Progestins: 6,6-Difluoronorethisterone</li>
<li>6,6-Difluoronorethisterone acetate</li>
<li>17α-Allyl-19-nortestosterone</li>
<li><a href="Allylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Allylestrenol" title="Allylestrenol">Allylestrenol</a></li>
<li>Altrenogest</li>
<li>Chloroethynylnorgestrel</li>
<li>Cingestol</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li>Dienogest</li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone</a></li>
<li>Ethynerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol</li>
<li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol</li>
<li>Lynestrenol phenylpropionate</li>
<li>Metynodiol</li>
<li>Metynodiol diacetate</li>
<li>Norelgestromin</li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone (norethindrone)</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li>Noretynodrel</li>
<li>Norgesterone</li>
<li><a href="Norgestimate.htm" tppabs="https://ptable.com/wiki/compounds/A/Norgestimate" title="Norgestimate">Norgestimate</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Norvinisterone</li>
<li>Oxendolone</li>
<li>Quingestanol</li>
<li>Quingestanol acetate</li>
<li>Tibolone</li>
<li>Tigestol</li>
<li>Tosagestin; Anabolic–androgenic steroids: 11β-Methyl-19-nortestosterone</li>
<li>11β-Methyl-19-nortestosterone dodecylcarbonate</li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol</li>
<li>Bolandiol dipropionate</li>
<li>Bolandione</li>
<li>Dimethisterone</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone</li>
<li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol (ethylnandrol)</a></li>
<li>Methyldienolone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone (R-1881)</a></li>
<li>Methoxydienone (methoxygonadiene)</li>
<li>Mibolerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a></li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethandrolone, normethisterone)</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li>
<li>Trenbolone (trienolone)</li>
<li>Trenbolone esters (e.g., trenbolone acetate, trenbolone enanthate)</li>
<li>Trendione</li>
<li>Trestolone</li>
<li>Trestolone acetate</li></ul>

<ul><li><i>Spirolactone derivatives:</i> Canrenoic acid</li>
<li>Canrenone</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Mespirenone</li>
<li>Potassium canrenoate</li>
<li>Prorenone</li>
<li>SC-5233 (spirolactone)</li>
<li>SC-8109</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li></ul>

<ul><li><i>Nonsteroidal:</i> 3,8-Dihydrodiligustilide</li>
<li>LG-2527</li>
<li><span class="new">LG-100128</span></li>
<li>Riligustilide</li>
<li><span class="new">RWJ-26819</span></li>
<li><span class="new">RWJ-49853</span></li>
<li><span class="new">RWJ-60130</span></li>
<li>Tanaproget</li>
<li>ZM-182345</li></ul>

<ul><li><i>Unknown:</i> ORG-47241</li>
<li>ORG-201745</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SPRMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Dihydroethisterone</li>
<li>5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li>
<li>Asoprisnil</li>
<li>Asoprisnil ecamate</li>
<li>Guggulsterone</li>
<li><span class="new">J1042</span></li>
<li><span class="new">LG-120838</span></li>
<li>Metapristone (RU-42633)</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone (RU-486)</a></li>
<li><span class="new">ORF-9371</span></li>
<li>ORF-9326</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RMI-12936</span></li>
<li>Telapristone</li>
<li>Ulipristal acetate</li>
<li>Vilaprisan</li>
<li><span class="new">ZK-137316</span></li></ul>

<ul><li><i>Nonsteroidal:</i> <a href="Apigenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Apigenin" title="Apigenin">Apigenin</a></li>
<li><a href="Kaempferol.htm" tppabs="https://ptable.com/wiki/compounds/A/Kaempferol" title="Kaempferol">Kaempferol</a></li>
<li><span class="new">LG-120920</span></li>
<li><a href="Naringenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Naringenin" title="Naringenin">Naringenin</a></li>
<li><span class="new">PRA-910</span></li>
<li><a href="Syringic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Syringic_acid" title="Syringic acid">Syringic acid</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Aglepristone</li>
<li>Lilopristone</li>
<li>Lonaprisan</li>
<li>Onapristone</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-31806</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RTI 3021–022</span></li>
<li>Toripristone</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> Darolutamide</li>
<li><span class="new">LG-001447</span></li>
<li><span class="new">LG-100127</span></li>
<li><span class="new">LG-100128</span></li>
<li><span class="new">LG-120830</span></li>
<li><span class="new">LG-121046</span></li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li><span class="new">ZM-150271</span></li>
<li><span class="new">ZM-172406</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>mPR</abbr><br>(<abbr>PAQR</abbr>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>5β-Dihydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycortisone (21-hydroxyprogesterone)</a></li>
<li>11-Deoxycortisol (17α,21-dihydroxyprogesterone)</li>
<li>17α-Hydroxyprogesterone</li>
<li><a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">Allopregnanolone</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>Androgen receptor modulators</dd>
<dd>Estrogen receptor modulators</dd>
<dd>List of progestogens</dd></dl>
</div></td></tr></tbody></table></div></div></td></tr></tbody></table></div>


















<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-02" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Medroxyprogesterone_acetate&oldid=970843301  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Medroxyprogesterone_acetate&oldid=970843301'" tppabs="https://en.wikipedia.org/wiki/?title=Medroxyprogesterone_acetate&oldid=970843301">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>